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Preface
Reports of verified cases of tuberculosis 
(RVCT) are submtted to the Dvson of Tu-
berculoss Elmnaton (DTBE), Centers for 
Dsease Control and Preventon (CDC), by 60 
reportng areas (the 50 states, the Dstrct of 
Columba, New York Cty, Puerto Rco, and 
seven other jurisdictions in the Pacific and 
Carbbean).  In January 1993, an expanded 
system was developed to collect addtonal n-
formaton for each reported TB case n order to 
better montor trends n TB and TB control.  A 
software package (SURVS-TB) for data entry, 
analyss, and transmsson of case reports to 
CDC was desgned and mplemented as part of 
the expanded TB survellance system.  In 1998, 
the Tuberculoss Informaton Management Sys-
tem (TIMS) replaced SURVS-TB. 
Ths publcaton, Reported Tuberculosis in the 
United States, 2008, presents the summary 
data for TB cases reported to CDC, verified, 
and counted for 2008.  It s smlar to prevous 
publcatons (see page x, #19) and contans sx 
major sections.  The first section presents trends 
n the overall TB case counts and case rates by 
selected demographc and clncal characters-
tcs.  The second secton presents overall case 
counts and case rates for the Unted States by 
selected demographc characterstcs for 2008.  
In the thrd secton, TB case counts and case 
rates are presented by state and other jursdc-
tons wth tables of selected demographc and 
clncal characterstcs.  In the fourth secton, 
data collected as part of the expanded system 
(e.g., ntal drug resstance, HIV status) are 
presented by reportng area.  Select tables 
report data from the Pacific and Caribbean ju-
risdictions.  The fifth section provides TB case 
counts and case rates by metropoltan statstcal 
areas (MSAs: see Techncal Notes, page 9, for 
further detals) wth tables of selected demo-
graphc and clncal characterstcs.  Fnally, the 
sixth section presents figures from the annual 
survellance slde set, whch emphasze key 
recent trends n TB epdemology n the Unted 
States.  The sldes wth accompanyng text can 
also be vewed and downloaded from the DTBE 
home page, whch s accessble va the Internet at 
http://www.cdc.gov/tb/.
To help nterpret the data, an Executve Commen-
tary (page 3) and Techncal Notes (page 9) have 
been ncluded.  In addton, the applcable case 
definition (MMWR 1997;46 [No. RR 10]:40-41) 
and “Recommendatons for Countng Reported 
Tuberculoss Cases” are provded n Appendces 
A and B, respectvely (page 119).  The recommen-
datons for countng TB cases, whch update the 
original January 1977 recommendations, were first 
publshed n Reported Tuberculosis in the United 
States, 1996.  
After the publcaton of updated Guidelines for 
Targeted Tuberculin Testing and Treatment of La-
tent Tuberculosis Infection n Aprl 20001, DTBE, 
CDC, began recevng reports of severe adverse 
events (.e., hosptalzaton or death) related to the 
use of a 2-month course of rfampn and pyrazn-
amde (RZ) for treatment of latent tuberculoss 
nfecton (LTBI).  Subsequently, DTBE requested 
and receved reports and conducted on-ste nves-
tgatons of lver njury n persons on treatment 
for LTBI, and treatment gudelnes were revsed 
accordngly.2 
Severe adverse events among persons recevng 
treatment for LTBI contnue to be a publc health 
concern and data on the annual number and trends 
of such events are needed.  To ths end, DTBE 
organzed a workng group on treatment for LTBI 
adverse events n September 2003.  Ths work-
ng group was charged wth the development of 
a natonal survellance system wth the followng 
objectves:
To assist public health officials, policy 
makers, and healthcare provders n the 
preventon of severe adverse events, and
To serve as the bass for perodc evalua-
ton of gudelnes for treatment for LTBI 
and revson of these gudelnes as needed.
•
•
xThe Natonal System for Severe Adverse 
Events Assocated wth Treatment of LTBI has 
been mplemented and ncludes collaboratons 
among CDC, FDA, and other partcpatng 
agencies to ensure interagency notification of 
severe adverse events.  Mechansms for qual-
ty assurance and tmely dssemnaton of data 
have been developed. 
DTBE urges hospces, hosptals, jals, prsons, 
and private medical offices to report, through 
ther local health departments, all severe ad-
verse events (e.g., lver njury, metabolc ac-
doss, anaphylaxs, sezure, severe dermatts) 
leadng to hosptalzaton or death of a person 
recevng treatment for LTBI that occurred after 
January 1, 2004, to DTBE by telephone (404-
639-8401) or e-mal (LManangan@cdc.gov).
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State TB Resources on the Internet*
AL http://www.adph.org/tb/
AK http://www.ep.alaska.gov/d/tb.stm
AR None
AZ http://www.azdhs.gov/phs/ods/tuberculoss
CA http://ww2.cdph.ca.gov/programs/tb/Pages/default.aspx
CO http://www.cdphe.state.co.us/dc/tb/tbhome.html
CT http://www.ct.gov/dph/cwp/vew.asp?a=3136&q=388584
DC http://doh.dc.gov/doh/cwp/view,a,1374,q,580737.asp
DE http://dhss.delaware.gov/dph/dpc/tbelmnaton.html
FL http://www.doh.state.fl.us/disease_ctrl/tb/
GA http://health.state.ga.us/ep/tuber.asp
HI http://www.hawa.gov/health/tb
IA http://www.idph.state.ia.us/adper/tb_control.asp
ID http://www.healthandwelfare.idaho.gov/Health/DiseasesConditions/Tuberculosis/tabid/378/Default.aspx
IL http://www.dph.state.l.us/health/nfect/reportds/tb.htm
IN http://www.n.gov/sdh/19662.htm
KS http://www.kdheks.gov/tb/statistical_information.html
KY http://chfs.ky.gov/dph/tb.htm
LA http://www.dhh.louisiana.gov/offices/?ID=273
MA http://www.mass.gov/dph/cdc/tb
MD http://www.edcp.org/tb/ndex.cfm
ME http://www.mane.gov/dhhs/boh/ddc/ep/tuberculoss/
MI http://www.mchgan.gov/tb
MN http://www.health.state.mn.us/dvs/depc/dseases/tb/stats.html
MO http://www.dhss.mo.gov/Tuberculoss/Data.html
MT http://www.dphhs.mt.gov/PHSD/epdemology/commun-dsease-ep-tuberculoss.shtml
MS http://www.msdh.state.ms.us/msdhsite/_static/14,0,125.html 
ND http://www.ndhealth.gov/dsease/tb/
NC http://www.ep.state.nc.us/ep/tb
NE http://www.dhhs.ne.gov/cod/Tuberculoss/tbndex.htm
NH http://www.dhhs.state.nh.us/DHHS/CDCS/tbnfo.htm
NJ http://www.state.nj.us/health/cd/tbhome.htm
NM http://www.health.state.nm.us/PHD/Infectious_Diseases/TB/2007_NM_TB_CaseRates.pdf
NYC http://www.nyc.gov/html/doh/html/tb/tb-reports.shtml
NV http://www.health.nv.gov/CD_HIV_TBProgram.htm
NY http://www.nyhealth.gov/statstcs/dseases/communcable/tuberculoss/
OH http://www.odh.oho.gov/healthstats/dsease/tb/tb1.aspx
OK http://www.ok.gov/health/Disease,_Prevention,_Preparedness/Acute_Disease_Service/Disease_Information/
 CDD_Tuberculosis_Page.html
OR http://oregon.gov/DHS/ph/tb/
PA http://www.health.state.pa.us/PHP/TB/tb.htm
RI http://www.health.r.gov/dsease/communcable/tb/ndex.php
PR http://www.salud.gov.pr/Programas/ProgramaTuberculoss/ Pages/DatosEstadstcosTuberculoss.aspx 
SC http://www.scdhec.net/health/dsease/tb/ndex.htm
SD http://doh.sd.gov/tb
TN http://health.state.tn.us/CEDS/TB/ndex.htm 
TX http://www.dshs.state.tx.us/dcu/dsease/tb/statstcs/
UT http://www.health.utah.gov/cdc/tb_home.htm
VA http://www.vdh.vrgna.gov/epdemology/DseasePreventon/Programs/Tuberculoss/
VT http://healthvermont.gov/prevent/tb/Tuberculoss.aspx
WA http://www.doh.wa.gov/cfh/tb
WI http://www.dhfs.wsconsn.gov/tb
WV http://www.wvtb.org
WY http://www.health.wyo.gov/PHSD/tb/ndex.html
*As reported to CDC by U.S. reporting area TB programs as of July 2009. Includes responses from the reporting areas of New York City 
(NYC) and Puerto Rico (PR).
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Executive Commentary
Highlights of 2008 Report
Since 1953, in cooperation with state and local health departments, the Centers for Disease Control 
and Prevention (CDC) have collected information on each newly reported case of tuberculosis (TB) 
disease in the United States.  Currently, each individual TB case report (Report of Verified Case of 
Tuberculosis, or RVCT) is submitted electronically to CDC’s Division of Tuberculosis Elimination.  
The following are the highlights of the 2008 report:
1. Updated case counts for each year from 1993 through 2007.
2. Case counts:  12,904 TB cases were reported to CDC from the 50 states and the District of Co-
lumbia (DC) for 2008, representing a 2.9% decrease from 2007 (Table1).
• Eighteen states reported increased case counts from 2007 (Table 28).
• California, Texas, New York, and Florida accounted for 49% of the national case total (Table 
28).  
• For the fifth consecutive year, Hispanics (29%) exceeded all other racial or ethnic groups 
with the largest percentage of total cases (Table 2).
• Asians (26%) surpassed non-Hispanic blacks or African-Americans1 (25%) as the second 
largest racial or ethnic group.
• Blacks or African-Americans born in the United States represented 42% of TB cases in U.S.-
born persons and accounted for approximately 17% of the national case total (Tables 17, 18).
• Asians born outside the United States represented 43% of TB cases in foreign-born persons 
and accounted for approximately 25% of the national case total (Tables 17, 18).
3. Case rates:  In 2008, the TB case rate declined from 4.4 to 4.2 per 100,000 persons, representing 
a 3.8% decrease from 2007. 
• Eleven states and DC reported rates above the national average (Table 20).
• Thirty states met the definition for low incidence, or ≤3.5 cases per 100,000 population 
(Table 20).
• The TB case rate was 2.0 per 100,000 for U.S.-born persons and 20.3 for foreign-born per-
sons (Table 5). 
• Asians continued to have the highest case rate (25.6 per 100,000 persons) among all racial or 
ethnic groups (Table 2).
4. Burden among the foreign-born:  The percentage of cases occurring in foreign-born persons con-
tinued to increase and was 59% of the national case total.
• Foreign-born Hispanics and Asians together represented 80% of TB cases in foreign-born 
persons, and accounted for 47% of the national case total (Tables 17, 18).
• In 29 states and the District of Columbia, ≥ 50% of TB cases occurred among foreign-born 
persons (Table 23).
• In 14 states, ≥70% of TB cases occurred among foreign-born persons (Table 23).
• The top five countries of origin of foreign-born persons with TB were Mexico, Philippines, 
Vietnam, India and China (Table 6).
5. Drug resistance:  1.0% of reported cases, compared to 1.1% in 2007, had primary multidrug re-
sistance, which is defined as no previous history of TB disease and resistance to at least isoniazid 
and rifampin (Table 10).
1Hispanic and non-Hispanic are ethnicities. All races are non-Hispanic. The category “non-Hispanic blacks or African-Americans” 
includes U.S. - born and foreign-born persons unless otherwise specified.   
Tuberculosis in the United States
In 2008, the number of TB cases reported 
(12,904) and case rate (4.2 cases per 100,000) 
both decreased; this represented declines of 
2.9% and 3.8%, respectively, compared to 2007.  
Since the 1992 TB resurgence peak in the United 
States, the number of TB cases reported annually 
has decreased by approximately 50%.  However, 
the trend of the declining annual case rate has 
slowed, from an annual average decline of 5.6% 
for 1993 through 2002 to an annual average de-
cline of 2.6% for 2003 through 2008 (Table 1).
The proportion of total cases occurring in for-
eign-born persons has been increasing since 
1993.  In 2008, 59% of TB cases occurred in 
foreign-born persons.  Foreign-born persons 
have accounted for the majority of TB cases in 
the United States every year since 2001.  More-
over, the case rate among foreign-born persons 
in 2008 was approximately 10 times higher than 
among U.S.-born persons (Table 5).
Tuberculosis deaths decreased by 0.6%, from 
648 deaths in 2005 to 644 deaths in 2006, the 
most recent years for which data are available 
(Table 1).
Age
Since 1993, TB case rates have declined annu-
ally for all age groups.  TB case rates vary by 
well-known factors such as age, race and ethnic-
ity, and country of origin.  In 2008, TB case rates 
declined or remained constant for all age groups.  
The highest burden of disease continues to be 
among older adults.  In 2008, adults aged 65 
years and older had a case rate of 6.4 cases per 
100,000, while children aged <14 years had the 
lowest rate at 1.3 cases per 100,000 (Table 4).    
Race and Ethnicity
In 2003, the race and ethnicity category, “non-
Hispanic, Asian or Pacific Islander,” was split 
into “non-Hispanic Asian” and “non-Hispanic 
Native Hawaiian or Other Pacific Islander.”  In 
2008, Asians had the highest TB case rate at 25.6 
cases per 100,000, which was a slight decrease 
from 26.7 in 2007.  In 2008, Native Hawaiians 
or Other Pacific Islanders had the second-highest 
TB case rate at 15.9 cases per 100,000, which is 
a marked decrease compared to 22.3 cases per 
100,000 reported in 2007.  Due to low case num-
bers among Native Hawaiians or Other Pacific 
Islanders, case rates fluctuate and must be inter-
preted with caution (Table 2).
Since 1993, TB case rates have declined between 
59% and 69% in the following racial and ethnic 
groups:  among Hispanic or Latinos from 19.9 to 
8.1 cases per 100,000; among blacks or African-
Americans from 28.5 to 8.8 cases per 100,000; 
and among non-Hispanic whites from 3.6 to 1.1 
cases per 100,000.  In 2008, the TB case rate for 
Asians was approximately three times higher 
than that for Hispanics or blacks or African-
Americans (Table 2).
Origin of Birth
Since 1993, the TB case rate among U.S.-born 
persons has declined annually.  In 2008, the TB 
case rate for U.S.-born persons was 2.0 cases 
per 100,000 representing a 73% decrease from 
7.4 cases per 100,000 in 1993. The TB case rate 
among foreign-born persons also declined dur-
ing the same interval, but was less substantial.  
In 2008, the TB case rate among foreign-born 
persons was 20.3 cases per 100,000 representing 
a 40% decrease from 34.0 cases per 100,000 in 
1993 (Table 5). 
The proportion of TB cases among persons born 
in the United States also has declined annually 
since 1993.  In 2008, 41% of TB cases were 
among U.S-born persons compared to 69% in 
1993 (Table 5).  In 29 states and the District of 
Columbia, ≥50% of TB cases occurred among 
foreign-born persons.  In 14 states (California, 
Colorado, Connecticut, Delaware, Maryland, 
Massachusetts, Minnesota, New Hampshire, 
New Jersey, New York, Oregon, Rhode Island, 
Virginia and Washington), ≥70% of TB cases oc-
curred among foreign-born persons (Table 23).
Country of Origin and World Region
From 2004 through 2008, the top five countries 
of origin of foreign-born persons with TB were 
Mexico, Philippines, Vietnam, India and China 
(Table 6).  However, the changes in the distribu-
tion of TB cases by world region of origin reflect 
the changing immigration patterns among per-
sons settling in the United States2.  Of the 7,563 
TB cases reported among foreign-born persons 
in 2008, 43% occurred among persons born in 
the Americas region, and 30% occurred among 
persons born in the Western Pacific region (Table 
19).  From 1993 to 2008, the proportion of cases 
increased among persons born in the Eastern 
Mediterranean region (3% in 1993 to 4.5% in 
2008), the Southeast Asia region (6% in 1993 
to 13% in 2008), and the African region (2% in 
1993 and 8% in 2008) (Table 19).
Multidrug-Resistant Tuberculosis
Since 1993, when the RVCT was expanded to 
include drug-susceptibility results, the propor-
tion of patients with primary multidrug-resistant 
TB (MDR TB), which is defined as no previous 
history of TB disease and resistance to at least 
isoniazid and rifampin, has decreased from 2.5% 
to 1.0% in 2008.  Since 1998, the percentage of 
U.S.-born patients with MDR TB has remained 
≤ 0.7%.  However, of the total number of re-
ported primary MDR TB cases, the proportion 
occurring in foreign-born persons increased from 
25.3% (103 of 407) in 1993 to 76.7% (66 of 86) 
in 2008 (Table 10). 
Extensively Drug-Resistant Tuberculosis
CDC has included an updated case count of 
extensively drug-resistant TB (XDR TB) cases 
from 1993 to 2008 in the slide set that accompa-
nies this report.  XDR TB is defined as resistance 
to isoniazid and rifampin plus resistance to any 
fluoroquinolone and at least one of three inject-
able second-line anti-TB drugs (i.e., amikacin,
2World Health Organization (WHO).  Global Tuberculosis 
Control 2009:  Epidemiology, Strategy, Financing.  Geneva, 
Switzerland:  World Health Organization, 2009 (WHO/HTM/
TB/2009.411).
kanamycin, or capreomycin)3,4.  Four cases of 
XDR TB were reported during 2008, compared 
to two cases in 2007.
Tuberculosis Therapy
The proportion of TB patients prescribed an 
initial treatment regimen of three or more anti-
TB drugs increased from 72% in 1993 to 87% in 
2008.  The proportion of patients who completed 
therapy within 1 year increased from 64% in 
1993 to 84% in 2006 (the latest year for which 
complete outcome data are available).  The 
proportion of persons receiving directly observed 
therapy at least for a portion of the treatment 
duration also increased from 36% in 1993 to 
88% in 2006, the latest year for which complete 
outcome data are available (Table 12).
Summary 
Essential elements for controlling TB in the 
United States include sufficient resources, in-
terventions targeted to populations at high risk 
for TB, and collaborative efforts with the inter-
national community to reduce the burden of TB 
globally.
During 1993 through 2008, TB case rates in 
the United States decreased for U.S.-born and 
foreign-born persons; however, the decrease 
among foreign-born persons continues to be less 
substantial.  Despite the decreasing case rate 
among foreign-born persons, well over half of 
the TB cases in the United States in 2008 oc-
curred in this population, and the case rate was 
approximately 10 times higher than among U.S.-
born persons.  To address the high TB case rates 
among foreign-born persons, CDC is collaborat-
ing with other national and international public 
health organizations to 1) improve overseas 
screening of immigrants and refugees by system-
atically monitoring and evaluating the screening 
process; 2) strengthen the current notification 
system that alerts local health departments about 
3Centers for Disease Control and Prevention (CDC).  Notice to 
readers:  revised definition of XDR-TB.  Morbid Mortal Weekly 
Report 2006; 55:1176.
4WHO.  Extensively drug-resistant tuberculosis (XDR-TB):  
recommendations for prevention and control.  Weekly Epidemiol 
Record 2006; 81:  430–432.
the arrival of immigrants or refugees who have 
suspected TB to enhance the evaluation and 
treatment of such persons; 3) improve coordina-
tion of TB control activities between the United 
States and Mexico to ensure completion of treat-
ment among TB patients who cross the border; 
4) test recent arrivals from high-incidence coun-
tries for latent TB infection and monitor treat-
ment completion; and 5) survey foreign-born TB 
patients in the United States to determine op-
portunities for improving prevention and control 
interventions.  In addition, CDC continues to 
strengthen collaborations with international part-
ners, including the World Health Organization’s 
Stop TB Partnership, to improve TB control in 
high-incidence countries.
Accelerating progress in national TB elimination 
activities will require broader prevention ef-
forts among high-risk population groups such as 
black or African-American and Asian communi-
ties, persons who are incarcerated, persons with 
excess alcohol and drug use, persons with human 
immunodeficiency virus infection, and persons 
living in poverty with limited access to medical 
care and stable housing.  
In addition, low-incidence areas in the United 
States require continued support to maintain 
the capacity and expertise needed to respond to 
future TB cases5 especially in light of chang-
ing immigration patterns.  CDC has updated the 
comprehensive national action plan to reflect 
the alignment of CDC priorities with the 2000 
Institute of Medicine report on TB and to ensure 
that priority prevention activities are undertaken 
with optimal collaboration and coordination 
among national and international public health 
partners6,7.  
5CDC.  Progressing toward tuberculosis elimination in low-in-
cidence areas of the United States:  Recommendations of the 
Advisory Council for the Elimination of Tuberculosis.  Morbid 
Mortal Weekly Report 2002; 51 (No. RR-5): 1–20.
6Institute of Medicine.  Ending Neglect:  The Elimination of 
Tuberculosis in the United States.  Washington, DC:  National 
Academy Press, 2000.
7CDC.  CDC’s Response to Ending Neglect:  The Elimination of 
Tuberculosis from the United States.  Atlanta, GA:  U.S. Depart-
ment of Health and Human Services, CDC, 2000.
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1Other U.S. jurisdictions include American Samoa, the Commonwealth of the Northern Mariana Islands, the Federated States of Mi-
cronesia, Guam, the Republic of the Marshall Islands, the Republic of Palau, and U.S. Virgin Islands.
Technical Notes
National Surveillance for Tuberculosis
All reporting areas (i.e., the 50 states, the District 
of Columbia, New York City, Puerto Rico, and 
other U.S. jurisdictions in the Pacific and Carib-
bean) report tuberculosis (TB) cases to CDC 
using a standard case report form, Report of 
Verified Case of Tuberculosis (RVCT), through 
2008.1 Reported TB cases are verified accord-
ing to the TB case definition for public health 
surveillance used in this document (MMWR 
1997;46[No. RR-10]:40–41).
Cases may be verified using the laboratory, the 
clinical case definition, or a provider diagnosis.  
A case may be verified by the laboratory case 
definition either by 1) isolation of Mycobacte-
rium tuberculosis complex from a clinical speci-
men, OR 2) detection of M. tuberculosis nucleic 
acid using an FDA approved nucleic acid am-
plification test and testing methods, OR 3) dem-
onstration of acid-fast bacilli (AFB) in a clinical 
specimen when a culture has not been or cannot 
be obtained.
A case may be verified by the clinical case defi-
nition in the presence of ALL of the following 
clinical criteria: 1) a positive tuberculin skin test 
(TST) result or interferon gamma release assay 
(IGRA), 2) other signs and symptoms compatible 
with TB, such as an abnormal, unstable (worsen-
ing or improving) chest radiograph, or clinical 
evidence of current disease, 3) treatment with 
two or more antituberculosis medications, and 4) 
a completed diagnostic evaluation.  
When cases of TB are diagnosed but do not meet 
the clinical case definition, reporting areas also 
have the option of verifying TB cases based on 
provider diagnosis.  Through 2008, the RVCT did 
not collect information on results from interferon 
gamma release assays such as the QuantiFER-
ON-TB Gold test.  If this test is performed in lieu 
of the TST, then the RVCT should reflect that the 
TST was not performed.  Cases without a TST 
that are diagnosed by a positive QuantiFERON-
TB Gold result are considered to have been con-
firmed by provider diagnosis.  Another example 
of a provider diagnosis would be in the case of 
anergic patients with a clinical picture consistent 
with TB but without laboratory evidence of M. 
tuberculosis.
In January 1993, in conjunction with state and 
local health departments, CDC implemented 
an expanded surveillance system for TB that 
would collect additional data to better moni-
tor and target groups at risk for TB disease, to 
estimate and follow the extent of drug-resistant 
TB, and to evaluate outcomes of TB cases.  The 
RVCT form for reporting TB cases was revised 
to collect information on occupation, the initial 
drug regimen, human immunodeficiency virus 
(HIV) test results, history of substance abuse and 
homelessness, and residence in correctional or 
long term-care facilities at the time of diagnosis.  
RVCT Follow Up Report-1 was added to collect 
drug susceptibility results for the initial M. tuber-
culosis isolate from patients with culture-positive 
disease.
To evaluate the outcomes of TB therapy, RVCT 
Follow Up Report-2 was added to collect in-
formation on the reason and date therapy was 
stopped, the type of health care provider, sputum 
culture conversion, the use of directly observed 
therapy (DOT), and the results of drug-suscepti-
bility testing for the final M. tuberculosis isolate 
from patients with culture-positive disease.
Since 1993, RVCT data have been reported to 
CDC using software specifically developed for 
expanded TB surveillance (i.e., SURVS-TB, 
1993–1997; TIMS, 1998–2008).  The instruc-
tions for completing the RVCT forms and the 
definitions for all data items were included in the 
software user’s guide.  The summary data pre-
sented in this publication for 2008 (and for 2006, 
Tables 39–44) and the trend data for 1993–2008 
(Tables 1–14) were received at CDC by May 20, 
2009.
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Completion of Tuberculosis Therapy
Tables 12, 41, 43, and 44 present rates of com-
pletion of TB therapy (COT).  Data collected by 
RVCT Follow Up Report-2 on date and reason 
therapy stopped (e.g., patient completed therapy, 
moved, was lost) were used to calculate rates 
of COT.  Cases were stratified by the indicated 
length of therapy, based on American Thoracic 
Society/CDC/Infectious Diseases Society of 
America treatment guidelines2 in effect dur-
ing the period covered, and the patient’s initial 
drug susceptibility test results, age, and site of 
disease.  The adequacy of the treatment regimen 
(e.g., the sufficiency of the duration of therapy, 
the appropriateness of the prescribed TB drugs) 
was not evaluated in this analysis. Acquired drug 
resistance during therapy with the need for a lon-
ger duration of therapy was also not considered 
in this analysis.
In Table 41, the first column shows the total 
number of cases reported during 2006.  The re-
maining columns are grouped under three head-
ings: therapy of 1 year or less indicated, therapy 
greater than 1 year indicated, and overall. Pa-
tients eligible to complete therapy within 1 year 
had to have been alive at diagnosis and initiated 
therapy with at least one drug. Eligible patients 
did not have rifampin resistance, did not die dur-
ing therapy, and did not have meningeal tuber-
culosis, regardless of age.  In addition, tubercu-
losis patients under the age of 15 years were not 
eligible to complete therapy within 1 year if they 
had disseminated disease (disseminated disease 
is defined as miliary tuberculosis and/or a posi-
tive tuberculosis blood culture). Patients with 
culture-negative disease, those with an unknown 
culture status, and those with culture-positive 
disease but unknown initial drug-susceptibility 
test results were included under the category of 1 
year or less of therapy indicated. Table 12 pres-
ents data only for cases where therapy of 1 year 
or less was indicated.   
In Table 41, each group under an indicated 
length of therapy has an initial column showing 
2CDC.  Treatment of Tuberculosis, American Thoracic Society, CDC, and the Infectious Diseases Society of America.  MMWR 
2003;52(No.RR-11):1-77.  
the number of cases in persons who were alive 
at diagnosis and prescribed an initial regimen of 
one or more drugs, and who did not die during 
therapy.  This number was used as the denomina-
tor in COT rate calculations.
COT rates, shown as percentages, were only 
calculated for areas reporting reason therapy 
stopped for at least 90% of cases shown in the 
overall column. For the group with an indi-
cated length of therapy of 1 year or less, rates 
are shown for both COT in 1 year or less (COT 
≤1 year) and for COT, regardless of duration 
(i.e., duration of therapy ≤1 year, >1 year, or 
unknown).  For COT ≤1 year, the numerator 
included only those patients completing therapy 
in ≤366 days (based on the dates therapy started 
and stopped).  Patients with missing dates were 
classified as “treatment not completed” for this 
calculation.
Rates of COT, regardless of duration, were 
calculated by dividing the number of patients 
reported as having completed therapy by the 
number of total eligible patients.  Patients with 
an outcome other than completed therapy (i.e., 
moved, lost, refused treatment, and other) were 
classified as “treatment not completed.”  Patients 
with an unknown outcome were also classified 
as “treatment not completed.”  For the remaining 
two groups of indicated therapy length (greater 
than 1 year and overall), only rates of COT, 
regardless of duration, are presented.  Table 12 
provides rates for COT ≤1 year and for COT, 
regardless of duration, only for the group with 
an indicated therapy of 1 year or less.  Table 
43 presents rates of COT by ethnicity and non-
Hispanic race and by state for those in whom 
therapy 1 year or less was indicated.
Site of TB Disease
Miliary disease is classified as both an extrapul-
monary and a pulmonary form of TB (Tables 8, 
9, 26, 27, and 47).  In publications prior to 1997, 
miliary disease was classified as extrapulmonary 
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TB unless pulmonary disease was reported as the 
major site of TB disease. 
Reporting of HIV Status 
Table 37 shows information on HIV status for 
persons with TB aged 25–44 years, the age 
group in which 71% of AIDS cases occur (CDC. 
HIV/AIDS Surveillance Report 2007; 15).  The 
information on HIV status for TB cases reported 
in 2008 is incomplete.  Reasons for incomplete 
reporting of HIV test results to the national TB 
surveillance system include concerns about 
confidentiality, which may limit the exchange 
of data between TB and HIV/AIDS programs; 
laws and regulations in certain states and local 
jurisdictions that have been interpreted as pro-
hibiting the HIV/AIDS program from sharing the 
HIV status of TB patients with the TB program, 
or from reporting patients with TB and AIDS to 
the TB program; and reluctance by health care 
providers to report HIV test results to the TB 
surveillance program staff.  In addition, health 
care providers may not offer HIV counseling, 
testing, and referral to some TB patients because 
of a lack of resources or of appropriately trained 
staff, or due to the perception that selected pa-
tients (e.g., foreign-born persons) are not at risk 
for HIV infection.
Data on the HIV-infection status of reported TB 
cases should be interpreted with caution.  These 
data are not representative of all TB patients with 
HIV infection.  HIV testing is performed after a 
patient receives counseling and gives informed 
consent.  Since testing is voluntary, some TB 
patients may decline HIV testing.  TB patients 
who are tested anonymously may choose not 
to share the results of HIV testing with their 
health care provider.  TB patients managed in 
the private sector may receive confidential HIV 
testing, but results may not be reported to the TB 
program in the health department.  In addition, 
many factors may influence HIV testing of TB 
patients, including the extent to which testing is 
targeted or routinely offered to specific groups 
(e.g., 25- to 44-year-old males, injecting drug 
users, homeless persons), and the availability of 
and access to HIV testing services.  These data 
may overrepresent or underrepresent the propor-
tion of TB patients known to be HIV infected in 
a reporting area.
 
Tabulation and Presentation of TB Data  
This report primarily presents summary data for 
TB cases reported to CDC in 2008.  Data from 
the RVCT Follow Up Report-2 (i.e., completion 
of therapy, use of directly observed therapy, and 
type of health care provider) are presented for 
cases reported in 2006.  In addition, trend data 
are presented in Tables 1 through 14.  TB cases 
are tabulated by the year in which the reporting 
area verified that the patient had TB and included 
the patient in its official annual TB case count.  
Previous to 2007, TB case counts for preceding 
years were not updated. The current summary 
reflects updated information on the numbers of 
cases of confirmed TB for each year from 1993 
to 2007.  Therefore, case counts for these years 
differ from those reported in the annual summa-
ries published before 2007.  Totals for the United 
States only include data from the 50 states, the 
District of Columbia, and New York City.  Age 
group tabulations are based on the patient’s age 
in the month and year the patient was reported 
to the health department as a suspected TB case.  
State or metropolitan area data tabulations are 
based on the patient’s residence at diagnosis of 
TB (see Appendix B: “Recommendations for 
Counting Reported Tuberculosis Cases”).
Tables 46 through 50 present data by metropoli-
tan statistical areas (MSAs) with an estimated 
2008 population of 500,000 or more.  MSAs 
are defined by the federal Office of Manage-
ment and Budget, and the definitions effective 
as of November 2007 were used for this pub-
lication (http://www.whitehouse.gov/omb/bul-
letins/fy2008/b08-01.pdf).  On June 6, 2003, the 
OMB announced new MSA definitions based 
on Census 2000 data and the information has 
been updated annually. Some MSA’s added or 
dropped counties and some MSA’s merged.  The 

MSA definitions apply to all areas except the six 
New England states; for these states, the New 
England County Metropolitan Areas (NECMAs) 
are used.  MSAs are named for a central city 
in the MSA or NECMA, may include several 
cities and counties, and may cross state boundar-
ies.  For example, the TB cases and case rates 
presented for the District of Columbia in Table 
20 include only persons residing within the 
geographic boundaries of the District.  However, 
the TB cases and case rates for the Washington, 
D.C., MSA (Table 46) include persons residing 
within the several counties in the metropolitan 
area, including counties in Maryland, Virginia, 
and West Virginia.
 
Rates
Rates are expressed as the number of cases 
reported each calendar year per 100,000 popula-
tion.  Population denominators used in calculat-
ing TB rates were based on official census and 
midyear (July 1) postcensal estimates from the 
U.S. Census Bureau.  Specifically, in Tables 1 
and 20, the U.S. total populations for 2000 to 
2008 were obtained from the Annual Estimates 
of the Population for the United States and 
States, and for Puerto Rico (July 1, 2000– July 
1, 2008).3 In 2003, two modifications were made 
to the RVCT form: 1) entries for multiple race 
(two or more races reported for a person) were 
allowed, and 2) the previous category of Asian/
Pacific Islander was divided into “Asian” and 
“Native Hawaiian or Other Pacific Islander.”  To 
calculate rates in Tables 2 and 3, denominators 
for 2000 to 2008 were obtained from the Annual 
Estimates of the Population by Sex, Race, and 
Hispanic or Latino Origin for the United States: 
April 1, 2000, to July 1, 2008.4 To calculate rates 
for Table 4, denominators were obtained from 
the Annual Estimates of the Population by Sex 
and Five-Year Age Groups for the United States: 
April 1, 2000, to July 1, 2008.5  Denomina-
tors for computing 2008 rates in Table 16 were 
obtained from U.S. Census Bureau Monthly 
Postcensal Resident Population, by single year of 
age, sex, race, and Hispanic origin: July 1, 2008.6 
In 2004, the method for calculating the annual 
percentage change in the TB case rate was modi-
fied.  Unrounded figures are applied to calculate 
the percentage change in the case rate.
In Table 5, the populations for U.S.-born and 
foreign-born persons for 1993 and 1994 were 
obtained from Quarterly Estimates of the United 
States Foreign-born and Native Resident Popula-
tions: April 1, 1990, to July 1, 1999.7  Denomi-
nators for computing the 1995–2008 rates were 
based on extrapolations from the U.S. Census 
Current Population Survey (March Supplement). 
Mortality Data
Official TB mortality statistics for the United 
States are compiled by the National Center for 
Health Statistics (NCHS), CDC.  The annual 
mortality rate is calculated as the number of 
deaths due to TB in that year, divided by the 
estimated population for the year, multiplied by 
100,000 (Table 1).  The number of deaths for 
2006 (preliminary) was obtained from the Na-
tional Center for Health Statistics, National Vital 
Statistics Report, Vol. 56, No. 16, June 11, 2008. 
The numbers of deaths for years after 2006 were 
not available at the time of this publication.
3 http://www.census.gov/popest/states/tables/NST-EST2008-01.xls
4 http://www.census.gov/popest/national/asrh/NC-EST2008/NC-EST2008-03.xls
5 http://www.census.gov/popest/national/asrh/NC-EST2008/NC-EST2008-01.xls
6 http://www.census.gov/popest/national/asrh/files/NC-EST2008-ALLDATA-R-File16.csv
7 http://www.census.gov/popest/archives/1990s/nat-nativity-sum.txt
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Table 1. Tuberculosis Cases, Case Rates per 100,000 Population, Deaths, and Death Rates 
per 100,000 Population, and Percent Change:  United States, 1953–2008
Tuberculosis Cases Tuberculosis Deaths
Percent ChangePercent Change
Number Rate Number RateNumber NumberRate RateYear
 Official tuberculosis mortality statistics were compiled by the National Center for Health Statistics, CDC, National Vital Statistics 
Reports. TB mortality statistics were unavailable at time of publication for years after 2006.
 The large decrease in death rate in 1979 occurred because late effects of tuberculosis (e.g., bronchiectasis or fibrosis) and pleu-
risy with effusion (without mention of cause) are no longer included in tuberculosis deaths.
Percent change in tuberculosis death rates is calculated with rounded figures. See Technical Notes (page 9). 
Note: 1993 to 2008 tuberculosis case counts and rates updated as of May 20, 2009, using Bridged-Race 1990–1999 Intercensal 
Population Estimates for 1990–1999 (ftp://ftp.cdc.gov/pub/health_statistics/nchs/datasets/nvss/bridgepop/documentationbridged-
intercena1.doc) (accessed July 29, 2009) and Annual Estimates of the Population for the United States and States, and for Puerto 
Rico (July 1, 2000– July 1, 2008)  (www.census.gov/popest/states/tables/NST-EST2008-01.xls) (accessed July 29, 2009).  Per-
centage change results reported to one decimal. Ellipses indicate data not available. Case data after 1974 are not comparable to 
prior years due to changes in the surveillance case definition that became effective in 1975.  See Surveillance Slides #2 and #3.
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 0  (69) . 0 (29) .0  (1)
 0  (67) .  (32) .  (1)
   (64) .  (35) .  (0)
 0  (63) .  (36) .  (1)
   (60) .  (39) 0.0 0 (1)
  0 (58) .  (42) .  (0)
 0 0 (56) .0 0 (43) .  (1)
000 0  (53) .  (47) .  (0)
00  0 (49) . 00 (50) .  (0)
00 0  (48) .  (51) .  (0)
00   (46) .  (53) .  (0)
00 00  (46) .  (54) .  (0)
00 0  (45) .  (55) .  (0)
00  0 (43) .  (57) .0  (0)
00   (41) .  (58) 0.  (0)
00 0  (41) .0  (59) 0.  (0)
 Table 4.  Tuberculosis Cases, Percentages, and Case Rates per 100,000 Population by Age 
Group: United States, 1993–2008 
Year
Total
Cases
0–14 15–24 25–44 45–64 > Unk..
No. No. No. No. No. No. (%)(%)(%)(%)(%)(%) Rate Rate Rate Rate Rate
Includes unknown and missing.
Note: Previously published rates for 1993–1999 have been updated using Bridged-Race 1990–1999 Intercensal Population Estimates  
(http://www.cdc.gov/nchs/about/major/dvs/popbridge/popbridge.htm) (accessed June 22, 2009). Denominators for computing 2000–2008 
case rates were obtained from the Annual Estimates of the Population by Sex and Five-Year Age Groups for the United States: April 1, 
2000, to July 1, 2008  (http://www.census.gov/popest/national/asrh/NC-EST2008/NC-EST200-03.xls) (accessed June 22, 2009).
Data for all years updated through May 20, 2009.
See Technical Notes (page 9).
Zero % (0) denotes <0.5%.
See Surveillance Slides #5 and #6.
Table 5.  Tuberculosis Cases, Percentages, and Case Rates per 100,000 
Population by Origin of Birth: United States, 1993–2008
Year
Total
Cases
U.S.-born Persons Foreign-born Persons Unknown or Missing
No. (%)No. (%) RateNo. (%) Rate
Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the 
Republic of the Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, 
the Republic of Palau, the U.S. Virgin Islands, and U.S. minor and outlying Pacific islands.
Note:  Denominators for computing rates for years 1993–1994 were obtained from Quarterly Estimates of the 
United States Foreign-born and Native Resident Populations: April 1, 1990–July 1, 1999, located at http://www.
census.gov/population/estimates/nation/nativity/fbtab001.txt (accessed June 22, 2009). Denominators for comput-
ing the 1995–2008 rates are based on the U.S. Census Bureau, Current Population Survey (March Supplement).  
Data for all years updated through May 20, 2009.
 See Technical Notes (page 9).
Zero % (0) denotes <0.5%.
See Surveillance Slides #11, #12, #15, and #16.
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 Table 6. Tuberculosis Cases and Percentages Among Foreign-born Persons1 by 
the Top 30 Countries2 of Origin of Birth: United States, 2004–2008
Country of Origin
00 00 00 00 00
Year
No. No. No. No. No.(%) (%) (%) (%) (%)
Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the 
Republic of the Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the 
Republic of Palau, the U.S. Virgin Islands, and U.S. minor and outlying Pacific islands.
The top 30 countries were selected based on their ranked 5-year average number of TB cases.
 Includes Not Specified for Country of Origin. Excludes missing.
Note: Zero (0) denotes <0.5%.
Data for all years updated through May 20, 2009.
Total Cases 7563 (100) 7757 (100) 7816 (100) 7727 (100) 7844 (100)
Mexico , (23) ,0 (24) , (25) ,0 (25) ,00 (26)
Philippines  (11)  (12)  (11)  (11) 0 (11)
Vietnam  (8)  (7)  (8)  (7)  (8)
India  (8)  (8)  (7)  (7)  (7)
China  (5)  (5)  (5)  (5)  (4)
Guatemala  (3)  (3) 0 (3)  (3) 0 (2)
Haiti  (3)  (2) 0 (3)  (3)  (3)
Korea, Republic of 0 (2)  (2) 0 (3)  (2)  (3)
Ethiopia 0 (2)  (2) 0 (3)  (2) 0 (2)
Honduras  (3)  (2)  (2)  (2)  (1)
Somalia 0 (2)  (2)  (3)  (2) 0 (2)
Peru  (2) 0 (2) 0 (2)  (2)  (2)
El Salvador  (2)  (2)  (2)  (2)  (2)
Ecuador  (1)  (1)  (2)  (2)  (2)
Cambodia  (1)  (1)  (1) 0 (1) 0 (1)
Dominican Republic  (1)  (1)  (1)  (1) 0 (1)
Pakistan  (1)  (1)  (1)  (1)  (1)
Lao, PDR  (1)  (1)  (1)  (1)  (1)
Kenya  (1)  (1)  (1)  (1)  (1)
Burma  (1)  (1)  (1)  (1)  (1)
Thailand  (1)  (1)  (1)  (1)  (1)
Liberia  (0)  (1)  (1)  (1)  (1)
Nepal 0 (1)  (1)  (1)  (0)  (1)
Columbia  (1)  (1)  (1)  (0)  (1)
Cuba  (1)  (1)  (1)  (1)  (1)
Bangladesh  (1)  (1)  (1)  (0)  (0)
Nigeria  (0)  (1)  (1)  (1)  (0)
Indonesia  (1)  (1)  (0)  (0)  (1)
Russia  (0)  (1)  (1)  (1)  (0)
Taiwan  (0)  (0)  (0)  (0)  (0)
All Others  (11)  (12)  (12)  (12) 0 (13)
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 Table 9.  Pulmonary Tuberculosis Cases and Percentages by Sputum Smear and Sputum 
Culture Results: United States, 1993–2008
Year
Total 
Pulmonary 
Cases
Sputum Smear Result Sputum Culture Result
Positive Negative
Not Done or 
Unknown Positive Negative
Not Done or  
Unknown
No. (%) No. (%) No. No. No. No.(%) (%) (%) (%)
 Includes cases among persons with both pulmonary and extrapulmonary disease and cases of miliary TB.
Note:   See Technical Notes (page 9).
Data for all years updated through May 20, 2009.
	Table	8.		Tuberculosis	Cases	and	Percentages	by	Case	Verification	Criterion	and	Site	of	
Disease: United States, 1993–2008
Year
Total
Cases
Verification Criterion Site of Disease
Positive
Culture
Positive
Smear
Clinical
Case Definition
Provider
Diagnosis Pulmonary
Extra-
pulmonary
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Based on the public health surveillance case definition for tuberculosis:  CDC. Case definitions for infectious conditions under public 
health surveillance.  MMWR 1997:46(No. RR-10):40–41.  See Appendix A.
Includes cases among persons with both pulmonary and extrapulmonary disease and cases of miliary TB.
Includes cases among persons with extrapulmonary TB disease only.
Excludes missing and unknowns.
Note: See Technical Notes for a description of national TB surveillance (page 9).
Data for all years updated through May 20, 2009.
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 Table 10. Tuberculosis Cases and Percentages, by Resistance to INH or Multidrug 
Resistance1 in Persons with No Previous History of TB, by Origin of Birth: United 
States, 1993–2008
Resistance to at least isoniazid and rifampin. 
Isolates may be resistant to other drugs.
All cases were culture positive, and initial drug susceptibility testing done.
Includes persons of unknown country of birth.
Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the Marshall Islands, Midway Is-
land, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin Islands, and U.S. minor and outlying Pacific islands.
Includes Not Specified for Country of Origin.  Excludes missing.
Note:  Data for all years updated through May 20, 2009.
Percentages are of total cases for given year with no previous history of TB, culture positive, and initial drug susceptibility testing done (total cases not shown). 
More than 95% of all persons in each group had drug-susceptibility test results reported for an initial isolate.
See Surveillance Slides #19 through #22.
Year
Resistance to Isoniazid Resistance to Isoniazid and Rifampin
Total Cases, Foreign-born,U.S.-born Total Cases, U.S.-born Foreign-born,
No. No. No. No. No. No.(%) (%) (%) (%) (%) (%)
Resistance to at least isoniazid and rifampin
Isolates may be resistant to other drugs.
All cases were culture positive, and initial drug susceptibility testing done.
Includes persons of unknown country of birth.
Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the Marshall Islands, Midway Is-
land, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin Islands, and U.S. minor and outlying Pacific islands.
 Includes Not Specified for Country of Origin.  Excludes missing.
Note:  Data for all years updated through May 20, 2009.
Percentages are of total cases for given year with previous history of TB, culture positive, and initial drug susceptibility testing done (total cases not shown). More 
than 95% of all persons in each group had drug-susceptibility test results reported for an initial isolate.
Table 11. Tuberculosis Cases and Percentages, by Resistance to INH or Multidrug 
Resistance1 in Persons with Previous History of TB, by Origin of Birth: United 
States, 1993–2008
Year
Resistance to Isoniazid Resistance to Isoniazid and Rifampin
Total Cases, Foreign-born,U.S.-born Total Cases, U.S.-born Foreign-born,
No. No. No. No. No. No.(%) (%) (%) (%) (%) (%)

 (12.9) (31.2) (40.9) (40.3) (21.7) (14.4) (64.1) (87.5)
 (7.0) (23.3) (56.3) (55.7) (28.1) (20.5) (69.0) (87.9)
 (5.2) (20.3) (63.4) (62.7) (37.2) (21.5) (73.9) (89.6)
 (4.2) (17.5) (67.9) (67.3) (42.5) (22.4) (76.4) (90.5)
 (3.2) (15.1) (72.4) (71.9) (46.9) (23.8) (78.2) (91.3)
 (2.6) (12.9) (74.7) (74.3) (47.6) (26.6) (80.6) (92.5)
 (2.2) (11.2) (77.2) (76.9) (49.4) (27.6) (80.8) (92.3)
000 (2.0) (10.4) (78.7) (78.5) (52.5) (25.8) (81.5) (92.6)
00 (1.7) (9.6) (80.1) (79.8) (53.6) (27.5) (81.5) (92.5)
00 (1.8) (8.9) (80.5) (80.3) (55.3) (27.8) (82.1) (92.4)
00 (1.4) (8.1) (81.5) (81.3) (56.5) (28.4) (82.8) (92.7)
00 (1.5) (6.3) (82.5) (82.4) (58.9) (27.7) (82.9) (91.8)
00 (1.3) (5.5) (83.8) (83.7) (57.9) (29.6) (83.0) (92.3)
00 (1.2) (4.8) (83.3) (83.2) (57.5) (30.4) (83.5) (92.5)
00 (1.1) (4.6) (83.3) (83.3) … … … …
00 (0.9) (3.5) (83.3) (83.2) … … … …
 Table 13.  Tuberculosis Cases and Percentages in Persons with HIV Test Results1 and with 
HIV Coinfection by Age Group: United States, 1993–2008
Year
25–44 Years Old All Ages
HIV Test
Results HIV Positive
HIV Test
Results HIV Positive
No. No. No. No.(%) (%) (%) (%)
Includes persons with positive, negative, or indeterminate HIV test results and persons from California with co-diagnosis of TB and 
AIDS. In California, the number of patients testing negative, indeterminate, refusing testing, not offered testing, test performed but status 
unknown, unknown, or missing HIV data is not reported to CDC. California has not reported AIDS test results since 2004. Rhode Island 
did not report HIV test results for years 1993–1997. Vermont did not report HIV test results for years 1993 - 2008.
Note:  Data for all years updated through May 20, 2009.
See Surveillance Slides #24 and #25. 
 Table 12.  Percentages of Tuberculosis Cases by Initial Drug Regimen, Use of Directly  
Observed Therapy (DOT), and Completion of Therapy (COT): United States, 1993–2008
Year
Initial Drug Regimen,
Directly Observed Therapy
Therapy <1 Year Indicated
IRZ IRZ, E/S DOT Only
Both DOT and Self-
Administered COT < Year COTI R
 Includes persons alive at diagnosis.
I=isoniazid; R=rifampin; Z=pyrazinamide; E=ethambutol; S=streptomycin.  Excludes cases with no information on initial drug regimen; 
1.11% received no initial drug therapy, 0.16% were started on one drug, and 11.03% had an initial multidrug regimen other than IR, IRZ, 
or IRZ,E/S.
Includes persons alive at diagnosis with initial drug regimen of one or more drugs prescribed.
Includes persons alive at diagnosis, with initial drug regimen of one or more drugs prescribed, who did not die during therapy.  Excludes 
persons with initial isolate resistant to rifampin and pediatric (aged <15) cases with meningeal, bone or joint, or miliary disease.  See 
Note: Data for all years updated through May 20, 2009.
Technical Notes for description of COT calculation (page 9).
See Surveillance Slides #26 and #27.
IRZE
  (46) 0 (29)  (30)  (15)
  (49)  (30)  (33) 0 (15)
  (52)  (26)  (36) 0 (13)
  (58)  (25)  (42)  (12)
  (60)  (21)  (44) 0 (11)
  (61) 0 (20)  (45)  (10)
  (63)  (19) 0 (48)  (10)
000  (63)  (17)  (50)  (9)
00  (64)  (16) 0 (51) 0 (9)
00  (66)  (16) 0 (53) 0 (9)
00  (68) 0 (16)  (55) 0 (9)
00  (70)  (14) 0 (59)  (8)
00  (69)  (13)  (58) 0 (7)
00  (70)  (12) 0 (60)  (7)
00  (73)  (11) 0 (62)  (7)
00 0 (72)  (10) 00 (62) 0 (6)

Table 14.  Tuberculosis Cases and Percentages by Reason Tuberculosis Therapy Stopped: 
United States, 1993–2006
Year
Total
Cases Completed Therapy Moved Lost Refused Died Unknown
Includes all cases in persons reported as alive at diagnosis and taking one or more TB drugs.
Died = died of any cause (not only TB).
Includes cases in persons reporting reason therapy stopped = Other, Missing, or Unknown. 
Note: Data for all years are updated through May 20, 2009.
Data complete through 2006 only.  See Technical Notes (page 9) for details.
No. (%) No. No. No. No. No.(%) (%) (%) (%) (%)No.
  0 (76.0) 0 (4.7) 0 (4.6)  (0.9) 0 (12.9)  (0.9)
 0  (77.1)  (5.2)  (3.2)  (0.8)  (11.9)  (1.9)
   (79.6)  (4.5)  (2.6)  (0.7)  (11.0)  (1.6)
 0 0 (81.3)  (3.9) 0 (2.6)  (0.8)  (9.8)  (1.7)
 0  (82.7)  (3.5)  (2.3)  (0.6)  (9.3) 00 (1.6)
   (84.0)  (3.0) 00 (2.3) 0 (0.6)  (9.0) 0 (1.2)
   (84.3)  (2.7)  (2.1) 0 (0.6)  (8.5)  (1.7)
000  00 (84.9) 0 (2.6)  (2.5)  (0.7)  (8.2)  (1.1)
00 0 0 (85.7)  (2.4)  (2.4)  (0.6)  (7.2)  (1.6)
00 0  (85.4)  (2.3)  (2.5)  (0.6) 0 (7.4)  (1.8)
00   (86.2)  (2.2)  (2.5)  (0.6)  (6.9)  (1.7)
00 0 0 (85.3)  (2.4)  (2.4)  (0.6)  (6.8) 0 (2.5)
00  0 (85.6)  (2.4)  (2.5)  (0.6)  (7.2)  (1.7)
00 0  (85.9)  (2.5)  (2.6)  (0.6)  (7.0) 00 (1.5)

Morbidity Tables
United States, 2008


Table 15.  Tuberculosis Cases by Hispanic Ethnicity and Non-Hispanic Race, Sex, and Age 
Group: United States, 2008
Persons of Hispanic or Latino ethnicity may be of any race or multiple race.             
Indicates two or more races reported for a person. Category first reported in 2003.        
Note: Case counts for race categories (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other 
Pacific Islander, and White) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. Multiple Race does 
not include persons of Hispanic ethnicity.
See Technical Notes (page 9).                 
See Surveillance Slide #10.
Age Group
Race/Ethnicity and Sex All Ages Under 5 5–14 15–24 25–44 45–64 >
Not 
Stated
Total Cases ,0  0 ,0 , , ,00 
Male ,  0  , ,0 , 0
Female ,    , , ,0 
Unknown  0  0 0 0 0 0
Hispanic or Latino ,    ,   0
Male ,    ,0   0
Female ,00       0
Unknown  0  0 0 0 0 0
Non-Hispanic
American Indian or Alaska Native        0
Male 0      0 0
Female   0     0
Unknown 0 0 0 0 0 0 0 0
Asian ,    ,   0
Male ,0      0 0
Female ,      0 0
Unknown 0 0 0 0 0 0 0 0
Black or African American ,  0  ,0 ,  
Male ,   0    0
Female ,0      0 
Unknown 0 0 0 0 0 0 0 0
Native Hawaiian or Other Pacific Islander        0
Male        0
Female        0
Unknown 0 0 0 0 0 0 0 0
White ,      0 0
Male ,       0
Female  0      0
Unknown 0 0 0 0 0 0 0 0
Multiple Race        0
Male  0      0
Female   0    0 0
Unknown 0 0 0 0 0 0 0 0
Unknown 0       0
Male 0       0
Female 0       0
Unknown 0 0 0 0 0 0 0 0

Table 16.  Tuberculosis Case Rates per 100,000 Population by Hispanic Ethnicity and Non-
Hispanic Race, Sex, and Age Group: United States, 2008
Persons of Hispanic or Latino origin may be of any race or multiple race.             
Indicates two or more races reported for a person. Category first reported in 2003.        
Note: Denominators for computing case rates were obtained from the U.S. Census Bureau Monthly Postcensal Resident Population, by 
single year of age, sex, race, and Hispanic origin: July 1, 2008 (http://www.census.gov/popest/national/asrh/files/NC-EST2008-ALLDATA-
R-File16.csv) (Accessed June 24, 2009).
Case counts for race categories (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific 
Islander, and White) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. Multiple Race does not 
include persons of Hispanic ethnicity.
See Technical Notes (page 9).                 
See Surveillance Slide #7.                 
Age Group
Race/Ethnicity and Sex All Ages Under 5 5–14 15–24 25–44 45 –64 >
Total Rate . . 0. . . .0 .
Male . . 0. . .0 .0 .0
Female . . 0. . . . .
Hispanic or Latino . . . . 0.0 . .
Male 0. . . 0.0 . . .0
Female . . . . . . .
American Indian or Alaska Native .0 . 0. . .0 . .
Male .0 . 0. . . . .
Female .0 . 0.0 . . . .
Asian . . . . . . .
Male . 0. . . . . .
Female . .0 . 0. . . .
Black or African American . . . . 0.0 . .
Male . . . . . 0. .
Female . . . . . . 0.
Native Hawaiian or Other Pacific Islander . . . . . . .
Male . 0. .0 . . . .
Female . . . . . . .
White . 0. 0.0 0. 0. . .
Male . 0. 0. 0. .0 . .
Female 0. 0. 0.0 0. 0. 0. .
Multiple Race 0. 0. 0. 0. .0 . .
Male . 0.0 0. 0. . . .
Female 0. 0. 0.0 0. . . 0.0

Age Group
Race/Ethnicity and Sex All Ages Under 5 5–14 15–24 25–44 45–64 >
Not 
Stated
Table 17.  Tuberculosis Cases in U.S.-born Persons by Hispanic Ethnicity and Non-Hispanic 
Race, Sex, and Age Group: United States, 2008
Persons of Hispanic or Latino origin may be of any race or multiple race.             
Indicates two or more races reported for a person. Category first reported in 2003.        
Note: Case counts for race categories (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other 
Pacific Islander, and White) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. Multiple race does 
not include persons of Hispanic ethnicity.
See Technical Notes (page 9).
See Surveillance Slide #13.
Total Cases ,    , , , 
Male ,  0 0  ,  0
Female ,       
Unknown  0  0 0 0 0 0
Hispanic or Latino 0    0 0  0
Male 0       0
Female        0
Unknown  0  0 0 0 0 0
Non-Hispanic
American Indian or Alaska Native        0
Male        0
Female   0     0
Unknown 0 0 0 0 0 0 0 0
Asian        0
Male 0       0
Female   0     0
Unknown 0 0 0 0 0 0 0 0
Black or African American , 0  0    
Male ,0       0
Female        
Unknown 0 0 0 0 0 0 0 0
Native Hawaiian or Other Pacific Islander 0       0
Male        0
Female        0
Unknown 0 0 0 0 0 0 0 0
White ,      0 0
Male ,      0 0
Female        0
Unknown 0 0 0 0 0 0 0 0
Multiple Race   0     0
Male  0 0     0
Female   0  0  0 0
Unknown 0 0 0 0 0 0 0 0
Unknown        0
Male  0      0
Female        0
Unknown 0 0 0 0 0 0 0 0
0
Table 18.  Tuberculosis Cases in Foreign-born Persons1 by Hispanic Ethnicity and Non-
Hispanic Race, Sex, and Age Group: United States, 2008
Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the 
Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin 
Islands, and U.S. minor and outlying Pacific islands.                 
Persons of Hispanic or Latino ethnicity may be of any race or multiple race.            
Indicates two or more races reported for a person. Category first reported in 2003.        
Note: Case counts for race categories (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other 
Pacific Islander, and White) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. Multiple race does 
not include persons of Hispanic ethnicity.
See Technical Notes (page 9). 
See Surveillance Slide #13.
Age Group
Race/Ethnicity and Sex All Ages Under 5 5–14 15–24 25–44 45–64 >
Not 
Stated
Total Cases ,   ,0 ,00 , , 0
Male ,    , ,  0
Female ,00    ,  0 0
Unknown 0 0 0 0 0 0 0 0
Hispanic or Latino ,   0 ,   0
Male ,    0  0 0
Female      0  0
Unknown 0 0 0 0 0 0 0 0
Non-Hispanic
American Indian or Alaska Native  0 0 0    0
Male  0 0 0    0
Female  0 0 0  0 0 0
Unknown 0 0 0 0 0 0 0 0
Asian ,  0 0 ,0   0
Male , 0      0
Female ,0       0
Unknown 0 0 0 0 0 0 0 0
Black or African American ,00   0    0
Male        0
Female    0    0
Unknown 0 0 0 0 0 0 0 0
Native Hawaiian or Other Pacific Islander  0 0     0
Male  0 0 0    0
Female  0 0     0
Unknown 0 0 0 0 0 0 0 0
White      0  0
Male 0       0
Female        0
Unknown 0 0 0 0 0 0 0 0
Multiple Race  0      0
Male  0  0    0
Female  0 0    0 0
Unknown 0 0 0 0 0 0 0 0
Unknown  0  0    0
Male  0 0 0    0
Female  0  0  0  0
Unknown 0 0 0 0 0 0 0 0

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
Eastern Mediterranean Region
Total Cases = 338
Algeria  Ethiopia 0 Niger 
Angola 0 Gabon  Nigeria 
Benin  Gambia  Rwanda 
Botswana  Ghana  Sao Tome and Principe 0
Burkina Faso  Guinea  Senegal 
Burundi  Guinea-Bissau 0 Seychelles 
Cameroon  Kenya  Sierra Leone 0
Cape Verde  Lesotho 0 South Africa 
Central African Republic  Liberia  Swaziland 0
Chad 0 Madagascar  Tanzania, UR 
Comoros  Malawi  Togo 
Congo, Republic of  Mali  Uganda 
Côte d’Ivoire  Mauritania  Zambia 
DR Congo  Mauritius 0 Zimbabwe 
Equatorial Guinea 0 Mozambique    
Eritrea  Namibia 
Anguilla 0 Cuba  Panama 
Antigua and Barbuda  Dominica  Paraguay 
Argentina  Dominican Republic  Peru 
Bahamas  Ecuador  Puerto Rico 
Barbados  El Salvador  St. Kitts and Nevis 0
Belize  Grenada  St. Lucia 
Bermuda  Guatemala  St. Vincent & Grenadines 0
Bolivia  Guyana  Suriname 0
Brazil  Haiti  Trinidad and Tobago 0
British Virgin Islands 0 Honduras  Turks and Caicos Islands 0
Canada  Jamaica  Uruguay 
Cayman Islands 0 Mexico , U.S. Virgin Islands 
Chile  Montserrat  United States of America ,
Colombia  Netherland Antilles 0 Venezuela 
Costa Rica  Nicaragua    
Afghanistan 0 Lebanon 0 Sudan 
Bahrain 0 Libyan Arab Jamahiriya  Syrian Arab Republic 
Djibouti 0 Morocco  Tunisia 0
Egypt  Oman 0 United Arab Emirates 0
Iran, Islamic Republic of  Pakistan  West Bank and Gaza 0
Iraq  Qatar 0 Yemen 
Jordan  Saudi Arabia 
Kuwait  Somalia 0
Table 19. Tuberculosis Cases by Country of Origin1: United States, 2008
African Region
Total Cases = 594 
Americas Region
Total Cases = 8,388

Albania   Germany  Norway 0
Andorra 0 Greece   Poland 
Armenia 0 Hungary  Portugal 
Austria  Iceland 0 Romania 
Azerbaijan  Ireland  Russian Federation 
Belarus  Israel  San Marino 0
Belguim  Italy  Serbia 
Bosnia and Herzegovina  Kazakhstan 0 Slovakia 0
Bulgaria  Kyrgyzstan  Slovenia 0
Croatia  Latvia 0 Spain 
Cyprus 0 Lithuania 0 Sweden 
Czech Republic 0 Luxembourg 0 Switzerland 
Czechoslovakia  Macedonia, TFYR  Tajikistan 0
Denmark  Malta 0 Turkey 
Estonia 0 Moldova, Republic of  Turkmenistan 
Finland 0 Monaco 0 Ukraine 
France  Montenegro  United Kingdom 
Georgia  Netherlands  Uzbekistan 
Yugoslavia 
Bangladesh  Korea, DPR  Sri Lanka 
Bhutan  Maldives 0 Thailand 
India  Myanmar  Timor-Leste 0
Indonesia  Nepal 0
American Samoa  Korea, Rep.  Philippines 
Australia 0 Lao, PDR  Samoa 
Brunei Darussalam 0 Malaysia  Singapore 
Cambodia  Marshall Islands, Republic of  Solomon Islands 0
China  Micronesia, Federated States of  Tokelau 0
China, Hong Kong SAR  Mongolia 0 Tonga 
China, Macao SAR 0 Nauru 0 Tuvalu 0
Cook Islands 0 New Caledonia 0 Vanuatu 0
Fiji  New Zealand 0 Viet nam 
French Polynesia 0 Niue 0 Wallis and Futuna 0
Guam  N. Mariana Islands, Commonwealth of 
Japan  Palau, Republic of 
Kiribati 0 Papua New Guinea 
Country as reported by patient.
Includes country codes currently reported via the National Tuberculosis Surveillance System that are not represented by WHO member 
states.
Note:  Regional composition of countries based on WHO Report Global Tuberculosis Control 2009, Epidemiology, Strategy, Financing, 
World Health Organization  (WHO/HTM/TB/2009.411) (http://www.who.int/tb/publications/global_report/en/).
Table 19.  (Cont’d) Tuberculosis Cases by Country of Origin1: United States, 2008
European Region
Total Cases = 262
Other2
Total Cases = 40
Unknown
Total Cases = 58
Southeast Asia Region
Total Cases = 963
Western	Pacific	Region
Total Cases = 2,261

This page intentionally left blank

Morbidity Tables
Reporting Areas, 2008


United States 12,904 13,288 4.2 4.4 -- -- 304,059,724
Alabama   . .   ,,00
Alaska 0 0 . .   ,
Arizona  0 . .   ,00,0
Arkansas  0 . .   ,,0
California , , . .   ,,
Colorado 0  . .  0 ,,
Connecticut  0 . .   ,0,
Delaware   . .   ,0
District of Columbia   . 0.0 -- -- ,
Florida   . .   ,,0
Georgia   . .0   ,,
Hawaii   . .   ,,
Idaho   0. 0.   ,,
Illinois  0 . .   ,0,
Indiana   . .0   ,,
Iowa   . . 0  ,00,
Kansas   .0 .   ,0,
Kentucky 0 0 . . 0  ,,
Louisiana   . .0   ,0,
Maine   0. .  0 ,,
Maryland   . .   ,,
Massachusetts   .0 .   ,,
Michigan   . .   0,00,
Minnesota   .0 .   ,0,
Mississippi   .0 .   ,,
Missouri 0  . .0   ,,0
Montana   0. .   ,0
Nebraska   . .   ,,
Nevada 0 0 . .0  0 ,00,
New Hampshire   . 0.   ,,0
New Jersey   . . 0  ,,
New Mexico 0  .0 .   ,,
New York ,00 , . .0   ,0,
North Carolina   . . 0  ,,
North Dakota   0. . 0  ,
Ohio   . .   ,,0
Oklahoma 00  . .   ,,
Oregon   .0 .   ,0,00
Pennsylvania   . .   ,,
Rhode Island   . .   ,00,
South Carolina   . .  0 ,,00
South Dakota   .0 .   0,
Tennessee   . .   ,,
Texas ,0 ,0 . .   ,,
Utah   .0 .   ,,
Vermont   .0 0.   ,0
Virginia  0 . .0   ,,0
Washington   . .   ,,
West Virginia   . .   ,,
Wisconsin  0 . .   ,,
Wyoming   0. 0.  0 ,
American Samoa,   . . -- -- ,
Fed. States of Micronesia,   .0 . -- -- 0,
Guam, 0  . . -- -- ,
Marshall Islands,   . 0. -- -- ,
N. Mariana Islands,   . . -- -- ,
Puerto Rico,   . . -- -- ,,0
Republic of Palau,   . . -- -- 0,0
U.S. Virgin Islands,  ... . ... -- -- 0,0
Table 20. Tuberculosis Cases and Case Rates per 100,000 Population: 
Reporting Areas, 2008 and 2007
Not ranked with the states. See Table 28 for District of Columbia ranking among states.
Not included in U.S. totals. 
Note: Denominators for computing 2007 and 2008 rates for states, the District of Columbia, and Puerto Rico were obtained from An-
nual Estimates of the Population for the United States and States, and for Puerto Rico: April 1, 2000–July 1, 2008 (NST-EST2008-01) 
(accessed June 25, 2009)  (http://www.census.gov/popest/states/tables/NST-EST2008-01.xls); for all other areas, from IDB Summary 
Demographic Data (http://www.census.gov/ipc/www/idb/summaries.html).
Ellipses indicate data not available.
See Technical Notes (page 9).
See Surveillance Slide #4.
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Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the 
Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin 
Islands, and U.S. minor and outlying Pacific islands.
Note: See Surveillance Slide #14.
Table 23. Tuberculosis Cases and Percentages, U.S.-born and Foreign-born Persons: 
States, 2008
States
Total
Cases No. No. No.(%) (%) (%)
U.S.-born Persons Foreign-born Persons Unknown Origin
United States 12,904 5,283 (40.9) 7,563 (58.6) 58 (0.4)
Alabama   (77.3) 0 (22.7) 0 (0.0)
Alaska 0  (76.0)  (24.0) 0 (0.0)
Arizona   (34.8)  (65.2) 0 (0.0)
Arkansas   (79.5)  (18.1)  (2.4)
California ,  (24.9) ,0 (74.7)  (0.4)
Colorado 0 0 (29.1)  (70.9) 0 (0.0)
Connecticut   (22.4)  (77.6) 0 (0.0)
Delaware   (34.8)  (65.2) 0 (0.0)
District of Columbia   (48.1)  (51.9) 0 (0.0)
Florida  0 (52.8) 0 (47.2) 0 (0.0)
Georgia   (59.0)  (41.0) 0 (0.0)
Hawaii   (30.6)  (69.4) 0 (0.0)
Idaho   (36.4)  (63.6) 0 (0.0)
Illinois   (39.9)  (60.1) 0 (0.0)
Indiana  0 (59.3)  (40.7) 0 (0.0)
Iowa   (34.7)  (65.3) 0 (0.0)
Kansas  0 (35.1)  (64.9) 0 (0.0)
Kentucky 0  (57.4)  (42.6) 0 (0.0)
Louisiana   (80.2)  (19.8) 0 (0.0)
Maine   (11.1)  (88.9) 0 (0.0)
Maryland   (29.1)  (70.9) 0 (0.0)
Massachusetts   (17.6)  (82.4) 0 (0.0)
Michigan  0 (55.3)  (44.1)  (0.5)
Minnesota   (26.5)  (73.5) 0 (0.0)
Mississippi  0 (93.2)  (6.8) 0 (0.0)
Missouri 0  (43.9) 0 (56.1) 0 (0.0)
Montana   (66.7)  (33.3) 0 (0.0)
Nebraska  0 (30.3)  (69.7) 0 (0.0)
Nevada 0  (31.4) 0 (68.6) 0 (0.0)
New Hampshire   (26.3)  (73.7) 0 (0.0)
New Jersey   (23.5)  (76.5) 0 (0.0)
New Mexico 0  (46.7)  (53.3) 0 (0.0)
New York ,00  (23.9) 0 (75.6)  (0.5)
North Carolina   (63.6)  (36.4) 0 (0.0)
North Dakota   (66.7)  (33.3) 0 (0.0)
Ohio   (54.0)  (46.0) 0 (0.0)
Oklahoma 00 0 (80.0)  (18.0)  (2.0)
Oregon   (24.0)  (76.0) 0 (0.0)
Pennsylvania   (46.3)  (47.3)  (6.5)
Rhode Island   (22.2)  (77.8) 0 (0.0)
South Carolina   (69.7)  (30.3) 0 (0.0)
South Dakota   (75.0)  (25.0) 0 (0.0)
Tennessee   (69.1)  (30.1)  (0.7)
Texas ,0  (51.6)  (48.4) 0 (0.0)
Utah  0 (37.0)  (63.0) 0 (0.0)
Vermont   (50.0)  (50.0) 0 (0.0)
Virginia  0 (27.4)  (72.6) 0 (0.0)
Washington   (27.6)  (72.4) 0 (0.0)
West Virginia   (75.0)  (25.0) 0 (0.0)
Wisconsin   (36.8)  (50.0)  (13.2)
Wyoming   (40.0)  (60.0) 0 (0.0)

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Table 25. Tuberculosis Cases and Percentages in Foreign-born Persons1 by Number of Years 
in the United States: States, 2008
State
Total
Cases
Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the 
Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin 
Islands, and U.S. minor and outlying Pacific islands.
                 
<1 Year 1–4 5–9 10–19 >0 Unknown or 
Missing
No. No. No. No. No. No.(%) (%) (%) (%) (%) (%)
United States 7,563 1,319 (17.4) 1,564 (20.7) 1,177 (15.6) 1,263 (16.7) 1,425 (18.8) 815 (10.8)
Alabama 0  (17.5)  (42.5)  (15.0)  (7.5)  (12.5)  (5.0)
Alaska   (50.0)  (16.7)  (8.3)  (8.3) 0 (0.0)  (16.7)
Arizona   (23.0)  (14.2)  (18.9)  (7.4)  (18.2)  (18.2)
Arkansas   (13.3)  (26.7)  (13.3)  (26.7)  (20.0) 0 (0.0)
California ,0 0 (13.4)  (13.7)  (11.8)  (16.8)  (27.9)  (16.4)
Colorado   (32.9) 0 (13.7)  (12.3)  (12.3)  (16.4)  (12.3)
Connecticut  0 (13.2)  (34.2)  (22.4)  (17.1)  (10.5)  (2.6)
Delaware   (26.7)  (20.0)  (26.7)  (20.0)  (6.7) 0 (0.0)
District of Columbia   (17.9)  (46.4)  (10.7)  (10.7)  (14.3) 0 (0.0)
Florida 0  (19.8) 0 (24.4)  (18.7)  (11.8)  (19.8)  (5.6)
Georgia   (17.9)  (25.0)  (19.9)  (18.4) 0 (15.3)  (3.6)
Hawaii   (19.8)  (14.0)  (9.3)  (25.6) 0 (23.3)  (8.1)
Idaho  0 (0.0)  (71.4)  (14.3) 0 (0.0)  (14.3) 0 (0.0)
Illinois   (14.9)  (16.3)  (18.1)  (23.4)  (17.4)  (9.9)
Indiana   (33.3)  (16.7)  (2.1)  (10.4)  (4.2)  (33.3)
Iowa   (28.1)  (28.1)  (12.5)  (12.5)  (18.8) 0 (0.0)
Kansas   (32.4)  (5.4) 0 (27.0)  (18.9)  (16.2) 0 (0.0)
Kentucky  0 (23.3)  (41.9)  (16.3)  (11.6)  (7.0) 0 (0.0)
Louisiana  0 (22.2)  (26.7)  (15.6)  (17.8)  (17.8) 0 (0.0)
Maine  0 (0.0)  (37.5)  (37.5)  (12.5)  (12.5) 0 (0.0)
Maryland   (23.4)  (27.4)  (16.8)  (17.3)  (14.2)  (1.0)
Massachusetts   (20.0)  (28.4)  (16.7)  (16.3)  (16.7)  (1.9)
Michigan   (15.7)  (18.1)  (14.5)  (19.3)  (13.3)  (19.3)
Minnesota   (22.6)  (29.0)  (16.1)  (8.4) 0 (6.5)  (17.4)
Mississippi   (12.5)  (37.5)  (12.5)  (25.0)  (12.5) 0 (0.0)
Missouri 0  (25.0) 0 (33.3)  (20.0) 0 (16.7)  (5.0) 0 (0.0)
Montana   (33.3) 0 (0.0)  (33.3) 0 (0.0)  (33.3) 0 (0.0)
Nebraska   (26.1)  (30.4)  (17.4)  (17.4)  (8.7) 0 (0.0)
Nevada 0  (15.7)  (15.7)  (12.9)  (30.0)  (25.7) 0 (0.0)
New Hampshire   (28.6)  (21.4)  (14.3)  (14.3)  (14.3)  (7.1)
New Jersey   (10.5)  (15.8)  (14.6)  (11.8)  (7.1) 0 (40.2)
New Mexico   (18.8)  (9.4)  (6.3)  (28.1) 0 (31.3)  (6.3)
New York 0  (15.9)  (23.8)  (18.6)  (19.1)  (17.3)  (5.3)
North Carolina   (18.9)  (28.7)  (18.9)  (18.0)  (9.8)  (5.7)
North Dakota  0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)  (100.0)
Ohio   (22.4)  (34.7)  (15.3)  (6.1)  (9.2)  (12.2)
Oklahoma   (22.2)  (27.8) 0 (0.0)  (11.1)  (16.7)  (22.2)
Oregon   (12.3)  (15.8)  (5.3)  (7.0)  (3.5)  (56.1)
Pennsylvania   (21.3)  (26.2)  (18.0)  (14.8)  (11.5)  (8.2)
Rhode Island   (17.9)  (7.1) 0 (0.0) 0 (0.0)  (3.6) 0 (71.4)
South Carolina   (21.1)  (40.4)  (19.3)  (7.0)  (10.5)  (1.8)
South Dakota   (50.0)  (25.0)  (25.0) 0 (0.0) 0 (0.0) 0 (0.0)
Tennessee   (16.5)  (32.9)  (25.9)  (20.0)  (4.7) 0 (0.0)
Texas   (20.5)  (18.3)  (15.6)  (22.6)  (23.0) 0 (0.0)
Utah   (17.6)  (29.4) 0 (0.0)  (29.4)  (23.5) 0 (0.0)
Vermont  0 (0.0) 0 (0.0) 0 (0.0)  (100.0) 0 (0.0) 0 (0.0)
Virginia   (25.0)  (26.4)  (20.3)  (12.7)  (15.6) 0 (0.0)
Washington   (10.9)  (21.2)  (17.0)  (15.8) 0 (12.1)  (23.0)
West Virginia   (14.3)  (14.3)  (28.6)  (28.6)  (14.3) 0 (0.0)
Wisconsin   (14.7)  (38.2)  (23.5)  (14.7)  (8.8) 0 (0.0)
Wyoming   (33.3)  (33.3) 0 (0.0) 0 (0.0) 0 (0.0)  (33.3)

United States 12,904 9,121 (70.7) 2,638 (20.4) 1,136 (8.8) 239
Alabama   (84.7) 0 (11.4)  (4.0) 
Alaska 0  (88.0)  (10.0)  (2.0) 
Arizona   (78.9)  (19.8)  (1.3) 
Arkansas   (75.9) 0 (12.0)  (9.6) 
California , , (71.7)  (19.9)  (8.4) 
Colorado 0  (54.4)  (28.2)  (17.5) 
Connecticut   (65.3)  (25.5)  (9.2) 
Delaware  0 (43.5)  (21.7)  (34.8) 
District of Columbia   (72.2)  (27.8) 0 (0.0) 0
Florida   (81.2)  (15.8)  (2.9) 
Georgia   (73.4)  (18.2)  (8.2) 
Hawaii  0 (82.3)  (11.3)  (6.5) 
Idaho   (100.0) 0 (0.0) 0 (0.0) 0
Illinois   (59.5)  (29.2)  (11.3) 
Indiana   (75.4) 0 (16.9)  (7.6) 
Iowa   (59.2) 0 (40.8) 0 (0.0) 0
Kansas   (64.9)  (26.3)  (8.8) 
Kentucky 0  (76.2)  (17.8)  (5.9) 
Louisiana   (83.3)  (13.7)  (3.1) 
Maine   (55.6)  (44.4) 0 (0.0) 0
Maryland   (66.9)  (24.1)  (9.0) 
Massachusetts   (61.7)  (19.5)  (18.8) 
Michigan   (60.6)  (23.9)  (13.3) 0
Minnesota   (53.1)  (37.0)  (10.0) 0
Mississippi   (81.4)  (12.7)  (5.9) 
Missouri 0  (71.0)  (21.5)  (7.5) 
Montana   (55.6)  (22.2)  (22.2) 0
Nebraska   (72.7)  (27.3) 0 (0.0) 0
Nevada 0  (74.5)  (17.6)  (7.8) 0
New Hampshire   (73.7)  (21.1)  (5.3) 0
New Jersey   (65.4) 0 (24.2)  (10.4) 
New Mexico 0  (60.0)  (26.7)  (13.3) 
New York ,00  (64.8)  (23.4)  (11.8) 
North Carolina  0 (68.7)  (19.7)  (11.6) 
North Dakota   (100.0) 0 (0.0) 0 (0.0) 0
Ohio   (68.5)  (25.4)  (6.1) 
Oklahoma 00  (75.0)  (14.0)  (11.0) 
Oregon   (72.0) 0 (13.3)  (14.7) 
Pennsylvania   (65.1)  (25.6)  (9.0) 
Rhode Island   (61.1)  (19.4)  (19.4) 
South Carolina   (60.6)  (22.3)  (17.0) 
South Dakota   (87.5) 0 (0.0)  (12.5) 
Tennessee  0 (73.4)  (16.7)  (9.9) 
Texas ,0 , (76.1)  (16.6) 0 (7.3) 
Utah   (66.7)  (25.9)  (7.4) 0
Vermont   (16.7)  (33.3)  (50.0) 
Virginia   (74.0)  (16.4)  (9.6) 
Washington   (54.4)  (30.3)  (15.4) 
West Virginia   (85.7)  (7.1)  (7.1) 0
Wisconsin   (63.2) 0 (29.4)  (7.4) 
Wyoming   (40.0)  (60.0) 0 (0.0) 0
American Samoa   (100.0) 0 (0.0) 0 (0.0) 0
Fed. States of Micronesia   (77.5)  (15.4)  (4.9) 
Guam 0  (85.6)  (8.9)  (5.6) 
Marshall Islands   (68.8)  (21.6)  (7.2) 
N. Mariana Islands   (94.1) 0 (0.0)  (5.9) 0
Puerto Rico   (85.3)  (13.7)  (1.1) 
Republic of Palau   (76.5)  (17.6) 0 (0.0) 0
U.S. Virgin Islands   (25.0)  (25.0)  (50.0) 0
Table 26. Tuberculosis Cases and Percentages by Pulmonary and Extrapulmonary Disease: 
Reporting Areas, 2008
Reporting Area
Total
Cases
Pulmonary Extrapulmonary
Pulmonary and
Extrapulmonary Cases
Total Miliary
No. No. No. No.(%) (%) (%)
Includes cases with pulmonary listed as major site of disease and no additional site of disease.
Includes cases with pleural, lymphatic, bone and/or joint, meningeal, peritoneal, genitourinary, or other site, excluding pulmonary, listed 
as major site of disease.
Includes miliary cases.
Not included in U.S. totals.
Note: 9 cases had missing and/or unknown site of disease.

U
ni
te
d 
St
at
es
2,
63
8
46
7
(1
7.
7)
1,
10
3
(4
1.
8)
29
7
(1
1.
3)
14
0
(5
.3
)
12
5
(4
.7
)
16
0
(6
.1
)
34
5
(1
3.
1)
A
la
ba
m
a
0

(2
5.
0)

(3
0.
0)

(5
.0
)

(1
0.
0)

(1
0.
0)

(5
.0
)

(1
5.
0)
A
la
sk
a


(2
0.
0)

(4
0.
0)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)

(4
0.
0)
A
riz
on
a


(2
0.
0)

(2
8.
9)

(1
1.
1)

(8
.9
)

(6
.7
)

(8
.9
)

(1
5.
6)
A
rk
an
sa
s
0

(5
0.
0)

(3
0.
0)

(1
0.
0)
0
(0
.0
)
0
(0
.0
)

(1
0.
0)
0
(0
.0
)
C
al
ifo
rn
ia


0
0
(1
8.
6)


(4
3.
8)

(9
.5
)

(5
.8
)

(4
.8
)

(4
.3
)

(1
3.
2)
C
ol
or
ad
o


(1
0.
3)
0
(3
4.
5)

(6
.9
)

(1
0.
3)

(6
.9
)
0
(0
.0
)

(3
1.
0)
C
on
ne
ct
ic
ut


(1
2.
0)

(6
4.
0)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)

(1
2.
0)

(1
2.
0)
D
el
aw
ar
e


(2
0.
0)

(6
0.
0)
0
(0
.0
)
0
(0
.0
)

(2
0.
0)
0
(0
.0
)
0
(0
.0
)
D
is
tri
ct
 o
f C
ol
um
bi
a


(2
6.
7)

(6
0.
0)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)

(1
3.
3)
0
(0
.0
)
Fl
or
id
a



(1
9.
2)

(3
6.
4)

(1
5.
2)

(1
.3
)

(5
.3
)

(9
.3
)
0
(1
3.
2)
G
eo
rg
ia


(2
0.
7)

(4
1.
4)

(5
.7
)

(2
.3
)

(6
.9
)

(6
.9
)

(1
6.
1)
H
aw
ai
i


(2
1.
4)

(3
5.
7)

(7
.1
)

(7
.1
)
0
(0
.0
)

(7
.1
)

(2
1.
4)
Ill
in
oi
s



(1
3.
1)
0
(3
6.
5)

(1
0.
9)

(8
.8
)

(5
.1
)

(1
0.
2)

(1
5.
3)
In
di
an
a
0

(2
5.
0)

(2
5.
0)

(1
5.
0)

(1
5.
0)
0
(0
.0
)

(5
.0
)

(1
5.
0)
Io
w
a
0

(3
0.
0)

(3
0.
0)

(1
5.
0)

(1
0.
0)
0
(0
.0
)
0
(0
.0
)

(1
5.
0)
K
an
sa
s


(1
3.
3)

(4
0.
0)
0
(0
.0
)

(6
.7
)

(6
.7
)

(2
0.
0)

(1
3.
3)
K
en
tu
ck
y


(2
2.
2)

(3
8.
9)

(1
1.
1)

(5
.6
)

(5
.6
)

(5
.6
)

(1
1.
1)
Lo
ui
si
an
a

0
(3
2.
3)

(2
2.
6)

(6
.5
)

(1
2.
9)
0
(0
.0
)
0
(0
.0
)

(2
5.
8)
M
ai
ne

0
(0
.0
)

(5
0.
0)
0
(0
.0
)

(2
5.
0)

(2
5.
0)
0
(0
.0
)
0
(0
.0
)
M
ar
yl
an
d


(2
3.
9)

(3
5.
8)

(1
7.
9)

(3
.0
)

(3
.0
)

(3
.0
)

(1
3.
4)
M
as
sa
ch
us
et
ts


(1
3.
7)
0
(3
9.
2)

(9
.8
)

(7
.8
)
0
(0
.0
)

(1
3.
7)

(1
5.
7)
M
ic
hi
ga
n


(8
.9
)

(3
5.
6)

(8
.9
)

(4
.4
)

(4
.4
)

(8
.9
)

(2
8.
9)
M
in
ne
so
ta


(7
.7
)

(5
7.
7)

(6
.4
)

(6
.4
)

(1
.3
)

(7
.7
)
0
(1
2.
8)
M
is
si
ss
ip
pi


(2
6.
7)

(2
0.
0)

(2
0.
0)
0
(0
.0
)
0
(0
.0
)

(6
.7
)

(2
6.
7)
M
is
so
ur
i


(1
3.
0)

(5
6.
5)

(8
.7
)

(4
.3
)
0
(0
.0
)

(8
.7
)

(8
.7
)
M
on
ta
na

0
(0
.0
)
0
(0
.0
)

(5
0.
0)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)

(5
0.
0)
N
eb
ra
sk
a


(2
2.
2)

(3
3.
3)
0
(0
.0
)

(2
2.
2)
0
(0
.0
)
0
(0
.0
)

(2
2.
2)
N
ev
ad
a


(1
1.
1)

(2
7.
8)

(2
7.
8)

(5
.6
)

(5
.6
)

(1
6.
7)

(5
.6
)
N
ew
 H
am
ps
hi
re


(2
5.
0)

(5
0.
0)

(2
5.
0)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
N
ew
 J
er
se
y
0

0
(9
.8
)

(5
1.
0)

(2
0.
6)

(3
.9
)

(3
.9
)

(3
.9
)

(6
.9
)
Ta
bl
e 
27
. E
xt
ra
pu
lm
on
ar
y 
Tu
be
rc
ul
os
is
 C
as
es
 a
nd
 P
er
ce
nt
ag
es
 b
y 
Si
te
 o
f D
is
ea
se
: R
ep
or
tin
g 
A
re
as
, 2
00
8
To
ta
l
E
xt
ra
pu
lm
on
ar
y
C
as
es
O
th
er
P
le
ur
al
Ly
m
ph
at
ic
B
on
e 
an
d/
or
 J
oi
nt
G
en
ito
ur
in
ar
y
M
en
in
ge
al
P
er
ito
ne
al
N
o.
N
o.
N
o.
N
o.
N
o.
N
o.
N
o.
(%
)
(%
)
(%
)
(%
)
(%
)
(%
)
(%
)
S
ite
 o
f D
is
ea
se
R
ep
or
tin
g 
A
re
a

O
th
er
N
ew
 M
ex
ic
o


(1
2.
5)

(1
8.
8)

(2
5.
0)

(1
2.
5)

(1
2.
5)

(6
.3
)

(1
2.
5)
N
ew
 Y
or
k



(1
4.
6)


(4
5.
9)

(1
5.
3)

(5
.3
)

(5
.3
)
0
(3
.6
)

(1
0.
0)
N
or
th
 C
ar
ol
in
a


(1
9.
7)

(3
6.
4)

(1
6.
7)

(3
.0
)

(6
.1
)

(1
.5
)

(1
6.
7)
O
hi
o


(1
3.
0)

(4
4.
4)

(1
3.
0)

(3
.7
)

(7
.4
)

(9
.3
)

(9
.3
)
O
kl
ah
om
a


(2
1.
4)

(6
4.
3)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)

(1
4.
3)
O
re
go
n
0

(3
0.
0)

(4
0.
0)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)

(3
0.
0)
P
en
ny
sl
va
ni
a


(1
6.
2)

(4
9.
5)

(7
.1
)

(4
.0
)

(4
.0
)

(1
2.
1)

(7
.1
)
R
ho
de
 Is
la
nd

0
(0
.0
)

(4
2.
9)

(2
8.
6)

(1
4.
3)
0
(0
.0
)
0
(0
.0
)

(1
4.
3)
S
ou
th
 C
ar
ol
in
a


(2
1.
4)

(3
5.
7)

(1
1.
9)

(9
.5
)

(4
.8
)

(2
.4
)

(1
4.
3)
Te
nn
es
se
e


(1
7.
0)

(4
6.
8)

(8
.5
)

(4
.3
)

(6
.4
)

(4
.3
)

(1
2.
8)
Te
xa
s



(2
6.
9)
0
(3
6.
1)

(9
.6
)
0
(4
.0
)

(7
.2
)

(6
.8
)

(9
.2
)
U
ta
h

0
(0
.0
)

(4
2.
9)
0
(0
.0
)

(1
4.
3)

(1
4.
3)
0
(0
.0
)

(2
8.
6)
Ve
rm
on
t

0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)

(5
0.
0)
0
(0
.0
)

(5
0.
0)
V
irg
in
ia


(1
0.
4)

(5
8.
3)

(6
.3
)

(2
.1
)
0
(0
.0
)

(8
.3
)

(1
4.
6)
W
as
hi
ng
to
n

0
(1
4.
5)
0
(4
3.
5)
0
(1
4.
5)

(7
.2
)

(2
.9
)

(1
.4
)

(1
5.
9)
W
es
t V
irg
in
ia

0
(0
.0
)

(5
0.
0)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)

(5
0.
0)
0
(0
.0
)
W
is
co
ns
in
0

(1
0.
0)
0
(5
0.
0)

(1
5.
0)

(5
.0
)

(5
.0
)

(1
0.
0)
0
(0
.0
)
W
yo
m
in
g

0
(0
.0
)
0
(0
.0
)

(3
3.
3)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)

(6
6.
7)
A
m
er
ic
an
 S
am
oa

...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
Fe
d.
 S
ta
te
s 
of
 M
ic
ro
ne
si
a


(1
7.
9)

(5
7.
1)

(7
.1
)
0
(0
.0
)
0
(0
.0
)

(1
4.
3)

(3
.6
)
G
ua
m


0
(0
.0
)

(5
0.
0)

(3
7.
5)
0
(0
.0
)

(1
2.
5)
0
(0
.0
)
0
(0
.0
)
M
ar
sh
al
l I
sl
an
ds



(4
0.
7)

(4
4.
4)
0
(0
.0
)
0
(0
.0
)

(3
.7
)

(1
1.
1)
0
(0
.0
)
N
. M
ar
ia
na
 Is
la
nd
s
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
P
ue
rto
 R
ic
o


(3
0.
8)

(7
.7
)

(7
.7
)

(1
5.
4)

(7
.7
)

(1
5.
4)

(1
5.
4)
R
ep
ub
lic
 o
f P
al
au



(6
6.
7)

(3
3.
3)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
U
.S
. V
irg
in
 Is
la
nd
s


(1
00
.0
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
Ta
bl
e 
27
. (
C
on
t’d
) E
xt
ra
pu
lm
on
ar
y 
Tu
be
rc
ul
os
is
 C
as
es
 a
nd
 P
er
ce
nt
ag
es
 b
y 
Si
te
 o
f D
is
ea
se
: R
ep
or
tin
g 
A
re
as
, 2
00
8
 N
ot
 in
cl
ud
ed
 in
 U
.S
. t
ot
al
s.
 
N
ot
e:
 E
lli
ps
es
 in
di
ca
te
 d
at
a 
no
t a
va
ila
bl
e.
S
ee
 T
ec
hn
ic
al
 N
ot
es
 (p
ag
e 
9)
.
To
ta
l
E
xt
ra
pu
lm
on
ar
y
C
as
es
P
le
ur
al
Ly
m
ph
at
ic
B
on
e 
an
d/
or
 J
oi
nt
G
en
ito
ur
in
ar
y
M
en
in
ge
al
P
er
ito
ne
al
N
o.
N
o.
N
o.
N
o.
N
o .
N
o.
N
o.
(%
)
(%
)
(%
)
(%
)
(%
)
(%
)
(%
)
S
ite
 o
f D
is
ea
se
R
ep
or
tin
g 
A
re
a
0
>= 500 cases in 2008
California  .  . -. -. 
Texas 0 . 0 . -0. -. 
New York 00 .  .0 . . 
Florida  .  . -. -. 
100 - 499 cases in 2008
Georgia  .  .0 . -0. 
Illinois  . 0 . -. -0. 0
New Jersey  .  . -. -. 
Pennsylvania  .  . 0. . 
North Carolina  .  . -. -. 
Virginia  . 0 .0 -. -. 
Tennessee  .  . 0.0 . 
Maryland  .  . . . 0
Massachusetts  .0  . . .0 
Washington  .  . -. -. 
Louisiana  .  .0 . . 
Arizona  . 0 . -. -. 
Ohio  .  . -. -. 
Minnesota  .0  . -. -.0 
South Carolina  .  . -. -. 
Michigan  .  . -. -. 
Alabama  .  . 0.0 -0. 
Hawaii  .  . . 0. 
Mississippi  .0  . -. -.0 
Indiana  .  .0 -. -. 
Missouri 0 .  .0 -. -. 0
Colorado 0 .  . -. -.0 
Nevada 0 . 0 .0 0.0 -. 
Kentucky 0 . 0 . -. -. 
Oklahoma 00 .  . -. -. 
< 100 cases in 2008
Connecticut  . 0 . -. -. 
Arkansas  . 0 . -. -. 
Oregon  .0  . -0. -. 
Wisconsin  . 0 . -. -. 
New Mexico 0 .0  . . . 
Kansas  .0  . -. -. 
District of Columbia  .  0.0 -. -. 
Alaska 0 . 0 . 0.0 -0. 
Iowa  .  . .0 . 
Rhode Island  .  . -0.0 -. 
Nebraska  .  . .0 .0 
West Virginia  .  . . . 
Utah  .0  . -0. -. 
Delaware  .  . . . 0
New Hampshire  .  0. . . 
South Dakota  .0  . . . 
Idaho  0.  0. . 0.0 
Montana  0.  . -. -. 
Maine  0.  . -. -. 0
Vermont  .0  0. 00.0 . 
Wyoming  0.  0. 0.0 . 
North Dakota  0.  . -. -. 
Total 12904 4.2 13288 4.4 -2.9 -3.8
Table 28.  Tuberculosis Cases and Case Rates per 100,000 Population, Ranked and 
Grouped by Number of Cases: States and the District of Columbia, 2008 and 2007
State
00 00 2007–2008 % Change
No. Rate No. No.
Overall 
Rank by 
00 RateRate Rate
Includes New York City.
Note: Denominators for computing 2007 and 2008 rates for states and the District of Columbia were obtained from Annual 
Estimates of the Population for the United States and States, and for Puerto Rico: April 1, 2000–July 1, 2008 (NST-EST2008-01)  
(http://www.census.gov/popest/states/tables/NST-EST2008-01.xls) (accessed June 26, 2009).
See Table 20 for ranking of states without the District of Columbia.

Morbidity Tables
Reporting Areas, 2008 and 2006


United States 12,117 12,101 (99.9) 498 (4.1)
Alabama   (99.4)  (3.6)
Alaska   (100.0)  (2.2)
Arizona   (100.0) 0 (25.3)
Arkansas   (100.0)  (5.3)
California ,0 , (99.9)  (3.4)
Colorado   (100.0)  (4.3)
Connecticut   (100.0) 0 (0.0)
Delaware   (100.0) 0 (0.0)
District of Columbia   (100.0)  (2.0)
Florida 0 0 (100.0)  (3.2)
Georgia   (99.5)  (6.5)
Hawaii   (100.0)  (1.6)
Idaho   (100.0)  (11.1)
Illinois   (99.6)  (1.3)
Indiana 0 0 (100.0)  (1.8)
Iowa   (100.0) 0 (0.0)
Kansas   (100.0) 0 (0.0)
Kentucky   (100.0)  (3.1)
Louisiana   (99.6)  (5.9)
Maine   (100.0) 0 (0.0)
Maryland   (100.0)  (1.1)
Massachusetts   (100.0)  (1.9)
Michigan   (97.2)  (2.8)
Minnesota 0 0 (100.0)  (2.8)
Mississippi 0 0 (100.0)  (3.7)
Missouri 0 0 (100.0)  (1.0)
Montana   (100.0) 0 (0.0)
Nebraska   (100.0) 0 (0.0)
Nevada 0 0 (100.0)  (2.2)
New Hampshire   (100.0)  (5.3)
New Jersey   (100.0)  (0.5)
New Mexico   (100.0)  (5.2)
New York State   (100.0)  (1.0)
New York City 0 0 (100.0)  (0.7)
North Carolina 0 0 (100.0)  (3.6)
North Dakota   (100.0) 0 (0.0)
Ohio   (100.0)  (3.1)
Oklahoma   (97.7)  (5.9)
Oregon   (100.0)  (4.2)
Pennsylvania   (100.0) 0 (3.0)
Rhode Island   (100.0) 0 (0.0)
South Carolina   (100.0)  (1.2)
South Dakota   (100.0) 0 (0.0)
Tennessee   (100.0)  (5.2)
Texas ,0 ,0 (100.0)  (11.3)
Utah   (100.0) 0 (0.0)
Vermont   (100.0) 0 (0.0)
Virginia   (100.0)  (1.4)
Washington 0 0 (99.5)  (3.9)
West Virginia   (100.0) 0 (0.0)
Wisconsin   (100.0)  (1.5)
Wyoming   (100.0) 0 (0.0)
American Samoa   (66.7) ... ...
Fed. States of Micronesia   (97.9) 0 (0.0)
Guam   (100.0)  (3.1)
Marshall Islands 0 0 (100.0)  (2.0)
N. Mariana Islands   (100.0) 0 (0.0)
Puerto Rico   (100.0)  (3.2)
Republic of Palau   (92.9) 0 (0.0)
U.S. Virgin Islands   (100.0) 0 (0.0)
Table 29. Tuberculosis Cases and Percentages by Residence in Correctional Facilities, 
Age > 15: Reporting Areas, 2008
Reporting Area
Total 
Cases
Cases with Information on Residence
 in Correctional Facilities
Cases Reported As Residents
 of Correctional Facilities
No. No.(%) (%)
Resident of correctional facility at time of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the Dis-
trict of Columbia). Counts and percentages shown only for reporting areas with information reported for >% of cases.
Excludes New York City.
Not included in U.S. totals.
Note: Ellipses indicate data not available.

United States 12,117 12,008 (99.1) 680 (5.7)
Alabama   (100.0)  (4.2)
Alaska   (97.8)  (24.4)
Arizona   (88.9)  (8.0)
Arkansas   (100.0)  (5.3)
California ,0 , (99.5) 0 (6.3)
Colorado   (100.0)  (6.5)
Connecticut   (100.0)  (2.1)
Delaware   (100.0) 0 (0.0)
District of Columbia   (100.0)  (9.8)
Florida 0 0 (99.6)  (7.2)
Georgia   (98.4)  (11.4)
Hawaii   (100.0)  (0.8)
Idaho   (100.0) 0 (0.0)
Illinois  0 (96.7)  (3.9)
Indiana 0 0 (99.1)  (7.4)
Iowa   (100.0)  (4.2)
Kansas   (100.0)  (4.2)
Kentucky   (100.0)  (5.2)
Louisiana   (99.6)  (11.3)
Maine   (100.0)  (11.1)
Maryland   (100.0)  (3.4)
Massachusetts   (99.6)  (3.1)
Michigan   (95.6)  (6.9)
Minnesota 0 0 (100.0)  (6.1)
Mississippi 0 0 (100.0)  (13.8)
Missouri 0 0 (100.0)  (6.7)
Montana   (100.0) 0 (0.0)
Nebraska   (100.0)  (3.6)
Nevada 0 0 (100.0)  (7.8)
New Hampshire   (100.0) 0 (0.0)
New Jersey   (100.0)  (3.4)
New Mexico   (100.0)  (6.9)
New York State   (98.6)  (2.8)
New York City 0 0 (97.7)  (4.2)
North Carolina 0 0 (100.0)  (5.2)
North Dakota   (100.0) 0 (0.0)
Ohio   (99.5)  (5.8)
Oklahoma   (96.6)  (9.5)
Oregon   (100.0)  (9.7)
Pennsylvania   (98.5)  (1.5)
Rhode Island   (100.0) 0 (0.0)
South Carolina   (100.0)  (6.5)
South Dakota   (100.0) 0 (0.0)
Tennessee   (100.0)  (6.7)
Texas ,0 ,0 (100.0)  (4.6)
Utah   (100.0) 0 (0.0)
Vermont   (100.0) 0 (0.0)
Virginia   (100.0)  (1.4)
Washington 0 0 (99.5)  (7.8)
West Virginia   (100.0)  (7.4)
Wisconsin   (97.0)  (1.6)
Wyoming   (100.0) 0 (0.0)
American Samoa   (33.3) ... ...
Fed. States of Micronesia   (91.7) 0 (0.0)
Guam   (100.0) 0 (0.0)
Marshall Islands 0  (96.1)  (2.0)
N. Mariana Islands   (97.1) 0 (0.0)
Puerto Rico   (100.0)  (5.4)
Republic of Palau   (92.9) 0 (0.0)
U.S. Virgin Islands   (100.0) 0 (0.0)
Reporting Area
Total 
Cases
Cases with Information
on Homeless Status
Cases Reported As
Being Homeless 
No. No.(%) (%)
Table 30. Tuberculosis Cases and Percentages by Homeless Status,1 Age >15: Reporting 
Areas, 2008
Homeless within past 12 months of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the District of 
Columbia). Counts and percentages shown only for reporting areas with information reported for >% of cases.
Excludes New York City.
Not included in U.S. totals. 
Note: Ellipses indicate data not available.

United States 12,117 12,101 (99.9) 257 (2.1)
Alabama   (99.4)  (2.4)
Alaska   (100.0) 0 (0.0)
Arizona   (100.0)  (3.0)
Arkansas   (100.0)  (6.6)
California ,0 ,0 (100.0)  (2.2)
Colorado   (100.0)  (2.2)
Connecticut   (100.0)  (5.2)
Delaware   (100.0) 0 (0.0)
District of Columbia   (100.0) 0 (0.0)
Florida 0 0 (100.0)  (0.7)
Georgia   (99.8)  (1.8)
Hawaii   (100.0) 0 (0.0)
Idaho   (100.0)  (11.1)
Illinois   (99.6)  (3.1)
Indiana 0 0 (100.0)  (0.9)
Iowa   (100.0)  (4.2)
Kansas   (100.0)  (2.1)
Kentucky   (100.0)  (2.1)
Louisiana   (99.6)  (5.0)
Maine   (100.0) 0 (0.0)
Maryland   (100.0) 0 (3.8)
Massachusetts   (100.0)  (1.6)
Michigan   (95.6)  (6.4)
Minnesota 0 0 (100.0)  (1.7)
Mississippi 0 0 (100.0)  (4.6)
Missouri 0 0 (100.0)  (1.9)
Montana   (100.0)  (12.5)
Nebraska   (100.0) 0 (0.0)
Nevada 0 0 (100.0)  (1.1)
New Hampshire   (100.0) 0 (0.0)
New Jersey   (100.0)  (1.5)
New Mexico   (100.0)  (1.7)
New York State   (100.0)  (2.1)
New York City 0 0 (100.0)  (0.2)
North Carolina 0 0 (100.0)  (1.9)
North Dakota   (100.0) 0 (0.0)
Ohio   (100.0)  (4.2)
Oklahoma   (97.7)  (5.9)
Oregon   (100.0) 0 (0.0)
Pennsylvania   (100.0)  (3.9)
Rhode Island   (100.0)  (3.1)
South Carolina   (100.0)  (2.4)
South Dakota   (100.0)  (25.0)
Tennessee   (100.0)  (4.9)
Texas ,0 ,0 (100.0)  (1.0)
Utah   (100.0) 0 (0.0)
Vermont   (100.0) 0 (0.0)
Virginia   (100.0)  (1.8)
Washington 0 0 (99.5)  (2.5)
West Virginia   (100.0)  (7.4)
Wisconsin   (100.0)  (3.0)
Wyoming   (100.0) 0 (0.0)
American Samoa   (66.7) ... ...
Fed. States of Micronesia   (97.2)  (7.8)
Guam   (100.0) 0 (0.0)
Marshall Islands 0 0 (100.0) 0 (0.0)
N. Mariana Islands   (100.0) 0 (0.0)
Puerto Rico   (100.0) 0 (0.0)
Republic of Palau   (92.9) 0 (0.0)
U.S. Virgin Islands   (100.0) 0 (0.0)
Reporting Area
Total 
Cases
Cases with Information on
Residence in Long-term Care Facilities
Cases Reported As Residents of
Long-term Care Facilities
No. No.(%) (%)
Table 31. Tuberculosis Cases and Percentages by Residence in Long-term Care Facilities,1 
Age >15: Reporting Areas, 2008
Resident of long-term care facility at time of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the 
District of Columbia). Counts and percentages shown only for reporting areas with information reported for >% of cases.
Excludes New York City.
Not included in U.S. totals. 
Note: Ellipses indicate data not available.

United States 12,117 11,821 (97.6) 212 (1.8)
Alabama   (99.4)  (0.6)
Alaska   (93.5)  (2.3)
Arizona   (84.3)  (3.6)
Arkansas   (100.0) 0 (0.0)
California ,0 , (97.7)  (1.5)
Colorado   (100.0)  (3.2)
Connecticut   (99.0) 0 (0.0)
Delaware   (100.0) 0 (0.0)
District of Columbia   (100.0) 0 (0.0)
Florida 0 00 (99.2)  (1.8)
Georgia   (98.2)  (2.1)
Hawaii   (44.3) ... ...
Idaho   (88.9) 0 (0.0)
Illinois   (92.7) 0 (2.4)
Indiana 0 0 (99.1)  (1.9)
Iowa   (100.0) 0 (0.0)
Kansas   (100.0) 0 (0.0)
Kentucky   (100.0) 0 (0.0)
Louisiana   (95.5)  (6.6)
Maine   (100.0) 0 (0.0)
Maryland   (99.2)  (2.3)
Massachusetts   (98.4)  (0.8)
Michigan   (95.6)  (4.6)
Minnesota 0 0 (100.0)  (1.7)
Mississippi 0 0 (100.0) 0 (0.0)
Missouri 0 0 (100.0) 0 (0.0)
Montana   (100.0) 0 (0.0)
Nebraska   (100.0) 0 (0.0)
Nevada 0  (98.9)  (1.1)
New Hampshire   (94.7) 0 (0.0)
New Jersey   (100.0)  (1.5)
New Mexico   (100.0) 0 (0.0)
New York State   (98.6)  (0.4)
New York City 0  (97.6)  (1.5)
North Carolina 0 0 (100.0)  (0.6)
North Dakota   (100.0) 0 (0.0)
Ohio   (99.5)  (1.6)
Oklahoma   (88.5)  (5.2)
Oregon   (100.0)  (4.2)
Pennsylvania   (97.6)  (0.9)
Rhode Island   (100.0) 0 (0.0)
South Carolina   (98.2)  (0.6)
South Dakota   (100.0) 0 (0.0)
Tennessee   (100.0)  (3.0)
Texas ,0 ,0 (100.0)  (3.3)
Utah   (100.0) 0 (0.0)
Vermont   (100.0) 0 (0.0)
Virginia   (100.0) 0 (0.0)
Washington 0  (97.1)  (1.0)
West Virginia   (100.0) 0 (0.0)
Wisconsin   (92.4)  (1.6)
Wyoming   (100.0) 0 (0.0)
Amercian Samoa   (66.7) ... ...
Fed. States of Micronesia   (91.0) 0 (0.0)
Guam   (98.5) 0 (0.0)
Marshall Islands 0 00 (98.0) 0 (0.0)
N. Mariana Islands   (100.0) 0 (0.0)
Puerto Rico   (100.0)  (16.1)
Republic of Palau   (92.9) 0 (0.0)
U.S. Virgin Islands   (100.0) 0 (0.0)
Reporting Area
Total 
Cases
Cases with Information on
Injecting Drug Use
Cases Reporting Injecting Drug Use
No. No.(%) (%)
Table 32. Tuberculosis Cases and Percentages by Injecting Drug Use,1 Age >15: 
Reporting Areas, 2008
Injecting drug use within past 12 months of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the 
District of Columbia). Counts and percentages shown only for reporting areas with information reported for >% of cases.
Excludes New York City.
Not included in U.S. totals. 
Note: Ellipses indicate data not available.

United States 12,117 11,792 (97.3) 858 (7.3)
Alabama   (98.8)  (11.4)
Alaska   (93.5)  (9.3)
Arizona   (83.8)  (7.2)
Arkansas   (100.0) 0 (0.0)
California ,0 , (97.4)  (7.1)
Colorado   (97.8)  (9.9)
Connecticut   (99.0)  (2.1)
Delaware   (100.0)  (4.8)
District of Columbia   (100.0)  (2.0)
Florida 0 0 (99.3) 0 (11.2)
Georgia   (98.2)  (12.1)
Hawaii   (43.4) ... ...
Idaho   (88.9) 0 (0.0)
Illinois   (91.2)  (6.5)
Indiana 0 0 (100.0)  (11.9)
Iowa   (100.0)  (4.2)
Kansas   (97.9)  (6.4)
Kentucky   (100.0)  (5.2)
Louisiana   (96.0)  (13.6)
Maine   (100.0) 0 (0.0)
Maryland   (98.9)  (3.4)
Massachusetts   (99.2)  (2.7)
Michigan   (93.4)  (8.3)
Minnesota 0 0 (100.0)  (4.4)
Mississippi 0 0 (100.0)  (11.0)
Missouri 0 0 (100.0)  (4.8)
Montana   (100.0) 0 (0.0)
Nebraska   (100.0)  (3.6)
Nevada 0  (98.9)  (7.9)
New Hampshire   (94.7) 0 (0.0)
New Jersey   (100.0)  (3.9)
New Mexico   (100.0)  (1.7)
New York State   (97.9)  (2.1)
New York City 0  (97.1)  (6.0)
North Carolina 0 0 (100.0)  (14.3)
North Dakota   (100.0) 0 (0.0)
Ohio  0 (99.0)  (7.4)
Oklahoma   (88.5) 0 (13.0)
Oregon   (100.0)  (9.7)
Pennsylvania   (97.6)  (7.4)
Rhode Island   (100.0) 0 (0.0)
South Carolina   (98.2)  (10.8)
South Dakota   (100.0) 0 (0.0)
Tennessee   (99.6)  (11.7)
Texas ,0 ,0 (100.0)  (6.6)
Utah   (100.0) 0 (0.0)
Vermont   (100.0)  (16.7)
Virginia   (100.0)  (2.1)
Washington 0  (97.1)  (6.5)
West Virginia   (100.0)  (14.8)
Wisconsin   (92.4)  (1.6)
Wyoming   (100.0) 0 (0.0)
American Samoa   (66.7) ... ...
Fed. States of Micronesia   (92.4)  (3.7)
Guam   (89.2) 0 (0.0)
Marshall Islands 0  (93.1) 0 (0.0)
N. Mariana Islands   (100.0) 0 (0.0)
Puerto Rico   (100.0)  (22.6)
Republic of Palau   (85.7)  (8.3)
U.S. Virgin Islands   (100.0) 0 (0.0)
Reporting Area
Total 
Cases
Cases with Information on
Noninjecting Drug Use
Cases Reporting Noninjecting Drug Use
No. No.(%) (%)
Table 33. Tuberculosis Cases and Percentages by Noninjecting Drug Use,1 Age >15: 
Reporting Areas, 2008
Noninjecting drug use within past 12 months of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and 
the District of Columbia). Counts and percentages shown only for reporting areas with information reported for >% of cases.
Excludes New York City.
Not included in U.S. totals. 
Note: Ellipses indicate data not available.

United States 12,117 11,845 (97.8) 1,557 (13.1)
Alabama   (99.4)  (18.6)
Alaska   (89.1)  (39.0)
Arizona   (84.8)  (16.7)
Arkansas   (100.0)  (3.9)
California ,0 , (97.9)  (10.3)
Colorado   (98.9)  (13.0)
Connecticut   (99.0)  (4.2)
Delaware   (100.0)  (4.8)
District of Columbia   (100.0)  (5.9)
Florida 0 00 (99.2)  (18.1)
Georgia   (98.2) 00 (23.4)
Hawaii   (75.4)  (8.7)
Idaho   (88.9)  (12.5)
Illinois   (91.0)  (9.4)
Indiana 0 0 (99.1)  (25.0)
Iowa   (100.0)  (12.5)
Kansas   (100.0)  (10.4)
Kentucky   (99.0)  (16.8)
Louisiana   (96.0)  (28.5)
Maine   (100.0) 0 (0.0)
Maryland   (98.9)  (8.4)
Massachusetts   (98.8)  (7.1)
Michigan   (92.8)  (19.0)
Minnesota 0 0 (100.0)  (7.8)
Mississippi 0 0 (100.0)  (17.4)
Missouri 0 0 (100.0)  (8.7)
Montana   (100.0)  (50.0)
Nebraska   (100.0)  (14.3)
Nevada 0 0 (100.0)  (14.4)
New Hampshire   (94.7)  (5.6)
New Jersey   (100.0) 0 (7.3)
New Mexico   (100.0)  (12.1)
New York State   (97.9)  (6.4)
New York City 0  (97.5) 0 (13.0)
North Carolina 0 0 (100.0) 0 (13.0)
North Dakota   (100.0)  (33.3)
Ohio  0 (99.0) 0 (10.5)
Oklahoma   (88.5)  (16.9)
Oregon   (100.0)  (11.1)
Pennsylvania   (97.6)  (8.3)
Rhode Island   (96.9)  (3.2)
South Carolina   (98.8)  (26.3)
South Dakota   (100.0) 0 (0.0)
Tennessee   (99.6)  (18.4)
Texas ,0 ,0 (100.0)  (15.2)
Utah   (100.0)  (3.8)
Vermont   (100.0)  (16.7)
Virginia   (100.0)  (6.7)
Washington 0 00 (97.6)  (11.5)
West Virginia   (100.0)  (22.2)
Wisconsin   (92.4)  (13.1)
Wyoming   (100.0) 0 (0.0)
American Samoa   (66.7) ... ...
Fed. States of Micronesia   (88.3)  (2.3)
Guam   (100.0) 0 (0.0)
Marshall Islands 0  (86.3)  (17.0)
N. Mariana Islands   (91.2) 0 (0.0)
Puerto Rico   (100.0)  (12.9)
Republic of Palau   (85.7)  (16.7)
U.S. Virgin Islands   (100.0)  (25.0)
Reporting Area
Total 
Cases
Cases with Information on
Excess Alcohol Use
Cases Reporting
Excess Alcohol Use
No. No.(%) (%)
Table 34. Tuberculosis Cases and Percentages by Excess Alcohol Use,1 Age >15: 
Reporting Areas, 2008
Excess alcohol use within past 12 months of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the 
District of Columbia). Counts and percentages shown only for reporting areas with information reported for >% of cases.
Excludes New York City.
Not included in U.S. totals. 
Note: Ellipses indicate data not available.

United States 12,904 12,650 12,616 (99.7) (0.9) (3.5) (83.3) (83.2)
Alabama    (100.0) (0.0) (6.0) (86.1) (86.1)
Alaska 0 0  (98.0) (2.0) (6.1) (89.8) (89.8)
Arizona    (100.0) (2.2) (5.3) (63.1) (62.7)
Arkansas    (100.0) (16.9) (18.2) (50.6) (50.6)
California , , , (99.9) (0.4) (2.1) (88.7) (88.7)
Colorado 0 0 0 (100.0) (1.0) (0.0) (85.1) (85.1)
Connecticut    (100.0) (1.0) (4.1) (87.6) (86.6)
Delaware    (100.0) (0.0) (8.7) (91.3) (91.3)
District of Columbia    (98.1) (0.0) (1.9) (98.1) (98.1)
Florida  0 0 (100.0) (0.4) (4.6) (87.3) (87.3)
Georgia    (100.0) (0.0) (5.6) (58.5) (58.1)
Hawaii    (100.0) (2.4) (4.8) (77.4) (77.4)
Idaho    (100.0) (0.0) (9.1) (90.9) (90.9)
Illinois    (100.0) (0.4) (3.2) (79.7) (79.7)
Indiana    (100.0) (1.7) (7.8) (85.3) (85.3)
Iowa    (100.0) (0.0) (4.2) (91.7) (91.7)
Kansas    (100.0) (0.0) (15.8) (77.2) (77.2)
Kentucky 0   (100.0) (2.0) (2.0) (61.2) (61.2)
Louisiana  0 0 (100.0) (0.5) (2.3) (93.6) (93.6)
Maine    (100.0) (0.0) (0.0) (100.0) (100.0)
Maryland    (100.0) (1.8) (2.6) (90.1) (89.7)
Massachusetts    (98.4) (0.4) (0.8) (84.1) (84.1)
Michigan    (100.0) (3.4) (7.9) (61.2) (61.2)
Minnesota  0 0 (100.0) (1.0) (2.9) (88.6) (88.6)
Mississippi    (100.0) (1.8) (9.0) (75.7) (75.7)
Missouri 0 0 0 (100.0) (0.0) (4.7) (67.0) (67.0)
Montana    (100.0) (0.0) (0.0) (87.5) (87.5)
Nebraska    (100.0) (0.0) (15.2) (78.8) (78.8)
Nevada 0 0 0 (100.0) (0.0) (0.0) (100.0) (100.0)
New Hampshire    (100.0) (0.0) (15.8) (73.7) (68.4)
New Jersey    (100.0) (1.2) (2.6) (85.9) (85.9)
New  Mexico 0   (100.0) (0.0) (0.0) (91.2) (91.2)
New York State 0   (100.0) (0.3) (2.3) (87.6) (87.6)
New York City  0 0 (100.0) (0.6) (2.4) (87.3) (87.3)
North Carolina    (100.0) (0.3) (2.8) (89.9) (89.9)
North Dakota    (100.0) (0.0) (0.0) (100.0) (100.0)
Ohio  0 0 (100.0) (1.4) (6.7) (85.6) (85.6)
Oklahoma 00   (97.9) (5.3) (15.8) (68.4) (68.4)
Oregon    (100.0) (1.4) (2.7) (90.5) (90.5)
Pennsylvania    (99.7) (1.3) (2.1) (46.3) (46.3)
Rhode Island    (100.0) (2.8) (0.0) (86.1) (86.1)
South Carolina  0 0 (100.0) (1.7) (6.7) (84.4) (84.4)
South Dakota    (100.0) (0.0) (43.8) (50.0) (50.0)
Tennessee    (100.0) (0.0) (3.6) (65.3) (65.3)
Texas ,0 , , (98.6) (1.3) (2.6) (89.6) (89.6)
Utah    (100.0) (0.0) (3.8) (92.3) (92.3)
Vermont    (100.0) (0.0) (0.0) (80.0) (80.0)
Virginia    (99.3) (0.3) (3.8) (88.6) (88.6)
Washington    (100.0) (0.9) (2.2) (88.5) (88.5)
West Virginia    (100.0) (0.0) (3.8) (92.3) (92.3)
Wisconsin    (100.0) (0.0) (2.9) (85.3) (85.3)
Wyoming    (100.0) (0.0) (20.0) (80.0) (80.0)
American Samoa    (100.0) (0.0) (0.0) (100.0) (100.0)
Fed. States of Micronesia    (97.2) (0.0) (9.1) (69.3) (69.3)
Guam 0 0 0 (100.0) (0.0) (18.9) (76.7) (76.7)
Marshall Islands   0 (99.2) (0.0) (5.0) (94.2) (94.2)
N. Mariana Islands    (100.0) (0.0) (0.0) (100.0) (100.0)
Puerto Rico    (100.0) (0.0) (1.2) (96.5) (96.5)
Republic of Palau    (94.1) (0.0) (12.5) (81.3) (81.3)
U.S. Virgin Islands    (100.0) (0.0) (0.0) (100.0) (100.0)
Table 35. Tuberculosis Cases and Percentages by Initial Drug Regimen: 
Reporting Areas, 2008
Overall U.S. percentage based on 52 reporting areas (50 states, New York City, and the District of Columbia). Counts and percentages 
shown only for reporting areas with information reported for >% of cases.
I=isoniazid; R=rifampin; Z=pyrazinamide; E=ethambutol; S=streptomycin.
 Streptomycin is no longer considered a first-line drug.  CDC.  Treatment of Tuberculosis. American Thoracic Society, CDC, and Infec-
tious Diseases Society of America.  MMWR 2003;52(No.RR-11): 1–77.
Excludes New York City.
Not included in U.S. totals. 
Note: Excluding cases with no information on drug regimen, 140 (1.11%) persons were not started on any drugs, 20 (0.16%) were 
started on one drug, and 1,392 (11.03%) had an initial multidrug regimen other than IR, IRZ, or IRZ,E/S.
Reporting Area
Total 
Cases
Cases with Information on
Initial Drug Regimen
Percentage of Cases in Persons with
Initial Drug Regimen,
No. (%) IRZ
Cases in 
Persons 
Alive at 
Diagnosis IR IRZ,E/S IRZE
0
United States 10,030 9,365 (93.4) 782 (8.4) 103 (1.1)
Alabama  0 (94.0)  (2.1) 0 (0.0)
Alaska   (95.6)  (2.3) 0 (0.0)
Arizona   (96.2)  (3.9) 0 (0.0)
Arkansas   (94.0)  (4.8) 0 (0.0)
California , ,0 (95.0)  (10.5) 0 (1.5)
Colorado   (100.0)  (12.1) 0 (0.0)
Connecticut   (100.0)  (14.3)  (2.4)
Delaware   (100.0) 0 (0.0) 0 (0.0)
District of Columbia   (100.0)  (4.5) 0 (0.0)
Florida   (93.7)  (7.5)  (0.7)
Georgia   (97.5)  (9.3)  (0.3)
Hawaii   (98.0)  (11.3) 0 (0.0)
Idaho   (88.9) 0 (0.0) 0 (0.0)
Illinois   (93.5)  (10.2)  (0.6)
Indiana   (96.9)  (2.1) 0 (0.0)
Iowa   (89.7)  (11.4) 0 (0.0)
Kansas   (86.4)  (13.2) 0 (0.0)
Kentucky   (87.1)  (6.8)  (1.4)
Louisiana  0 (91.4)  (5.3) 0 (0.0)
Maine   (100.0) 0 (0.0) 0 (0.0)
Maryland   (100.0)  (8.7)  (1.8)
Massachusetts  0 (96.0)  (9.5)  (1.6)
Michigan   (98.1) 0 (6.4)  (1.3)
Minnesota   (100.0)  (11.4)  (1.3)
Mississippi   (94.2)  (2.5)  (1.2)
Missouri   (100.0)  (5.8) 0 (0.0)
Montana   (100.0)  (25.0) 0 (0.0)
Nebraska   (92.3)  (12.5) 0 (0.0)
Nevada   (97.1)  (10.4)  (1.5)
New Hampshire   (100.0)  (20.0) 0 (0.0)
New Jersey  0 (99.1)  (10.6)  (2.5)
New Mexico 0  (98.0)  (6.1) 0 (0.0)
New York State 0  (98.3)  (9.3)  (0.4)
New York City   (97.1)  (9.1)  (1.6)
North Carolina   (99.6)  (6.0)  (0.4)
North Dakota   (100.0) 0 (0.0) 0 (0.0)
Ohio   (98.7) 0 (6.5)  (0.6)
Oklahoma   (96.3)  (3.8) 0 (0.0)
Oregon   (100.0)  (4.5) 0 (0.0)
Pennsylvania   (65.0) ... ... ... ...
Rhode Island   (100.0)  (8.7) 0 (0.0)
South Carolina   (95.5)  (4.7)  (1.6)
South Dakota   (100.0) 0 (0.0) 0 (0.0)
Tennessee  0 (97.4)  (3.2) 0 (0.0)
Texas ,  (82.6)  (7.6)  (1.4)
Utah   (100.0)  (4.3)  (4.3)
Vermont   (100.0) 0 (0.0) 0 (0.0)
Virginia   (84.1)  (7.9)  (0.5)
Washington   (97.9)  (7.6)  (2.2)
West Virginia   (96.0) 0 (0.0) 0 (0.0)
Wisconsin 0  (85.0)  (7.8)  (2.0)
Wyoming   (100.0) 0 (0.0) 0 (0.0)
American Samoa ... ... ... ... ... ... ...
Fed. States of Micronesia   (42.9) ... ... ... ...
Guam   (91.7)  (3.0) 0 (0.0)
Marshall Islands   (91.7)  (3.0) 0 (0.0)
N. Mariana Islands   (58.3) -- -- -- --
Puerto Rico 0 0 (100.0)  (5.6)  (1.1)
Republic of Palau   (62.5) ... ... ... ...
U.S. Virgin Islands  0 (0.0) -- -- -- --
Patients tested to at least isoniazid and rifampin
Isolates may be resistant to other drugs. Overall U.S. percentage based on 52 reporting areas (50 states, New York City, and the District 
of Columbia). Counts and percentages shown only for reporting areas with information reported for >% of cases.
Excludes New York City.
Not included in U.S. totals. 
Note: Ellipses indicate data not available.
Table 36. Culture-Positive Tuberculosis Cases and Percentages with Drug-Susceptibility 
Results, by Resistance to INH or Multidrug Resistance: Reporting Areas, 2008
Reporting Area
Total 
Culture 
Positive 
Cases
Cases with Initial Drug-
Susceptibility Testing Performed
Resistance
No. (%)
Isoniazid Isoniazid and Rifampin
No. No.(%) (%)

United States 4,242 3,036 (71.6) -- --
Alabama   (95.5)  (4.8)
Alaska   (76.5) 0 (0.0)
Arizona   (86.1)  (7.4)
Arkansas   (87.5)  (21.4)
California  0 (0.0) ... ...
Colorado   (97.0)  (6.3)
Connecticut 0  (72.5) ... ...
Delaware   (84.6)  (9.1)
District of Columbia   (100.0)  (25.0)
Florida   (92.1)  (27.0)
Georgia   (94.4)  (15.0)
Hawaii   (60.0) ... ...
Idaho   (100.0) 0 (0.0)
Illinois   (91.6)  (11.2)
Indiana   (78.8)  (7.7)
Iowa 0 0 (100.0) 0 (0.0)
Kansas 0 0 (100.0)  (5.0)
Kentucky   (96.3)  (3.8)
Louisiana   (83.8)  (17.7)
Maine   (100.0) 0 (0.0)
Maryland 0  (96.1)  (21.2)
Massachusetts  0 (72.2) ... ...
Michigan   (81.0)  (10.6)
Minnesota   (93.1)  (11.9)
Mississippi   (100.0)  (15.6)
Missouri   (92.1)  (8.6)
Montana   (100.0) 0 (0.0)
Nebraska   (75.0) 0 (0.0)
Nevada   (100.0)  (6.9)
New Hampshire   (100.0) 0 (0.0)
New Jersey   (83.5)  (10.9)
New Mexico   (91.7)  (18.2)
New York State 0 00 (91.7)  (7.0)
New York City   (84.3)  (16.4)
North Carolina   (95.8)  (14.9)
North Dakota   (100.0) 0 (0.0)
Ohio 0  (90.0) 0 (0.0)
Oklahoma 0 0 (100.0)  (10.0)
Oregon   (93.1)  (7.4)
Pennsylvania 0  (82.7)  (12.8)
Rhode Island   (75.0)  (22.2)
South Carolina   (93.2)  (14.5)
South Dakota   (75.0) 0 (0.0)
Tennessee   (100.0)  (12.8)
Texas 0  (86.9)  (16.4)
Utah   (100.0) 0 (0.0)
Vermont  0 (0.0) -- --
Virginia 0  (85.1)  (3.5)
Washington   (90.1)  (6.8)
West Virginia   (50.0) ... ...
Wisconsin   (84.0)  (14.3)
Wyoming   (66.7) ... ...
American Samoa  0 (0.0) -- --
Fed. States of Micronesia   (44.4) ... ...
Guam   (94.1)  (12.5)
Marshall Islands   (58.3) ... ...
N. Mariana Islands   (100.0) 0 (0.0)
Puerto Rico   (100.0) 0 (41.7)
Republic of Palau   (100.0) 0 (0.0)
U.S. Virgin Islands   (100.0)  (50.0)
Table 37. Tuberculosis Cases and Percentages Among Persons Aged 25–44 by HIV Status: 
Reporting Areas, 2008
Includes only those cases in persons with negative, positive, or indeterminate HIV test results.
Counts and percentages shown only for reporting areas with information reported for >75% of cases. All 2008 California and Vermont 
cases had an unknown HIV status because these HIV data were not available at time of publication.
Excludes New York City.
Not included in U.S. totals. 
Note: Ellipses indicate data not available.
See Technical Notes (page 9).
Reporting Area
Total  
Cases
Cases with Information on HIV Status Cases in Persons with HIV-Positive Results
No. (%) No. (%)

United States 12,117 11,528 (95.1) (52.5) (3.4) (0.1) (1.2) (42.7) (0.1)
Alabama   (98.8) (61.4) (3.0) (0.0) (1.8) (33.7) (0.0)
Alaska   (82.6) (71.1) (2.6) (0.0) (0.0) (23.7) (2.6)
Arizona   (80.3) (60.4) (2.5) (0.0) (4.4) (32.1) (0.6)
Arkansas   (57.9) ... ... ... ... ... ...
California ,0 , (96.0) (56.4) (3.4) (0.1) (1.7) (38.3) (0.0)
Colorado   (97.8) (45.1) (1.1) (0.0) (2.2) (51.6) (0.0)
Connecticut   (100.0) (41.7) (3.1) (0.0) (1.0) (54.2) (0.0)
Delaware   (100.0) (23.8) (14.3) (0.0) (4.8) (57.1) (0.0)
District of Columbia   (100.0) (92.2) (0.0) (0.0) (0.0) (7.8) (0.0)
Florida 0 0 (99.8) (57.9) (2.9) (0.1) (2.4) (36.7) (0.0)
Georgia   (81.2) (35.3) (2.5) (0.3) (1.7) (60.2) (0.0)
Hawaii   (78.7) (43.8) (6.3) (0.0) (0.0) (50.0) (0.0)
Idaho   (100.0) (55.6) (0.0) (0.0) (0.0) (44.4) (0.0)
Illinois   (94.1) (47.4) (4.9) (0.0) (0.2) (47.4) (0.0)
Indiana 0 0 (98.2) (58.9) (3.7) (0.0) (0.0) (37.4) (0.0)
Iowa   (100.0) (50.0) (6.3) (0.0) (0.0) (41.7) (2.1)
Kansas   (95.8) (34.8) (8.7) (0.0) (0.0) (56.5) (0.0)
Kentucky   (99.0) (42.1) (3.2) (0.0) (5.3) (49.5) (0.0)
Louisiana  00 (89.7) (56.0) (1.5) (0.0) (1.0) (41.5) (0.0)
Maine   (100.0) (33.3) (11.1) (0.0) (0.0) (55.6) (0.0)
Maryland   (99.2) (43.2) (3.4) (0.4) (0.0) (51.9) (1.1)
Massachusetts   (98.4) (49.0) (5.5) (0.0) (0.4) (44.7) (0.4)
Michigan   (21.5) ... ... ... ... ... ...
Minnesota 0 0 (100.0) (60.0) (1.7) (1.7) (0.0) (36.7) (0.0)
Mississippi 0 0 (100.0) (59.6) (2.8) (0.0) (0.0) (36.7) (0.9)
Missouri 0 0 (100.0) (49.0) (10.6) (0.0) (0.0) (40.4) (0.0)
Montana   (100.0) (75.0) (12.5) (0.0) (0.0) (12.5) (0.0)
Nebraska   (100.0) (53.6) (0.0) (0.0) (0.0) (46.4) (0.0)
Nevada 0 0 (100.0) (38.9) (2.2) (0.0) (0.0) (57.8) (1.1)
New Hampshire   (94.7) (44.4) (5.6) (0.0) (0.0) (50.0) (0.0)
New Jersey   (100.0) (48.7) (5.1) (0.5) (1.2) (44.3) (0.2)
New Mexico   (100.0) (55.2) (3.4) (0.0) (1.7) (39.7) (0.0)
New York State   (95.8) (50.9) (3.2) (0.0) (0.4) (45.1) (0.4)
New York City 0  (96.8) (47.7) (3.0) (0.1) (0.0) (49.0) (0.1)
North Carolina 0 0 (100.0) (33.8) (1.9) (0.6) (1.9) (61.7) (0.0)
North Dakota   (100.0) (66.7) (0.0) (0.0) (0.0) (33.3) (0.0)
Ohio   (98.4) (52.4) (3.2) (0.0) (1.1) (43.4) (0.0)
Oklahoma   (65.5) ... ... ... ... ... ...
Oregon   (100.0) (44.4) (1.4) (0.0) (1.4) (52.8) (0.0)
Pennsylvania   (99.4) (37.0) (3.0) (0.0) (0.3) (59.6) (0.0)
Rhode Island   (96.9) (48.4) (6.5) (0.0) (0.0) (45.2) (0.0)
South Carolina   (100.0) (56.2) (1.8) (0.0) (1.8) (40.2) (0.0)
South Dakota   (100.0) (87.5) (12.5) (0.0) (0.0) (0.0) (0.0)
Tennessee   (99.3) (57.0) (3.0) (0.0) (1.9) (37.7) (0.4)
Texas ,0 ,0 (99.9) (62.7) (3.1) (0.2) (0.2) (33.7) (0.1)
Utah   (100.0) (61.5) (3.8) (0.0) (0.0) (34.6) (0.0)
Vermont   (100.0) (50.0) (16.7) (0.0) (0.0) (33.3) (0.0)
Virginia   (100.0) (53.7) (2.1) (0.0) (0.0) (44.2) (0.0)
Washington 0  (95.1) (42.6) (5.6) (0.0) (2.6) (48.2) (1.0)
West Virginia   (100.0) (51.9) (7.4) (0.0) (0.0) (40.7) (0.0)
Wisconsin   (97.0) (35.9) (4.7) (0.0) (1.6) (57.8) (0.0)
Wyoming   (100.0) (0.0) (20.0) (0.0) (0.0) (80.0) (0.0)
American Samoa   (33.3) ... ... ... ... ... ...
Fed. States of Micronesia  0 (82.8) (81.7) (1.7) (0.0) (0.0) (16.7) (0.0)
Guam   (87.7) (63.2) (1.8) (0.0) (0.0) (35.1) (0.0)
Marshall Islands 0  (95.1) (50.5) (0.0) (0.0) (0.0) (49.5) (0.0)
N. Mariana Islands   (94.1) (28.1) (0.0) (0.0) (0.0) (71.9) (0.0)
Puerto Rico   (100.0) (80.6) (0.0) (0.0) (0.0) (19.4) (0.0)
Republic of Palau   (92.9) (38.5) (7.7) (7.7) (0.0) (46.2) (0.0)
U.S. Virgin Islands   (100.0) (0.0) (0.0) (0.0) (0.0) (100.0) (0.0)
Table 38. Tuberculosis Cases and Percentages by Occupation, Age >15: 
Reporting Areas, 2008
Occupation within past 24 months of TB diagnosis. Overall U.S. percentage based on 52 reporting areas (50 states, New York City, and 
the District of Columbia). Percentages shown only for reporting areas with information reported for >% of cases.
Excludes New York City.
Not included in U.S. totals. 
Note: Ellipses indicate data not available.
Reporting Area
Total 
Cases
Cases with
Information on 
Occupation
Percentage of Cases by Occupation
No. (%)
Unemployed 
Past 24 Mos.
Health Care 
Worker
Correctional 
Employee
Migrant 
Worker
Other 
Occupation
Multiple
Occupations

United States 13,727 13,405 13,269 (99.0) (60.0) (18.4) (21.6)
Alabama    (95.8) (76.1) (7.1) (16.8)
Alaska 0   (100.0) (17.6) (1.5) (80.9)
Arizona  0  (89.5) (77.7) (12.4) (9.9)
Arkansas 0 00 00 (100.0) (94.0) (6.0) (0.0)
California , , ,0 (99.2) (51.3) (30.3) (18.4)
Colorado    (100.0) (73.6) (4.1) (22.3)
Connecticut    (100.0) (12.9) (38.8) (48.2)
Delaware    (100.0) (78.6) (7.1) (14.3)
District of Columbia    (100.0) (66.7) (26.4) (6.9)
Florida ,0 ,00 ,00 (99.4) (75.2) (9.3) (15.5)
Georgia 0   (96.9) (67.9) (9.5) (22.7)
Hawaii    (100.0) (39.5) (14.0) (46.5)
Idaho 0 0 0 (100.0) (35.0) (35.0) (30.0)
Illinois    (98.0) (39.4) (31.0) (29.6)
Indiana    (100.0) (33.6) (3.3) (63.1)
Iowa 0   (100.0) (0.0) (0.0) (100.0)
Kansas    (100.0) (49.4) (10.4) (40.3)
Kentucky    (97.6) (63.0) (9.9) (27.2)
Louisiana 0   (97.9) (64.9) (12.6) (22.5)
Maine    (100.0) (100.0) (0.0) (0.0)
Maryland    (100.0) (86.8) (7.0) (6.2)
Massachusetts    (99.6) (38.7) (9.4) (52.0)
Michigan    (96.8) (57.3) (14.7) (28.0)
Minnesota    (100.0) (59.2) (37.6) (3.3)
Mississippi  0 0 (100.0) (92.7) (6.4) (0.9)
Missouri 0 0 0 (99.0) (24.8) (19.8) (55.4)
Montana    (91.7) (45.5) (0.0) (54.5)
Nebraska    (100.0) (0.0) (33.3) (66.7)
Nevada 0 00  (99.0) (83.8) (10.1) (6.1)
New Hampshire    (100.0) (5.9) (11.8) (82.4)
New Jersey 0   (100.0) (70.8) (25.6) (3.6)
New Mexico    (100.0) (47.8) (19.6) (32.6)
New York State  0  (95.5) (59.7) (25.8) (14.6)
New York City    (100.0) (36.7) (20.8) (42.5)
North Carolina    (100.0) (69.2) (3.8) (27.0)
North Dakota 0 0 0 (100.0) (0.0) (20.0) (80.0)
Ohio    (100.0) (61.1) (17.1) (21.8)
Oklahoma    (100.0) (95.0) (1.4) (3.5)
Oregon    (100.0) (50.0) (9.0) (41.0)
Pennsylvania    (99.7) (79.2) (19.0) (1.8)
Rhode Island    (100.0) (92.3) (3.8) (3.8)
South Carolina    (100.0) (79.3) (6.6) (14.1)
South Dakota    (100.0) (78.6) (0.0) (21.4)
Tennessee    (99.6) (51.1) (9.3) (39.6)
Texas , , , (100.0) (68.3) (19.5) (12.2)
Utah    (100.0) (58.8) (5.9) (35.3)
Vermont    (100.0) (28.6) (42.9) (28.6)
Virginia   0 (99.7) (79.7) (12.8) (7.5)
Washington    (100.0) (68.1) (8.2) (23.7)
West Virginia    (77.3) (29.4) (11.8) (58.8)
Wisconsin  0  (97.1) (0.0) (0.0) (100.0)
Wyoming    (100.0) (0.0) (25.0) (75.0)
American Samoa    (50.0) ... ... ...
Fed. States of Micronesia    (27.8) ... ... ...
Guam   0 (92.6) (70.0) (0.0) (30.0)
Marshall Islands    (25.9) ... ... ...
N. Mariana Islands    (84.8) (97.4) (2.6) (0.0)
Puerto Rico  0 0 (100.0) (84.8) (10.5) (4.8)
Republic of Palau 0 0 0 (100.0) (100.0) (0.0) (0.0)
U.S. Virgin Islands ... ... 0 ... ... ... ...
Most recent year for which data are available.
Health Department: All outpatient care provided by the state or local health department; Private/Other: All care (except contact inves-
tigation and dispensing of medication) provided by non–health department providers; Both Health Department and Private/Other: Both 
sectors involved in the care of the patient. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of 
Columbia). Percentages shown only for reporting areas with information reported for >% of cases.
Excludes New York City.
Not included in U.S. totals. 
Note: Ellipses indicate data not available.
Table 39. Tuberculosis Cases and Percentages by Type of Health Care Provider: 
Reporting Areas, 20061
Reporting Area
Total  
Cases
Percentage of Cases by
Type of Health Care Provider
No. (%)
Health 
Department
Private/
Other
Both Health 
Department and 
Private/Other
Cases in 
Persons 
Alive at 
Diagnosis
Cases with Information on
Type of Health Care Provider

United States 13,727 13,306 13,203 (99.2) (57.5) (30.4)
Alabama  0  (99.5) (19.6) (80.4)
Alaska 0   (100.0) (97.1) (2.9)
Arizona  00  (91.7) (81.8) (13.8)
Arkansas 0 00  (99.0) (10.1) (44.4)
California , , ,0 (99.1) (61.5) (22.3)
Colorado    (100.0) (91.7) (5.0)
Connecticut    (100.0) (28.2) (44.7)
Delaware    (100.0) (82.1) (17.9)
District of Columbia    (100.0) (51.4) (22.2)
Florida ,0  0 (99.3) (47.1) (48.1)
Georgia 0   (98.6) (74.8) (20.2)
Hawaii    (100.0) (2.6) (74.6)
Idaho 0   (100.0) (21.1) (47.4)
Illinois    (99.5) (52.3) (16.8)
Indiana    (100.0) (61.5) (36.1)
Iowa 0   (100.0) (69.2) (20.5)
Kansas    (100.0) (89.6) (10.4)
Kentucky    (97.6) (50.6) (46.9)
Louisiana 0   (99.0) (86.5) (7.8)
Maine    (100.0) (93.8) (6.3)
Maryland    (100.0) (94.7) (4.1)
Massachusetts    (100.0) (33.5) (45.9)
Michigan    (96.8) (32.2) (34.6)
Minnesota    (100.0) (81.1) (17.0)
Mississippi  0 0 (100.0) (30.9) (69.1)
Missouri 0 0 0 (100.0) (41.2) (45.1)
Montana    (91.7) (54.5) (36.4)
Nebraska    (100.0) (58.3) (0.0)
Nevada 0 00  (99.0) (90.9) (8.1)
New Hampshire    (100.0) (88.2) (5.9)
New Jersey 0   (100.0) (49.9) (19.4)
New Mexico    (100.0) (80.4) (19.6)
New York State  0 0 (99.7) (21.4) (73.1)
New York City    (100.0) (1.7) (67.0)
North Carolina    (100.0) (98.3) (1.4)
North Dakota 0 0 0 (100.0) (30.0) (50.0)
Ohio    (99.6) (70.8) (19.3)
Oklahoma  0 0 (100.0) (98.6) (0.0)
Oregon    (98.7) (70.1) (24.7)
Pennsylvania    (98.8) (41.9) (43.5)
Rhode Island    (100.0) (7.7) (88.5)
South Carolina    (100.0) (92.0) (6.6)
South Dakota    (100.0) (57.1) (35.7)
Tennessee    (100.0) (94.0) (5.2)
Texas , , , (100.0) (64.8) (33.0)
Utah    (100.0) (91.2) (8.8)
Vermont    (100.0) (28.6) (28.6)
Virginia    (97.8) (70.5) (27.2)
Washington    (99.6) (75.1) (17.4)
West Virginia  0  (75.0) (53.3) (40.0)
Wisconsin    (98.6) (64.7) (27.9)
Wyoming    (100.0) (50.0) (25.0)
American Samoa    (100.0) (100.0) (0.0)
Fed. States of Micronesia    (28.6) ... ...
Guam    (94.4) (0.0) (98.0)
Marshall Islands    (25.9) ... ...
N. Mariana Islands    (86.7) (87.2) (12.8)
Puerto Rico  0 0 (100.0) (74.0) (0.0)
Republic of Palau 0 0 0 (100.0) (30.0) (50.0)
U.S. Virgin Islands ... ... ... ... ... ...
Table 40. Tuberculosis Cases and Percentages by Directly Observed Therapy (DOT): 
Reporting Areas, 20061
Most recent year for which data are available.
Includes persons alive at diagnosis with an initial drug regimen of one or more drugs prescribed.
Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of Columbia). Percentages shown only for 
reporting areas with information reported for >% of cases.
Excludes New York City.
Not included in U.S. totals. 
Note: Ellipses indicate data not available.
Reporting Area
Total  
Cases
Percentage of Cases by
Directly Observed Therapy
No. (%) DOT Only
Both DOT and 
Self-Administered
Cases with 
Initial Drug 
Regimen 
Prescribed
Cases with Information on
Directly Observed Therapy

Table 41. Tuberculosis Cases and Percentages by Completion of Tuberculosis Therapy 
(COT): Reporting Areas, 20061
Most recent year for which data are available.
Initial isolate susceptible to rifampin (n=9,070) or susceptibility unknown (n=185); culture negative (n=2,242); culture status un-
known (n=538); age unknown (n=1).
Initial isolate rifampin resistant, or pediatric patients (aged <15) with meningeal, bone, joint, or miliary disease.
Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed, who did not die during 
therapy. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of Columbia). Percentages 
shown only for reporting areas with information reported for >0% of cases.
Excludes New York City.
Not included in U.S. totals. 
Note: Ellipses indicate data not available. See Technical Notes for description of Completion of Therapy calculation (page 9).
Reporting Area
Total  
Cases
All Drug Therapy
No. COT(%) No. COT(%)
Therapy <1 Year Indicated
COT <1 Year(%)
Therapy >1 Year Indicated
No. COT(%)
United States 13,727 12036 (83.5) (92.5) 339 (86.7) 12375 (92.3)
Alabama   (86.7) (92.7)  (100.0)  (93.0)
Alaska 0  (90.5) (95.2)  (100.0)  (95.3)
Arizona   (76.9) (83.2)  (66.7)  (82.8)
Arkansas 0 0 (90.0) (92.2) 0 -- 0 (92.2)
California ,  (80.7) (92.9)  (86.1)  (92.7)
Colorado  0 (88.9) (95.4)  (100.0)  (95.7)
Connecticut   (87.0) (94.8)  (100.0)  (95.1)
Delaware   (83.3) (95.8)  (100.0)  (96.0)
District of Columbia   (70.3) (82.8)  (100.0)  (83.1)
Florida ,0  (89.3) (95.3)  (84.6)  (95.2)
Georgia 0  (82.4) (92.1)  (92.3)  (92.1)
Hawaii  0 (79.2) (94.1)  (50.0) 0 (93.2)
Idaho 0  (77.8) (100.0) 0 --  (100.0)
Illinois  00 (78.8) (87.0)  (81.8)  (86.9)
Indiana   (90.5) (94.8)  (100.0)  (94.9)
Iowa 0  (86.5) (94.6)  (100.0)  (94.7)
Kansas   (93.2) (98.6)  (100.0)  (98.7)
Kentucky   (82.7) (89.3) 0 --  (89.3)
Louisiana 0  (77.0) (89.3)  (100.0)  (89.4)
Maine   (100.0) (100.0) 0 --  (100.0)
Maryland   (90.7) (95.6)  (100.0)  (95.7)
Massachusetts  0 (86.3) (93.3)  (100.0)  (93.4)
Michigan  00 (79.5) (86.5)  (50.0) 0 (86.1)
Minnesota  00 (90.0) (93.5)  (85.7) 0 (93.2)
Mississippi   (83.5) (92.8) 0 --  (92.8)
Missouri 0  (76.1) (84.8)  (66.7)  (84.2)
Montana  0 (90.0) (100.0)  (0.0)  (90.9)
Nebraska   (100.0) (100.0) 0 --  (100.0)
Nevada 0  (90.2) (96.3)  (66.7)  (94.3)
New Hampshire   (93.3) (100.0) 0 --  (100.0)
New Jersey 0  (84.7) (92.4)  (100.0)  (92.6)
New Mexico   (81.1) (100.0)  (50.0)  (97.4)
New York State   (84.9) (94.1) 0 (90.0)  (94.0)
New York City   (84.4) (92.3)  (79.5)  (91.8)
North Carolina   (87.3) (96.2) 0 (90.0)  (96.0)
North Dakota 0 0 (60.0) (60.0) 0 -- 0 (60.0)
Ohio  0 (82.9) (91.2)  (100.0)  (91.6)
Oklahoma   (81.4) (94.6) 0 --  (94.6)
Oregon   (91.5) (100.0)  (100.0)  (100.0)
Pennsylvania   (82.0) (93.2)  (91.7) 0 (93.2)
Rhode Island   (79.2) (91.7)  (100.0)  (92.3)
South Carolina   (86.6) (90.7)  (100.0)  (90.8)
South Dakota   (50.0) (100.0) 0 --  (100.0)
Tennessee   (88.3) (98.3)  (100.0) 0 (98.3)
Texas ,  (81.4) (91.0)  (88.9) 0 (91.0)
Utah   (84.4) (93.8) 0 --  (93.8)
Vermont   (83.3) (83.3) 0 --  (83.3)
Virginia   (85.3) (93.8) 0 (90.0) 0 (93.7)
Washington   (81.9) (92.0)  (87.5)  (91.9)
West Virginia   ... ... 0 --  ...
Wisconsin   (85.5) (91.9)  (66.7)  (90.8)
Wyoming   (100.0) (100.0) 0 --  (100.0)
American Samoa   (100.0) (100.0) 0 --  (100.0)
Fed. States of Micronesia   ... ... 0 --  ...
Guam   (86.5) (86.5) 0 ...  (86.5)
Marshall Islands   ... ...  ...  ...
N. Mariana Islands   ... ...  ...  ...
Puerto Rico   (96.6) (98.9)  (100.0) 0 (98.9)
Republic of Palau 0  (66.7) (77.8) 0 --  (77.8)
U.S. Virgin Islands … … … … … ... … …

United States 13,306 11,425 (85.9) 328 (2.5) 346 (2.6) 76 (0.6) 931 (7.0) 200 (1.5)
Alabama 0  (83.7)  (1.6)  (2.6)  (0.5)  (10.0)  (1.6)
Alaska   (89.7) 0 (0.0)  (1.5)  (1.5)  (5.9)  (1.5)
Arizona 00  (77.0)  (4.3)  (4.0) 0 (0.0)  (7.0)  (7.7)
Arkansas 00  (83.0) 0 (0.0)  (4.0) 0 (0.0) 0 (10.0)  (3.0)
California , , (85.9)  (3.3)  (1.9)  (0.6)  (7.4)  (1.0)
Colorado  0 (90.9)  (0.8)  (3.3) 0 (0.0)  (5.0) 0 (0.0)
Connecticut   (91.8)  (1.2)  (1.2) 0 (0.0)  (3.5)  (2.4)
Delaware   (85.7)  (3.6) 0 (0.0) 0 (0.0)  (10.7) 0 (0.0)
District of Columbia   (75.0)  (6.9)  (5.6)  (1.4)  (9.7)  (1.4)
Florida   (88.9)  (1.7)  (1.7)  (0.2)  (6.6)  (0.9)
Georgia   (86.3)  (0.8)  (3.9)  (1.2)  (6.4)  (1.4)
Hawaii   (84.2)  (3.5)  (1.8) 0 (0.0)  (9.6)  (0.9)
Idaho   (94.7) 0 (0.0) 0 (0.0) 0 (0.0)  (5.3) 0 (0.0)
Illinois   (80.4)  (2.7)  (2.5)  (0.5)  (7.4)  (6.3)
Indiana   (91.0)  (0.8)  (2.5)  (0.8)  (4.1)  (0.8)
Iowa   (92.3)  (5.1) 0 (0.0) 0 (0.0)  (2.6) 0 (0.0)
Kansas   (96.1) 0 (0.0)  (1.3) 0 (0.0)  (2.6) 0 (0.0)
Kentucky   (80.7)  (3.6)  (3.6) 0 (0.0)  (9.6)  (2.4)
Louisiana  0 (82.1)  (3.6)  (4.1)  (0.5)  (8.2)  (1.5)
Maine   (81.3) 0 (0.0) 0 (0.0) 0 (0.0)  (18.8) 0 (0.0)
Maryland   (90.9)  (1.2)  (2.1)  (0.4)  (4.9)  (0.4)
Massachusetts   (88.7) 0 (3.9)  (1.6) 0 (0.0)  (5.1)  (0.8)
Michigan   (79.8)  (2.8)  (4.1)  (2.3)  (7.3)  (3.7)
Minnesota   (91.0)  (3.8)  (1.4)  (1.4)  (2.4) 0 (0.0)
Mississippi 0 0 (81.8)  (2.7)  (0.9) 0 (0.0)  (11.8)  (2.7)
Missouri 0 0 (78.4)  (10.8) 0 (0.0) 0 (0.0)  (6.9)  (3.9)
Montana  0 (83.3) 0 (0.0) 0 (0.0) 0 (0.0)  (8.3)  (8.3)
Nebraska   (95.8) 0 (0.0) 0 (0.0) 0 (0.0)  (4.2) 0 (0.0)
Nevada 00  (83.0)  (1.0)  (2.0) 0 (0.0)  (12.0)  (2.0)
New Hampshire   (88.2) 0 (0.0) 0 (0.0) 0 (0.0)  (11.8) 0 (0.0)
New Jersey   (88.1)  (0.2)  (6.3)  (0.6)  (4.8) 0 (0.0)
New Mexico   (82.6)  (2.2) 0 (0.0) 0 (0.0)  (15.2) 0 (0.0)
New York State 0  (85.8)  (0.3)  (2.6)  (0.6)  (8.7)  (1.9)
New York City  0 (85.8)  (2.7)  (3.1)  (0.9) 0 (6.5)  (1.0)
North Carolina   (92.3)  (1.7)  (1.7) 0 (0.0)  (3.9)  (0.6)
North Dakota 0  (60.0)  (10.0) 0 (0.0) 0 (0.0) 0 (0.0)  (30.0)
Ohio   (83.8)  (2.1)  (1.7)  (2.6) 0 (8.5)  (1.3)
Oklahoma 0  (87.1)  (2.9) 0 (0.0) 0 (0.0)  (7.9)  (2.1)
Oregon   (92.3) 0 (0.0) 0 (0.0) 0 (0.0)  (7.7) 0 (0.0)
Pennsylvania   (85.9)  (1.8)  (1.5)  (0.3)  (7.8)  (2.7)
Rhode Island   (92.3) 0 (0.0)  (7.7) 0 (0.0) 0 (0.0) 0 (0.0)
South Carolina   (83.1)  (0.9)  (3.3)  (1.9)  (8.5)  (2.3)
South Dakota   (85.7) 0 (0.0) 0 (0.0) 0 (0.0)  (14.3) 0 (0.0)
Tennessee   (88.1)  (0.7)  (0.7) 0 (0.0)  (10.4) 0 (0.0)
Texas , , (84.7)  (3.0)  (4.4)  (0.4) 0 (6.9)  (0.5)
Utah  0 (88.2)  (2.9)  (2.9) 0 (0.0)  (5.9) 0 (0.0)
Vermont   (71.4) 0 (0.0) 0 (0.0) 0 (0.0)  (14.3)  (14.3)
Virginia   (88.7)  (1.9)  (2.2)  (0.6)  (5.3)  (1.3)
Washington   (84.6)  (5.1)  (0.8)  (0.8) 0 (7.9)  (0.8)
West Virginia 0  (65.0) 0 (0.0) 0 (0.0) 0 (0.0)  (10.0)  (25.0)
Wisconsin   (85.5)  (2.9)  (1.4)  (1.4)  (5.8)  (2.9)
Wyoming   (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
American Samoa   (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Fed. States of Micronesia   (27.3) 0 (0.0) 0 (0.0) 0 (0.0)  (1.3)  (71.4)
Guam   (83.3)  (7.4) 0 (0.0) 0 (0.0)  (3.7)  (5.6)
Marshall Islands   (14.8)  (7.4) 0 (0.0)  (3.7) 0 (0.0) 0 (74.1)
N. Mariana Islands   (71.1)  (13.3) 0 (0.0)  (2.2) 0 (0.0)  (13.3)
Puerto Rico 0  (85.6) 0 (0.0)  (1.0) 0 (0.0)  (13.5) 0 (0.0)
Republic of Palau 0  (70.0)  (20.0) 0 (0.0) 0 (0.0)  (10.0) 0 (0.0)
U.S. Virgin Islands … … … … … … … … … … … … …
Table 42. Tuberculosis Cases and Percentages by Reason Therapy Stopped: 
Reporting Areas, 20061
Most recent year for which data are available.
Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed. Percentage for U.S. based on 52 
reporting areas (50 states, New York City, and the District of Columbia).
Died = Died of any cause.
Includes cases reported as Other, Missing, or Unknown.
Excludes New York City.
Not included in U.S. totals. 
Note: Ellipses indicate data not available.
Reporting Area
Completed Moved Lost Refused Died Unknown
No. No. No. No. No. No.(%) (%) (%) (%) (%) (%)
Cases with 
Initial Drug 
Regimen 
Prescribed

United States 12,036 3593 (81.8) 138 (83.3) 3013 (84.5) 3230 (83.3) 1998 (85.2) 64 (85.9)
Alabama   (83.3) 0 -- 0 (80.0)  (90.5)  (85.7) 0 --
Alaska  0 --  (89.4) 0 (100.0)  (0.0)  (100.0)  (100.0)
Arizona   (75.1)  (44.4)  (82.8) 0 (100.0)  (76.2) 0 ...
Arkansas 0  (90.5) 0 --  (85.7)  (92.9)  (86.2)  (100.0)
California , 0 (79.2)  (80.0) 0 (82.1)  (76.6)  (83.4)  (76.5)
Colorado 0  (84.9) 0 --  (88.5)  (94.1)  (100.0)  (100.0)
Connecticut   (85.7) 0 --  (86.4)  (88.0)  (87.5) 0 --
Delaware   (81.8)  (100.0)  (100.0)  (75.0)  (100.0) 0 --
District of Columbia   (66.7) 0 --  (66.7)  (68.8)  (100.0)  (100.0)
Florida   (88.2) 0 --  (87.0)  (90.4)  (90.0)  (66.7)
Georgia  0 (78.4) 0 --  (82.5)  (81.7)  (91.4)  (100.0)
Hawaii 0 0 -- 0 --  (78.3) 0 --  (100.0)  (66.7)
Idaho   (50.0)  (100.0)  (100.0) 0 --  (85.7) 0 --
Illinois 00  (79.1)  (100.0)  (81.8)  (75.5)  (80.0) 0 --
Indiana   (96.4) 0 --  (81.3)  (87.1)  (92.7) 0 --
Iowa   (77.8)  (100.0) 0 (80.0)  (100.0) 0 (90.0) 0 ...
Kansas   (90.5) 0 --  (100.0)  (90.9)  (91.3)  (100.0)
Kentucky   (25.0) 0 --  (100.0)  (86.7)  (89.1) 0 --
Louisiana  0 (60.0)  (100.0)  (93.3) 00 (75.0)  (78.8) 0 --
Maine  0 -- 0 --  (100.0)  (100.0)  (100.0) 0 --
Maryland   (85.4) 0 --  (94.4) 0 (92.2)  (86.4) 0 --
Massachusetts 0  (85.1) 0 --  (89.5)  (82.1)  (87.8)  (100.0)
Michigan 00  (86.4)  (100.0)  (82.4)  (66.7) 0 (92.0)  (100.0)
Minnesota 00  (78.3)  (100.0)  (88.1) 0 (93.5)  (85.7)  (100.0)
Mississippi   (91.7)  (100.0)  (33.3)  (84.6)  (88.0) 0 --
Missouri   (70.6) 0 --  (77.8)  (92.6) 0 (63.3) 0 --
Montana 0 0 --  (100.0)  (100.0)  (100.0)  (66.7) 0 --
Nebraska   (100.0)  (100.0)  (100.0)  (100.0)  (100.0)  (100.0)
Nevada  0 (80.0) 0 --  (96.2)  (100.0)  (91.7) 0 --
New Hampshire   (100.0) 0 --  (100.0)  (100.0)  (80.0) 0 --
New Jersey  0 (86.3) 0 --  (83.8) 0 (81.2) 0 (88.3) 0 --
New Mexico   (82.6)  (81.8)  (50.0) 0 --  (100.0) 0 --
New York State   (87.4) 0 --  (84.4)  (90.6)  (73.5) 0 --
New York City   (85.2) 0 --  (87.1)  (81.1) 0 (83.8)  (66.7)
North Carolina  0 (85.7)  (87.5)  (87.5)  (89.0) 0 (85.0)  (87.5)
North Dakota 0  (100.0)  (0.0)  (66.7)  (100.0)  (50.0) 0 --
Ohio 0  (81.3) 0 --  (83.3) 0 (84.5)  (80.6) 0 --
Oklahoma   (95.7)  (77.8)  (84.2)  (77.8)  (76.5) 0 --
Oregon   (85.7) 0 --  (92.6)  (91.7)  (94.4) 0 --
Pennsylvania   (83.8) 0 --  (87.0) 0 (75.0) 0 (88.3)  (100.0)
Rhode Island   (81.8) 0 --  (100.0)  (60.0)  (66.7) 0 --
South Carolina   (68.0)  (100.0)  (100.0)  (89.8)  (83.8) 0 --
South Dakota  0 ...  (50.0)  (33.3)  (50.0)  (100.0) 0 --
Tennessee   (87.9) 0 --  (90.9) 0 (85.2)  (92.0)  (100.0)
Texas ,  (81.1)  (100.0)  (85.9)  (75.8)  (85.9)  (100.0)
Utah   (92.3) 0 --  (88.9)  (83.3)  (50.0) 0 --
Vermont  0 ... 0 --  (100.0)  (50.0)  (100.0) 0 --
Virginia   (82.9) 0 --  (87.2)  (86.6)  (80.0) 0 --
Washington   (74.4)  (85.7)  (82.8)  (87.1)  (81.6)  (100.0)
West Virginia  ... ... ... ... ... ... ... ... ... ... ... ...
Wisconsin   (81.0)  (100.0)  (92.3)  (88.9)  (87.5)  (0.0)
Wyoming  0 --  (100.0)  (100.0)  (100.0)  (100.0) 0 --
American Samoa  0 -- 0 --  (100.0) 0 -- 0 -- 0 --
Fed. States of Micronesia  ... ... ... ... ... ... ... ... ... ... ... ...
Guam  0 -- 0 -- 0 (88.0) 0 --  (0.0)  (100.0)
Marshall Islands  ... ... ... ... ... ... ... ... ... ... ... ...
N. Mariana Islands  ... ... ... ... ... ... ... ... ... ... ... ...
Puerto Rico   (96.6) 0 -- 0 -- 0 -- 0 -- 0 --
Republic of Palau  0 -- 0 --  (62.5) 0 -- 0 --  (100.0)
U.S. Virgin Islands … … … … … … … … … … … … …
Table 43. Completion of Tuberculosis Therapy (COT) Cases and Percentages1 by Hispanic 
Ethnicity and Non-Hispanic Race: Reporting Areas, 20062
Percentages shown only for reporting areas with information reported for >90% of cases, and indicate the percentage of those who completed 
therapy within 1 year. 
Most recent year for which data are available.
Therapy < 1 year indicated in persons alive at diagnosis with an initial regimen of one or more drugs prescribed, who did not die during therapy. 
Persons of Hispanic or Latino origin may be of any race.
Excludes New York City.
Not included in U.S. totals. 
Note: Case counts and percentage for race categories do not include persons of Hispanic ethnicity. Ellipses indicate data not available.
See Technical Notes for description of Completion of Therapy calculation (page 9).
Reporting Area
Total
Cases
Unknown or 
MissingWhiteBlackHispanic
American Indian 
or Alaska Native
Asian or Pacific 
Islander
Non-Hispanic
No. (%) No. No. No. No.(%) (%) (%) (%)No. (%)

United States 13127 (82.1) 13061 (82.8) 12785 (82.9) 12350 (83.0) 12036 (83.5)
Alabama 0 (90.0)  (86.2)  (89.9)  (89.7)  (86.7)
Alaska  (88.9)  (92.2)  (84.2)  (93.0)  (90.5)
Arizona  (80.2) 0 (79.6)  (74.8)  (83.7)  (76.9)
Arkansas  (86.8)  (87.9)  (88.6) 0 ... 0 (90.0)
California  (82.7) 0 (81.5)  (81.8)  (80.8)  (80.7)
Colorado  (84.4) 0 (93.1)  (96.6)  (96.5) 0 (88.9)
Connecticut  (70.8) 00 (76.0)  (77.6)  (82.8)  (87.0)
Delaware  (90.9)  (85.7)  (93.1)  (87.5)  (83.3)
District of Columbia  (98.7)  (91.2)  (93.9)  (87.8)  (70.3)
Florida  (82.4)  (85.9)  (85.9)  (88.6)  (89.3)
Georgia  (78.9) 0 (79.6)  (83.4)  (82.0)  (82.4)
Hawaii  (69.9)  (79.6) 0 (80.4)  (74.7) 0 (79.2)
Idaho  ...  (84.6) 0 (80.0)  (76.2)  (77.8)
Illinois  (77.6)  (80.8) 0 (79.9)  (80.0) 00 (78.8)
Indiana 0 (96.2)  (95.8)  (93.7)  (91.0)  (90.5)
Iowa  (81.8)  (91.9)  (76.6)  (84.6)  (86.5)
Kansas  (83.6)  (78.1)  (84.2)  (86.0)  (93.2)
Kentucky  (85.3) 0 (85.8) 0 (87.3) 0 (87.5)  (82.7)
Louisiana 0 (81.6)  (81.7)  (73.2)  ...  (77.0)
Maine  (77.8)  (69.6)  (66.7)  (75.0)  (100.0)
Maryland  (87.7)  (87.9)  (90.7)  (88.4)  (90.7)
Massachusetts  (76.8)  (80.2)  (77.7)  (78.7) 0 (86.3)
Michigan  (82.0) 0 (84.9)  (87.0) 0 (80.1) 00 (79.5)
Minnesota  (85.3) 00 (89.5)  (91.0)  (92.9) 00 (90.0)
Mississippi  (83.0) 0 (73.1) 0 (85.1)  (84.5)  (83.5)
Missouri  (86.0) 0 (73.3)  (82.0)  (85.7)  (76.1)
Montana 0 (90.0)  (100.0)  (92.9)  (87.5) 0 (90.0)
Nebraska  (70.8)  (68.0)  (86.5)  (75.9)  (100.0)
Nevada 0 (98.6)  (91.7)  (90.9) 0 ...  (90.2)
New Hampshire  (88.9)  (92.3)  (100.0)  (75.0)  (93.3)
New Jersey  (79.1) 0 (81.8)  (82.3) 0 (85.7)  (84.7)
New Mexico  (83.7)  (86.5)  (84.8)  (80.8)  (81.1)
New York State  (77.1)  (83.4)  (86.3)  (87.6)  (84.9)
New York City 0 (86.2)  (86.7) 0 (84.5)  (82.0)  (84.4)
North Carolina  (90.7)  (89.5)  (92.5) 0 (85.9)  (87.3)
North Dakota  (100.0)  (50.0)  (100.0)  (50.0) 0 (60.0)
Ohio  (80.4)  (90.7) 0 (87.9)  (87.0) 0 (82.9)
Oklahoma  (86.3)  (70.1)  (80.5)  (85.6)  (81.4)
Oregon 0 (88.1)  (84.4)  (89.7)  (93.7)  (91.5)
Pennsylvania  (75.6)  (79.5) 0 ... 0 ...  (82.0)
Rhode Island  (68.2) 0 (90.0)  (85.7)  (82.9)  (79.2)
South Carolina  (80.2)  (86.6)  (82.2)  (87.4)  (86.6)
South Dakota  (88.9)  (68.8)  (44.4)  (53.8)  (50.0)
Tennessee  (84.4)  (81.0)  (86.1)  (88.8)  (88.3)
Texas  (76.6)  (77.0)  (76.5)  (82.2)  (81.4)
Utah 0 (93.3)  (97.1)  (96.9)  (96.2)  (84.4)
Vermont  (87.5)  (100.0)  (66.7)  (100.0)  (83.3)
Virginia  (86.7)  (87.6)  (88.4)  (82.6)  (85.3)
Washington  (83.2)  (82.5)  (88.1)  (83.2)  (81.9)
West Virginia  (65.4)  (70.6)  (81.0)  (58.3)  ...
Wisconsin  (83.6)  (86.9)  (79.8)  (83.6)  (85.5)
Wyoming  (100.0)  (100.0)  (100.0) 0 --  (100.0)
American Samoa 0 -- 0 --  ...  ...  (100.0)
Fed. States of Micronesia 0 -- 0 --  ...  ...  ...
Guam  ...  (87.9)  (84.4)  (79.7)  (86.5)
Marshall Islands 0 -- 0 --  ...  ...  ...
N. Mariana Islands 0 (70.0)  (78.6)  (87.0)  ...  ...
Puerto Rico  (79.6)  (70.8)  (79.8)  (87.2)  (96.6)
Republic of Palau 0 --  (57.1)  (80.0) 0 (100.0)  (66.7)
U.S. Virgin Islands 0 -- 0 -- 0 -- 0 -- 0 --
Reporting Area
00 00 00 00 00
Year
No. No. No.No.(%) (%) (%) (%) (%)
Table 44. Tuberculosis Cases and Percentages in Persons Completing Therapy for Whom 
Therapy Was Indicated for One Year or Less: Reporting Areas, 2002–20061
Most recent year for which data are available.
Total cases for which therapy less than 1 year indicated in persons alive at diagnosis, with an initial regimen of one or more drugs pre-
scribed, who did not die during therapy. 
Percentage of total cases in persons who completed therapy for whom therapy less than 1 year was indicated.
Excludes New York City.
Not included in U.S. totals. 
Note: Ellipses indicate data not available.
See Technical Notes for description of Completion of Therapy calculation (page 9).
No.

Morbidity Tables
Cities and Metropolitan Statistical Areas, 2008
0

Albuquerque, NM  0
Anaheim, CA  
Arlington, TX  
Atlanta, GA  
Austin, TX  
Baltimore, MD  
Birmingham, AL  
Boston, MA  
Buffalo, NY  
Charlotte, NC 0 
Chicago, IL  
Cincinnati, OH 0 
Cleveland, OH  
Colorado Springs, CO 0 
Columbus, OH  
Corpus Christi, TX  
Dallas, TX  
Denver, CO 0 0
Detroit, MI  
El Paso, TX  0
Fort Worth, TX  
Fresno, CA  
Honolulu, HI 0 
Houston, TX  
Indianapolis, IN  
Jacksonville, FL 00 
Kansas City, MO  0
Las Vegas, NV  
Long Beach, CA  
Los Angeles, CA  0
Louisville, KY  0
Memphis, TN  
Mesa, AZ  
Miami, FL  
Milwaukee, WI  
Minneapolis, MN  
Nashville, TN  0
Newark, NJ  
New Orleans, LA  
New York, NY  0
Norfolk, VA  
Oakland, CA  
Oklahoma City, OK  
Omaha, NE  
Philadelphia, PA  
Phoenix, AZ  
Pittsburgh, PA  
Portland, OR  
Sacramento, CA  
St. Louis, MO 0 
St. Paul, MN  0
San Antonio, TX  
San Diego, CA  
San Francisco, CA  
San Jose, CA 0 
Santa Ana, CA  
Seattle, WA  
Tampa, FL  
Toledo, OH  
Tucson, AZ  
Tulsa, OK  
Virginia Beach, VA  
Washington, DC  
Wichita, KS  
TOTAL - 64 CITIES 4,500 4,730
San Juan, PR 0 
Table 45. Tuberculosis Cases in Selected Cities: 2008 and 2007
Cases
00 00City
Historical list of cities.
Case counts are based on verified cases in persons residing within city limits. 
Residence within city limits was determined by the health department.
Change in case count from 2007 report due to a correction in jurisdiction assignment of a case

Table 46. Tuberculosis Cases and Case Rates per 100,000 Population: Metropolitan 
Statistical Areas with >500,000 Population, 2008 and 2007
Metropolitan 
Statistical Area
Cases Case Rates Population 
Estimates 
0000 0000 00
Akron, OH   (0.7) (0.7) ,
Albany-Schenectady-Troy, NY   (0.5) (1.9) ,
Albuquerque, NM   (2.7) (1.9) ,
Allentown-Bethlehem-Easton, PA-NJ   (2.1) (0.2) 0,0
Atlanta-Sandy Springs-Marietta, GA 00  (5.6) (5.2) ,,
Augusta-Richmond County, GA-SC   (4.9) (6.4) ,
Austin-Round Rock, TX   (3.4) (4.1) ,,0
Bakersfield, CA 0  (6.2) (4.8) 00,
Baltimore-Towson, MD  0 (3.3) (3.9) ,,
Baton Rouge, LA 0  (3.9) (3.6) ,
Birmingham-Hoover, AL   (2.9) (3.8) ,,0
Boise City-Nampa, ID   (1.0) (0.7) ,
Boston-Cambridge-Quincy, MA-NH 0  (4.6) (4.0) ,,
Bridgeport-Stamford-Norwalk, CT   (4.0) (5.8) ,00
Buffalo-Niagara Falls, NY  0 (1.6) (0.9) ,,0
Cape Coral-Fort Myers, FL   (5.4) (7.7) ,
Charleston-North Charleston, SC   (4.8) (7.0) ,0
Charlotte-Gastonia-Concord, NC-SC  0 (4.5) (3.0) ,0,
Chattanooga, TN-GA   (3.1) (3.1) ,
Chicago-Naperville-Joliet, IL   (4.6) (5.1) ,,
Cincinnati-Middleton, OH-KY-IN   (1.9) (2.1) ,,
Cleveland-Elyria-Mentor, OH   (2.8) (2.9) ,0,
Colorado Springs, CO 0  (1.6) (1.2) ,
Columbia, SC   (3.3) (4.3) ,0
Columbus, OH  0 (3.7) (4.6) ,,0
Dallas-Fort Worth-Arlington, TX   (5.9) (6.2) ,00,00
Dayton, OH 0  (1.2) (1.8) ,
Denver-Aurora, CO   (2.7) (3.2) ,0,
Des Moines-West Des Moines, IA   (1.3) (1.3) ,0
Detroit-Warren-Livonia, MI   (2.7) (3.1) ,,0
El Paso, TX  0 (9.0) (5.5) ,0
Fresno, CA   (8.0) (4.7) 0,
Grand Rapids-Wyoming, MI   (1.8) (3.0) ,
Greensboro-High Point, NC   (3.4) (4.5) 0,
Greenville, SC   (3.0) (2.9) ,
Harrisburg-Carlisle, PA   (3.2) (2.5) ,0
Hartford-West Hartford-East Hartford, CT   (2.0) (2.1) ,0,
Honolulu, HI 0 0 (11.2) (12.1) 0,0
Houston-Sugar Land-Baytown, TX   (8.0) (8.7) ,,
Indianapolis-Carmel, IN 0  (2.3) (2.8) ,,
Jackson, MS   (6.5) (6.7) ,
Jacksonville, FL 0  (8.1) (5.9) ,,
Kansas City, MO-KS   (2.3) (2.5) ,00,0
Knoxville, TN   (2.5) (2.4) ,
Lakeland, FL   (3.6) (5.1) 0,
Las Vegas-Paradise, NV   (4.9) (5.0) ,,
Little Rock-North Little Rock-Conway, AR   (2.4) (4.7) ,0
Los Angeles-Long Beach-Santa Ana, CA ,0 ,0 (8.2) (8.4) ,,0
Louisville-Jefferson County, KY-IN   (2.7) (3.2) ,,
Madison, WI   (1.4) (0.7) ,0
McAllen-Edinburg-Mission, TX 0  (12.4) (10.8) ,0
Memphis, TN-MS-AR   (7.5) (6.6) ,,
Miami-Fort Lauderdale-Pompano Beach, FL   (6.4) (6.2) ,,
Milwaukee-Waukesha-West Allis, WI   (2.3) (2.5) ,,0
Minneapolis-St. Paul-Bloomington, MN-WI   (5.1) (5.9) ,,
Modesto, CA   (4.1) (3.1) 0,

Nashville-Davidson-Murfreesboro-Franklin, TN 00  (6.4) (4.9) ,0,
New Haven-Milford, CT   (3.1) (3.0) ,0
New Orleans-Metairie-Kenner, LA  0 (6.3) (6.3) ,,0
New York-Northern New Jersey-Long Island, NY-NJ-PA , ,0 (7.6) (7.7) ,00,
Ogden-Clearfield, UT   (0.8) (0.8) ,
Oklahoma City, OK   (2.9) (3.4) ,0,
Omaha-Council Bluffs, NE-IA   (3.0) (1.7) ,
Orlando-Kissimmee, FL 0  (5.2) (5.8) ,0,
Oxnard-Thousand Oaks-Ventura, CA   (8.1) (7.3) ,0
Palm Bay-Melbourne-Titusville, FL 0  (1.9) (3.6) ,
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD   (4.9) (4.1) ,,
Phoenix-Mesa-Scottsdale, AZ 0 0 (3.5) (5.0) ,,
Pittsburgh, PA  0 (1.1) (1.3) ,,
Portland-South Portland-Biddeford, ME   (0.8) (2.3) ,0
Portland-Vancouver-Beaverton, OR-WA   (2.8) (3.1) ,0,
Poughkeepsie-Newburgh-Middletown, NY  0 (2.2) (1.5) ,
Providence-New Bedford-Fall River, RI-MA   (3.5) (3.6) ,,
Provo-Orem, UT  ... (0.2) ... 0,0
Raleigh-Cary, NC   (4.7) (6.1) ,0,
Richmond, VA  0 (3.1) (2.5) ,,
Riverside-San Bernardino-Ontario, CA  0 (3.7) (3.4) ,,
Rochester, NY   (1.6) (2.3) ,0,00
Sacramento-Arden Arcade-Roseville, CA   (5.9) (6.4) ,0,
St. Louis, MO-IL   (2.1) (2.0) ,,0
Salt Lake City, UT   (1.4) (1.9) ,,
San Antonio, TX   (4.5) (4.2) ,0,
San Diego-Carlsbad-San Marcos, CA  0 (8.8) (9.5) ,00,0
San Francisco-Oakland-Fremont, CA 0  (9.5) (10.8) ,,
San Jose-Sunnyvale-Santa Clara, CA  0 (10.9) (13.4) ,,
Sarasota-Bradenton-Venice, FL   (4.5) (4.8) ,
Scranton-Wilkes-Barre, PA   (2.2) (1.6) ,0
Seattle-Tacoma-Bellevue, WA  0 (4.9) (6.3) ,,
Springfield, MA   (0.9) (1.9) ,
Stockton, CA   (9.8) (7.6) ,
Syracuse, NY   (3.4) (2.6) ,
Tampa-St. Petersburg-Clearwater, FL   (4.1) (4.7) ,,
Toledo, OH   (1.2) (1.2) ,0
Tucson, AZ   (2.6) (4.1) ,0,0
Tulsa, OK   (2.4) (3.4) ,0
Virginia Beach-Norfolk-Newport News, VA-NC   (2.5) (2.5) ,,
Washington-Arlington-Alexandria, DC-VA-MD-WV 0  (7.5) (7.8) ,,0
Wichita, KS   (2.8) (2.9) 0,
Worchester, MA   (3.7) (2.3) ,0
Youngstown-Warren-Boardman, OH-PA   (1.1) (1.4) ,
Total - 100 Areas 10,153 10,456 (5.1) (5.3) 199,179,635
San Juan-Caguas-Guaynabo, PR   (2.9) (3.0) ,0,
Table 46. (Cont’d) Tuberculosis Cases and Case Rates per 100,000 Population: Metropolitan 
Statistical Areas with >500,000 Population, 2008 and 2007
Metropolitan 
Statistical Area
Cases Case Rates Population 
Estimates 
0000 0000 00
Note: In 2008, there was 1 metropolitan statistical area with a 2007 population of less than 500,000. Ellipses indicate that data not shown 
for those populations less than 500,000.  
2008 and 2007 population case counts and rates updated using U.S. Census Metropolitan Statistical Areas and Components, November 
2007, with Codes (http://www.whitehouse.gov/omb/bulletins/fy2008/b08-01.pdf) (accessed July 27, 2009).
See Technical Notes for definition of MSA (page 9).

Akron, OH   (60.0)  (20.0)  (20.0) 0
Albany-Schenectady-Troy, NY   (100.0) 0 (0.0) 0 (0.0) 0
Albuquerque, NM   (56.5)  (34.8)  (8.7) 0
Allentown-Bethlehem-Easton, PA-NJ  0 (58.8)  (35.3)  (5.9) 0
Atlanta-Sandy Springs-Marietta, GA 00 0 (70.0)  (19.7) 0 (10.0) 
Augusta-Richmond County, GA-SC   (61.5)  (23.1)  (15.4) 
Austin-Round Rock, TX   (66.1)  (26.8)  (7.1) 
Bakersfield, CA 0  (84.0)  (10.0)  (6.0) 
Baltimore-Towson, MD   (65.2)  (25.8)  (9.0) 
Baton Rouge, LA 0  (80.0)  (20.0) 0 (0.0) 0
Birmingham-Hoover, AL   (90.6)  (9.4) 0 (0.0) 0
Boise City-Nampa, ID   (100.0) 0 (0.0) 0 (0.0) 0
Boston-Cambridge-Quincy, MA-NH 0  (57.0)  (22.7)  (20.3) 
Bridgeport-Stamford-Norwalk, CT   (72.2)  (19.4)  (8.3) 
Buffalo-Niagara Falls, NY   (83.3)  (11.1)  (5.6) 0
Cape Coral-Fort Myers, FL   (90.6)  (9.4) 0 (0.0) 0
Charleston-North Charleston, SC   (71.0)  (12.9)  (16.1) 
Charlotte-Gastonia-Concord, NC-SC   (75.0)  (17.1)  (7.9) 
Chattanooga, TN-GA   (75.0)  (12.5)  (12.5) 
Chicago-Naperville-Joliet, IL   (60.1)  (29.1)  (10.8) 
Cincinnati-Middleton, OH-KY-IN   (76.2)  (9.5)  (14.3) 
Cleveland-Elyria-Mentor, OH   (64.4)  (25.4)  (10.2) 
Colorado Springs, CO 0  (40.0)  (30.0)  (30.0) 0
Columbia, SC   (70.8)  (16.7)  (12.5) 
Columbus, OH   (62.1)  (36.4)  (1.5) 0
Dallas-Fort Worth-Arlington, TX   (75.8)  (16.9)  (7.3) 0
Dayton, OH 0  (80.0)  (20.0) 0 (0.0) 0
Denver-Aurora, CO   (53.7)  (31.3) 0 (14.9) 
Des Moines-West Des Moines, IA   (57.1)  (42.9) 0 (0.0) 0
Detroit-Warren-Livonia, MI   (58.0)  (22.7) 0 (16.8) 0
El Paso, TX   (76.1) 0 (14.9)  (9.0) 
Fresno, CA   (83.6)  (11.0)  (5.5) 
Grand Rapids-Wyoming, MI   (42.9)  (50.0) 0 (0.0) 0
Greensboro-High Point, NC   (66.7)  (20.8)  (12.5) 0
Greenville, SC   (57.9)  (31.6)  (10.5) 
Harrisburg-Carlisle, PA  0 (58.8)  (29.4)  (11.8) 
Hartford-West Hartford-East Hartford, CT   (58.3)  (25.0)  (16.7) 
Honolulu, HI 0  (81.2)  (11.9)  (6.9) 
Houston-Sugar Land-Baytown, TX  0 (74.4)  (18.4)  (7.2) 
Indianapolis-Carmel, IN 0  (70.0)  (17.5)  (12.5) 0
Jackson, MS   (88.6)  (8.6)  (2.9) 0
Jacksonville, FL 0 0 (84.1)  (15.9) 0 (0.0) 0
Kansas City, MO-KS  0 (65.2)  (23.9)  (10.9) 
Knoxville, TN   (94.1)  (5.9) 0 (0.0) 0
Lakeland, FL   (81.0)  (9.5)  (9.5) 0
Lancaster, PA   (76.5)  (17.6)  (5.9) 0
Las Vegas-Paradise, NV   (75.8)  (15.4)  (8.8) 0
Little Rock-North Little Rock-Conway, AR   (75.0)  (12.5)  (6.3) 0
Los Angeles-Long Beach-Santa Ana, CA ,0  (71.0)  (21.2)  (7.8) 
Louisville-Jefferson County, KY-IN   (85.3)  (11.8)  (2.9) 0
Madison, WI   (62.5)  (25.0)  (12.5) 
McAllen-Edinburg-Mission, TX 0  (84.4)  (7.8)  (7.8) 
Memphis, TN-MS-AR   (55.2)  (30.2)  (14.6) 
Miami-Fort Lauderdale-Pompano Beach, FL   (79.9)  (18.3)  (1.7) 
Milwaukee-Waukesha-West Allis, WI   (54.3)  (37.1)  (8.6) 
Minneapolis-St. Paul-Bloomington, MN-WI   (49.1)  (41.8)  (9.1) 0
Modesto, CA   (85.7)  (9.5)  (4.8) 0
Table 47. Tuberculosis Cases by Pulmonary and Extrapulmonary Disease: Metropolitan 
Statistical Areas with >500,000 Population, 2008
Metropolitan 
Statistical Area
Pulmonary Extrapulmonary
No. (%)
Total
Cases
Total
No. (%) No.
Cases in Persons with Both Pul-
monary and Extrapulm. Disease
Miliary
No. (%)

Nashville-Davidson-Murfreesboro-Franklin, TN 00  (84.0)  (6.0) 0 (10.0) 
New Haven-Milford, CT   (73.1)  (23.1)  (3.8) 0
New Orleans-Metairie-Kenner, LA   (84.7)  (9.7)  (5.6) 
New York-Northern New Jersey-Long Island, NY-NJ-PA  , 0 (64.3)  (23.9) 0 (11.8) 
Ogden-Clearfield, UT   (100.0) 0 (0.0) 0 (0.0) 0
Oklahoma City, OK   (80.0)  (11.4)  (8.6) 
Omaha-Council Bluffs, NE-IA   (68.0)  (32.0) 0 (0.0) 0
Orlando-Kissimmee, FL 0  (82.1)  (8.5) 0 (9.4) 
Oxnard-Thousand Oaks-Ventura, CA   (73.8)  (18.5)  (7.7) 0
Palm Bay-Melbourne-Titusville, FL 0  (80.0)  (20.0) 0 (0.0) 0
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD   (64.2)  (25.6)  (10.2) 
Phoenix-Mesa-Scottsdale, AZ 0  (77.3)  (21.3)  (1.3) 
Pittsburgh, PA   (63.0)  (29.6)  (7.4) 0
Portland-South Portland-Biddeford, ME   (75.0)  (25.0) 0 (0.0) 0
Portland-Vancouver-Beaverton, OR-WA   (77.0)  (14.8)  (8.2) 
Poughkeepsie-Newburgh-Middletown, NY   (40.0)  (53.3)  (6.7) 0
Providence-New Bedford-Fall River, RI-MA   (64.3)  (16.1)  (19.6) 
Provo-Orem, UT   (100.0) 0 (0.0) 0 (0.0) 0
Raleigh-Cary, NC  0 (58.8)  (23.5)  (17.6) 
Richmond, VA   (86.8)  (13.2) 0 (0.0) 0
Riverside-San Bernardino-Ontario, CA   (74.5)  (24.2)  (1.3) 
Rochester, NY  0 (58.8)  (23.5)  (17.6) 
Sacramento-Arden Arcade-Roseville, CA   (79.8)  (15.3)  (4.8) 0
St. Louis, MO-IL   (75.9)  (19.0)  (5.2) 
Salt Lake City, UT  0 (62.5)  (25.0)  (12.5) 0
San Antonio, TX   (82.6) 0 (10.9)  (6.5) 
San Diego-Carlsbad-San Marcos, CA   (64.0)  (20.1)  (15.9) 
San Francisco-Oakland-Fremont, CA 0  (69.6)  (21.5)  (8.9) 
San Jose-Sunnyvale-Santa Clara, CA   (66.7)  (24.7)  (8.6) 
Sarasota-Bradenton-Venice, FL   (77.4)  (19.4)  (3.2) 0
Scranton-Wilkes-Barre, PA   (58.3)  (25.0)  (16.7) 
Seattle-Tacoma-Bellevue, WA   (48.2)  (33.5) 0 (18.3) 
Springfield, MA   (100.0) 0 (0.0) 0 (0.0) 0
Stockton, CA   (80.3)  (7.6)  (12.1) 
Syracuse, NY   (86.4)  (13.6) 0 (0.0) 0
Tampa-St. Petersburg-Clearwater, FL   (85.6)  (10.8)  (3.6) 
Toledo, OH   (62.5)  (37.5) 0 (0.0) 0
Tucson, AZ   (84.6)  (11.5)  (3.8) 0
Tulsa, OK   (95.5)  (4.5) 0 (0.0) 0
Virginia Beach-Norfolk-Newport News, VA-NC   (76.2)  (21.4)  (2.4) 
Washington-Arlington-Alexandria, DC-VA-MD-WV 0  (70.1)  (20.7)  (9.2) 
Wichita, KS  0 (58.8)  (29.4)  (11.8) 0
Worchester, MA   (79.3)  (10.3)  (10.3) 
Youngstown-Warren-Boardman, OH-PA   (33.3)  (33.3)  (33.3) 
Total - 101 Areas 10,170 7,101 (69.8) 2,143 (21.1) 919 (9.0) 180
San Juan-Caguas-Guaynabo, PR   (86.7)  (12.0)  (1.3) 
Table 47. (Cont’d) Tuberculosis Cases by Pulmonary and Extrapulmonary Disease: 
Metropolitan Statistical Areas with >500,000 Population, 2008
Metropolitan 
Statistical Area
Total
Cases
Includes cases in persons with pulmonary listed as major site of disease and no additional site of disease.
Includes cases in persons with pleural, lymphatic, bone and/or joint, meningeal, peritoneal, genitourinary, or other site, excluding pulmo-
nary, listed as major site of disease.
Includes miliary cases.
Note: 7 (<0.1%) cases had missing and/or unknown site of disease. 
See Technical Notes for definition of MSA (page 9).
Pulmonary Extrapulmonary
No. (%)
Total
No. (%) No.
Cases in Persons with Both Pul-
monary and Extrapulm. Disease
Miliary
No. (%)

Table 48. Tuberculosis Cases by Age Group: Metropolitan Statistical Areas with >500,000 
Population, 2008
Akron, OH   0     0
Albany-Schenectady-Troy, NY  0 0    0 0
Albuquerque, NM  0  0  0  0
Allentown-Bethlehem-Easton, PA-NJ  0      0
Atlanta-Sandy Springs-Marietta, GA 00       0
Augusta-Richmond County, GA-SC  0 0     0
Austin-Round Rock, TX        0
Bakersfield, CA 0       0
Baltimore-Towson, MD        0
Baton Rouge, LA 0 0 0     0
Birmingham-Hoover, AL  0 0     0
Boise City-Nampa, ID  0    0  0
Boston-Cambridge-Quincy, MA-NH 0 0      0
Bridgeport-Stamford-Norwalk, CT   0     0
Buffalo-Niagara Falls, NY        0
Cape Coral-Fort Myers, FL        0
Charleston-North Charleston, SC   0     0
Charlotte-Gastonia-Concord, NC-SC        0
Chattanooga, TN-GA   0     0
Chicago-Naperville-Joliet, IL        0
Cincinnati-Middleton, OH-KY-IN   0    0 0
Cleveland-Elyria-Mentor, OH    0    0
Colorado Springs, CO 0 0 0     0
Columbia, SC   0     0
Columbus, OH       0 0
Dallas-Fort Worth-Arlington, TX        0
Dayton, OH 0 0 0     0
Denver-Aurora, CO        0
Des Moines-West Des Moines, IA  0 0 0   0 0
Detroit-Warren-Livonia, MI   0     0
El Paso, TX        0
Fresno, CA        0
Grand Rapids-Wyoming, MI   0     0
Greensboro-High Point, NC        0
Greenville, SC  0      0
Harrisburg-Carlisle, PA  0 0     0
Hartford-West Hartford-East Hartford, CT   0     0
Honolulu, HI 0 0  0 0   0
Houston-Sugar Land-Baytown, TX    0    0
Indianapolis-Carmel, IN 0       0
Jackson, MS  0      0
Jacksonville, FL 0       0
Kansas City, MO-KS     0 0  0
Knoxville, TN  0 0 0    0
Lakeland, FL   0     0
Lancaster, PA  0 0     0
Las Vegas-Paradise, NV        0
Little Rock-North Little Rock-Conway, AR   0     0
Los Angeles-Long Beach-Santa Ana, CA ,0 0  0 0   0
Louisville-Jefferson County, KY-IN        0
Madison, WI  0 0 0    0
McAllen-Edinburg-Mission, TX 0    0   0
Memphis, TN-MS-AR        0
Miami-Fort Lauderdale-Pompano Beach, FL       0 0
Milwaukee-Waukesha-West Allis, WI   0     0
Metropolitan 
Statistical Area
Total
Cases Under 5 15 –24
Unknown 
or 
Missing5–14 25–44 45–64 >

Table 48. (Cont’d) Tuberculosis Cases by Age Group: Metropolitan Statistical Areas with 
>500,000 Population, 2008
Metropolitan 
Statistical Area Under 5
Total
Cases 15 –24
Unknown 
or 
Missing
Note: See Technical Notes for definition of MSA (page 9).
5–14 25–44 45–64 >
Minneapolis-St. Paul-Bloomington, MN-WI        0
Modesto, CA  0 0     0
Nashville-Davidson-Murfreesboro-Franklin, TN 00       0
New Haven-Milford, CT  0 0  0   0
New Orleans-Metairie-Kenner, LA   0 0    0
New York-Northern New Jersey-Long Island, NY-NJ-PA   ,       0
Ogden-Clearfield, UT  0 0 0 0   0
Oklahoma City, OK   0     
Omaha-Council Bluffs, NE-IA   0     0
Orlando-Kissimmee, FL 0  0    0 0
Oxnard-Thousand Oaks-Ventura, CA        0
Palm Bay-Melbourne-Titusville, FL 0 0 0 0    0
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD        0
Phoenix-Mesa-Scottsdale, AZ 0 0      0
Pittsburgh, PA  0      0
Portland-South Portland-Biddeford, ME  0 0 0    0
Portland-Vancouver-Beaverton, OR-WA        0
Poughkeepsie-Newburgh-Middletown, NY  0 0 0    0
Providence-New Bedford-Fall River, RI-MA     0   0
Provo-Orem, UT  0 0  0 0 0 0
Raleigh-Cary, NC        0
Richmond, VA   0     0
Riverside-San Bernardino-Ontario, CA        0
Rochester, NY   0     0
Sacramento-Arden Arcade-Roseville, CA    0    0
St. Louis, MO-IL   0     0
Salt Lake City, UT   0     0
San Antonio, TX        0
San Diego-Carlsbad-San Marcos, CA    0    0
San Francisco-Oakland-Fremont, CA 0     0  0
San Jose-Sunnyvale-Santa Clara, CA        0
Sarasota-Bradenton-Venice, FL        0
Scranton-Wilkes-Barre, PA  0 0 0  0  0
Seattle-Tacoma-Bellevue, WA        0
Springfield, MA  0 0     0
Stockton, CA       0 0
Syracuse, NY        0
Tampa-St. Petersburg-Clearwater, FL    0  0  0
Toledo, OH   0     0
Tucson, AZ      0  0
Tulsa, OK   0     0
Virginia Beach-Norfolk-Newport News, VA-NC        0
Washington-Arlington-Alexandria, DC-VA-MD-WV 0       0
Wichita, KS        0
Worchester, MA  0      0
Youngstown-Warren-Boardman, OH-PA  0 0 0    0
Total - 101 Areas 10,170 351 219 1,157 3,473 3,083 1,886 1
San Juan-Caguas-Guaynabo, PR        0

Akron, OH  0 0  0 0  0 0
Albany-Schenectady-Troy, NY  0 0   0  0 0
Albuquerque, NM     0 0 0 0 0
Allentown-Bethlehem-Easton, PA-NJ   0   0   0
Atlanta-Sandy Springs-Marietta, GA 00  0  0   0 0
Augusta-Richmond County, GA-SC   0   0  0 0
Austin-Round Rock, TX    0  0 0 0 0
Bakersfield, CA 0  0   0  0 0
Baltimore-Towson, MD   0 0  0  0 0
Baton Rouge, LA 0 0 0   0  0 
Birmingham-Hoover, AL   0   0  0 0
Boise City-Nampa, ID   0 0    0 0
Boston-Cambridge-Quincy, MA-NH 0  0   0   0
Bridgeport-Stamford-Norwalk, CT   0   0  0 0
Buffalo-Niagara Falls, NY  0 0   0  0 0
Cape Coral-Fort Myers, FL   0 0  0 0 0 0
Charleston-North Charleston, SC   0   0  0 0
Charlotte-Gastonia-Concord, NC-SC   0 0  0   0
Chattanooga, TN-GA   0   0  0 
Chicago-Naperville-Joliet, IL   0 0  0  0 
Cincinnati-Middleton, OH-KY-IN   0   0   0
Cleveland-Elyria-Mentor, OH   0   0  0 0
Colorado Springs, CO 0  0   0  0 0
Columbia, SC   0   0  0 0
Columbus, OH   0   0  0 0
Dallas-Fort Worth-Arlington, TX   0      0
Dayton, OH 0 0    0  0 0
Denver-Aurora, CO         0
Des Moines-West Des Moines, IA   0  0 0  0 0
Detroit-Warren-Livonia, MI   0   0  0 
El Paso, TX  0 0 0 0 0  0 0
Fresno, CA   0  0 0  0 0
Grand Rapids-Wyoming, MI   0   0  0 0
Greensboro-High Point, NC   0   0   0
Greenville, SC   0   0  0 0
Harrisburg-Carlisle, PA   0   0  0 0
Hartford-West Hartford-East Hartford, CT   0 0  0  0 0
Honolulu, HI 0  0      0
Houston-Sugar Land-Baytown, TX   0   0   0
Indianapolis-Carmel, IN 0  0  0 0 0 0 0
Jackson, MS   0   0  0 0
Jacksonville, FL 0  0   0  0 0
Kansas City, MO-KS   0   0  0 0
Knoxville, TN   0   0  0 0
Lakeland, FL   0   0  0 0
Lancaster, PA   0   0  0 0
Las Vegas-Paradise, NV      0  0 0
Little Rock-North Little Rock-Conway, AR   0   0  0 
Los Angeles-Long Beach-Santa Ana, CA ,0   0     0
Louisville-Jefferson County, KY-IN   0 0  0  0 0
Madison, WI   0  0 0  0 0
McAllen-Edinburg-Mission, TX 0  0  0 0   0
Memphis, TN-MS-AR    0  0 0 0 0
Miami-Fort Lauderdale-Pompano Beach, FL  0 0   0   0
Milwaukee-Waukesha-West Allis, WI   0 0  0  0 
Minneapolis-St. Paul-Bloomington, MN-WI      0  0 0
Modesto, CA   0  0 0  0 0
Table 49. Tuberculosis Cases by Hispanic Ethnicity and Non-Hispanic Race: Metropolitan 
Statistical Areas with >500,000 Population, 2008
Metropolitan 
Statistical Area Asian
American 
Indian or 
Alaska 
Native
Total
Cases
Black 
or 
African 
American
Native 
Hawaiian or 
Other Pacific 
Islander White
Multiple 
Race
Unknown
or 
Missing
Hispanic 
or 
Latino

Nashville-Davidson-Murfreesboro-Franklin, TN 00  0   0  0 0
New Haven-Milford, CT   0   0  0 0
New Orleans-Metairie-Kenner, LA   0   0  0 0
New York-Northern New Jersey-Long Island, NY-NJ-PA  ,   0     
Ogden-Clearfield, UT   0 0 0   0 0
Oklahoma City, OK      0  0 0
Omaha-Council Bluffs, NE-IA   0   0  0 0
Orlando-Kissimmee, FL 0 0    0  0 0
Oxnard-Thousand Oaks-Ventura, CA   0   0  0 0
Palm Bay-Melbourne-Titusville, FL 0  0 0 0 0  0 0
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD   0 00  0  0 0
Phoenix-Mesa-Scottsdale, AZ 0     0   0
Pittsburgh, PA   0   0  0 0
Portland-South Portland-Biddeford, ME  0 0   0  0 0
Portland-Vancouver-Beaverton, OR-WA   0 0    0 0
Poughkeepsie-Newburgh-Middletown, NY   0   0  0 0
Providence-New Bedford-Fall River, RI-MA      0  0 0
Provo-Orem, UT  0 0 0 0 0  0 0
Raleigh-Cary, NC   0 0  0   0
Richmond, VA   0   0  0 0
Riverside-San Bernardino-Ontario, CA  0       0
Rochester, NY   0   0  0 0
Sacramento-Arden Arcade-Roseville, CA   0  0   0 0
St. Louis, MO-IL        0 0
Salt Lake City, UT   0   0  0 0
San Antonio, TX   0  0 0   0
San Diego-Carlsbad-San Marcos, CA      0   0
San Francisco-Oakland-Fremont, CA 0        0
San Jose-Sunnyvale-Santa Clara, CA   0     0 0
Sarasota-Bradenton-Venice, FL   0   0  0 0
Scranton-Wilkes-Barre, PA   0  0 0  0 0
Seattle-Tacoma-Bellevue, WA      0  0 0
Springfield, MA   0   0  0 0
Stockton, CA   0   0  0 
Syracuse, NY  0 0   0  0 0
Tampa-St. Petersburg-Clearwater, FL   0   0  0 
Toledo, OH   0   0  0 0
Tucson, AZ  0    0  0 0
Tulsa, OK      0  0 0
Virginia Beach-Norfolk-Newport News, VA-NC   0   0  0 0
Washington-Arlington-Alexandria, DC-VA-MD-WV 0  0   0  0 0
Wichita, KS   0   0  0 0
Worchester, MA   0   0  0 0
Youngstown-Warren-Boardman, OH-PA  0 0   0  0 0
Total - 101 Areas 10,170 2,966 37 3,042 2,601 55 1,419 33 17
San Juan-Caguas-Guaynabo, PR   0  0 0 0 0 0
Table 49. (Cont’d) Tuberculosis Cases by Hispanic Ethnicity and Non-Hispanic Race: Metropolitan 
Statistical Areas with >500,000 Population, 2008
Persons of Hispanic or Latino origin may be of any race or multiple race.
Indicates two or more races reported for a person.
Note: Case counts for race categories (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other 
Pacific Islander, and White) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. Multiple Race does 
not include persons of Hispanic ethnicity.
See Technical Notes for definition of MSA and Hispanic ethnicity and non-Hispanic race (page 9).
Metropolitan 
Statistical Area Asian
American 
Indian or 
Alaska 
Native
Total
Cases
Black 
or 
African 
American
Native 
Hawaiian or 
Other Pacific 
Islander White
Multiple 
Race
Unknown
or 
Missing
Hispanic 
or 
Latino
0
Akron, OH   (60.0)  (40.0) 0 (0.0)
Albany-Schenectady-Troy, NY   (50.0)  (50.0) 0 (0.0)
Albuquerque, NM  0 (43.5)  (56.5) 0 (0.0)
Allentown-Bethlehem-Easton, PA-NJ   (41.2)  (52.9)  (5.9)
Atlanta-Sandy Springs-Marietta, GA 00  (51.3)  (48.7) 0 (0.0)
Augusta-Richmond County, GA-SC   (88.5)  (11.5) 0 (0.0)
Austin-Round Rock, TX  0 (53.6)  (46.4) 0 (0.0)
Bakersfield, CA 0  (30.0)  (68.0)  (2.0)
Baltimore-Towson, MD   (47.2)  (52.8) 0 (0.0)
Baton Rouge, LA 0  (73.3)  (26.7) 0 (0.0)
Birmingham-Hoover, AL   (78.1)  (21.9) 0 (0.0)
Boise City-Nampa, ID   (33.3)  (66.7) 0 (0.0)
Boston-Cambridge-Quincy, MA-NH 0  (16.4)  (83.6) 0 (0.0)
Bridgeport-Stamford-Norwalk, CT   (13.9)  (86.1) 0 (0.0)
Buffalo-Niagara Falls, NY  0 (55.6)  (44.4) 0 (0.0)
Cape Coral-Fort Myers, FL  0 (62.5)  (37.5) 0 (0.0)
Charleston-North Charleston, SC   (61.3)  (38.7) 0 (0.0)
Charlotte-Gastonia-Concord, NC-SC   (68.4)  (31.6) 0 (0.0)
Chattanooga, TN-GA   (50.0)  (50.0) 0 (0.0)
Chicago-Naperville-Joliet, IL   (38.5)  (61.5) 0 (0.0)
Cincinnati-Middleton, OH-KY-IN   (40.5)  (59.5) 0 (0.0)
Cleveland-Elyria-Mentor, OH   (72.9)  (27.1) 0 (0.0)
Colorado Springs, CO 0  (30.0)  (70.0) 0 (0.0)
Columbia, SC   (58.3) 0 (41.7) 0 (0.0)
Columbus, OH   (39.4) 0 (60.6) 0 (0.0)
Dallas-Fort Worth-Arlington, TX   (53.0)  (47.0) 0 (0.0)
Dayton, OH 0  (60.0)  (40.0) 0 (0.0)
Denver-Aurora, CO   (25.4) 0 (74.6) 0 (0.0)
Des Moines-West Des Moines, IA   (14.3)  (85.7) 0 (0.0)
Detroit-Warren-Livonia, MI   (59.7)  (39.5)  (0.8)
El Paso, TX   (40.3) 0 (59.7) 0 (0.0)
Fresno, CA   (35.6)  (64.4) 0 (0.0)
Grand Rapids-Wyoming, MI   (28.6) 0 (71.4) 0 (0.0)
Greensboro-High Point, NC   (50.0)  (50.0) 0 (0.0)
Greenville, SC   (21.1)  (78.9) 0 (0.0)
Harrisburg-Carlisle, PA   (23.5)  (64.7)  (11.8)
Hartford-West Hartford-East Hartford, CT   (25.0)  (75.0) 0 (0.0)
Honolulu, HI 0  (32.7)  (67.3) 0 (0.0)
Houston-Sugar Land-Baytown, TX   (53.0)  (47.0) 0 (0.0)
Indianapolis-Carmel, IN 0  (47.5)  (52.5) 0 (0.0)
Jackson, MS   (91.4)  (8.6) 0 (0.0)
Jacksonville, FL 0  (76.6)  (23.4) 0 (0.0)
Kansas City, MO-KS   (32.6)  (67.4) 0 (0.0)
Knoxville, TN   (76.5)  (11.8)  (11.8)
Lakeland, FL   (66.7)  (33.3) 0 (0.0)
Lancaster, PA   (70.6)  (29.4) 0 (0.0)
Las Vegas-Paradise, NV   (34.1) 0 (65.9) 0 (0.0)
Little Rock-North Little Rock-Conway, AR   (68.8)  (25.0)  (6.3)
Los Angeles-Long Beach-Santa Ana, CA ,0  (21.9)  (77.7)  (0.4)
Louisville-Jefferson County, KY-IN  0 (58.8)  (41.2) 0 (0.0)
Madison, WI   (12.5)  (75.0)  (12.5)
McAllen-Edinburg-Mission, TX 0  (30.0)  (70.0) 0 (0.0)
Memphis, TN-MS-AR   (74.0)  (26.0) 0 (0.0)
Miami-Fort Lauderdale-Pompano Beach, FL   (35.0)  (65.0) 0 (0.0)
Milwaukee-Waukesha-West Allis, WI   (42.9)  (48.6)  (8.6)
Minneapolis-St. Paul-Bloomington, MN-WI  0 (18.2)  (81.8) 0 (0.0)
Table 50. Tuberculosis Cases and Percentages, U.S.-born Persons and Foreign-born Per-
sons: Metropolitan Statistical Areas with >500,000 Population, 2008
Metropolitan 
Statistical Area
U.S.-born Persons
Foreign-born 
Persons Unknown
No. No.(%) (%)
Total
Cases No. (%)

Modesto, CA   (14.3)  (85.7) 0 (0.0)
Nashville-Davidson-Murfreesboro-Franklin, TN 00 0 (60.0) 0 (40.0) 0 (0.0)
New Haven-Milford, CT   (26.9)  (73.1) 0 (0.0)
New Orleans-Metairie-Kenner, LA   (72.2) 0 (27.8) 0 (0.0)
New York-Northern New Jersey-Long Island, NY-NJ-PA ,  (22.4) , (77.3)  (0.3)
Ogden-Clearfield, UT   (25.0)  (75.0) 0 (0.0)
Oklahoma City, OK   (77.1)  (17.1)  (5.7)
Omaha-Council Bluffs, NE-IA  0 (40.0)  (60.0) 0 (0.0)
Orlando-Kissimmee, FL 0  (58.5)  (41.5) 0 (0.0)
Oxnard-Thousand Oaks-Ventura, CA   (23.1) 0 (76.9) 0 (0.0)
Palm Bay-Melbourne-Titusville, FL 0 0 (100.0) 0 (0.0) 0 (0.0)
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD  0 (42.1)  (51.2)  (6.7)
Phoenix-Mesa-Scottsdale, AZ 0  (24.0)  (76.0) 0 (0.0)
Pittsburgh, PA   (55.6)  (44.4) 0 (0.0)
Portland-South Portland-Biddeford, ME   (25.0)  (75.0) 0 (0.0)
Portland-Vancouver-Beaverton, OR-WA   (23.0)  (77.0) 0 (0.0)
Poughkeepsie-Newburgh-Middletown, NY   (40.0)  (46.7)  (13.3)
Providence-New Bedford-Fall River, RI-MA   (26.8)  (73.2) 0 (0.0)
Provo-Orem, UT   (100.0) 0 (0.0) 0 (0.0)
Raleigh-Cary, NC   (54.9)  (45.1) 0 (0.0)
Richmond, VA  0 (52.6)  (47.4) 0 (0.0)
Riverside-San Bernardino-Ontario, CA   (27.5)  (72.5) 0 (0.0)
Rochester, NY   (35.3)  (64.7) 0 (0.0)
Sacramento-Arden Arcade-Roseville, CA   (27.4)  (69.4)  (3.2)
St. Louis, MO-IL   (50.0)  (50.0) 0 (0.0)
Salt Lake City, UT   (25.0)  (75.0) 0 (0.0)
San Antonio, TX   (62.0)  (38.0) 0 (0.0)
San Diego-Carlsbad-San Marcos, CA   (29.5)  (70.1)  (0.4)
San Francisco-Oakland-Fremont, CA 0 0 (25.0) 0 (75.0) 0 (0.0)
San Jose-Sunnyvale-Santa Clara, CA   (9.6)  (90.4) 0 (0.0)
Sarasota-Bradenton-Venice, FL   (54.8)  (45.2) 0 (0.0)
Scranton-Wilkes-Barre, PA   (50.0)  (50.0) 0 (0.0)
Seattle-Tacoma-Bellevue, WA   (23.2)  (76.8) 0 (0.0)
Springfield, MA   (33.3)  (66.7) 0 (0.0)
Stockton, CA   (25.8)  (72.7)  (1.5)
Syracuse, NY   (9.1) 0 (90.9) 0 (0.0)
Tampa-St. Petersburg-Clearwater, FL   (55.0) 0 (45.0) 0 (0.0)
Toledo, OH   (37.5)  (62.5) 0 (0.0)
Tucson, AZ   (46.2)  (53.8) 0 (0.0)
Tulsa, OK   (63.6)  (36.4) 0 (0.0)
Virginia Beach-Norfolk-Newport News, VA-NC   (42.9)  (57.1) 0 (0.0)
Washington-Arlington-Alexandria, DC-VA-MD-WV 0  (19.0)  (81.0) 0 (0.0)
Wichita, KS   (35.3)  (64.7) 0 (0.0)
Worchester, MA   (10.3)  (89.7) 0 (0.0)
Youngstown-Warren-Boardman, OH-PA   (83.3)  (16.7) 0 (0.0)
Total - 101 Areas 10,170 3,627 (35.7) 6,494 (63.9) 49 (0.5)
San Juan-Caguas-Guaynabo, PR   (84.0)  (16.0) 0 (0.0)
Table 50. (Cont’d) Tuberculosis Cases and Percentages, U.S.-born Persons and Foreign-born 
Persons: Metropolitan Statistical Areas with >500,000 Population, 2008
Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the 
Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin 
Islands, and U.S. minor and outlying Pacific islands. 
Note: See Technical Notes for definition of MSA (page 9).
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Tuberculosis in the United States
National Tuberculosis Surveillance System Highlights from 2008
Slide 1 (title slide). Tuberculosis in the United States—National Tuberculosis Surveillance System, High-
lights from 2008.  This slide set was prepared by the Division of Tuberculosis Elimination, Centers for Dis-
ease Control and Prevention (CDC), Department of Health and Human Services (DHHS).  It provides trends 
for the recent past and highlights from data collected through the National Tuberculosis Surveillance System 
for 2008.  Since 1953, through the cooperation of state and local health departments, CDC has collected 
information on the newly reported cases of tuberculosis (TB) disease in the United States.  The data presented 
here were primarily collected via the expanded TB case report introduced in 1993.  Currently, each individual 
TB case report (Report of Verified Case of Tuberculosis, or RVCT) is submitted electronically to CDC.  The 
data for this slide set are based on updates received by CDC as of May 20, 2009.  All case counts and rates for 
years 1993–2007 have been updated.
Slide 2. Reported TB Cases, United States, 1982–2008.  The resurgence of TB in the mid-1980s was 
marked by several years of increasing case counts until its peak in 1992.  Case counts began decreasing 
again in 1993, and 2008 marked the sixteenth year of decline in the total number of TB cases reported in the 
United States since the peak of the resurgence.  From 1992 until 2002, the total number of TB cases decreased 
5%–7% annually.  From 2002 to 2003, however, the total number of TB cases decreased by only 1.4%.  In 
2008, a total of 12,904 cases were reported from the 50 states and the District of Columbia.  This represents a 
decline of 2.9% from 2007 and of approximately 50% from 1992.  
Slide 3. TB Morbidity, United States, 2003-2008.  This slide provides the total number of reported U.S. TB 
cases and the associated TB rates for each of the past 6 years.  Rate is defined as cases per 100,000 popula-
tion.  The number of TB cases decreased from 15,056 in 2002 to 12,904 in 2008, and the TB rate also de-
creased from 5.2 in 2002 to 4.2 in 2008.  
Slide 4. TB Case Rates, United States, 2008.  This map shows TB rates for 2008.  Thirty states had a rate of 
less than or equal to 3.5 TB cases per 100,000, the interim goal for the year 2000 established by the Advisory 
Council for the Elimination of Tuberculosis.  This group of states has remained fairly constant over the last 
decade; five states (CT, MI, NM, OR, and PA) joined the group in 2000, one state (MO) joined the group in 
2001 (also in 1998 for one year only), and one state (KY) joined the group in 2003. In 2008, five more states 
(AZ, AR, OK, RI and WA) joined the group but one state (MA) left the group.  Eleven states and the District 
of Columbia (DC) reported a rate above the 2008 national average of 4.2 cases per 100,000: AK, CA, FL, GA, 
HI, LA, MD, NJ, NY, TN and TX.  These 11 states and DC accounted for 67% of the national total and expe-
rienced substantial overall decreases in cases and rates from 1992 through 2008, with the exception of a slight 
increase in the number of cases for MA in 2008 compared to 2007. 
Slide 5. TB Case Rates by Age Group, United States, 1993–2008.  This slide shows the last 16 years’ de-
clining trend in TB rates by age group.  The largest declines occurred in persons 65 years and older (from 17.7 
per 100,000 in 1993 to 6.4 in 2008), in adults aged 45 to 64 years (from 12.4 to 5.0), in adults aged 25 to 44 
years (from 11.5 to 5.1), and in children under 15 years of age (from 2.9 to 1.3), each group having decreased 
more than 50%.  The rate declined by 32% in those 15 to 24 years of age (from 5.0 to 3.4).
Slide 6. Reported TB Cases by Age Group, United States, 2008.  This pie chart shows the age distribution 
of persons reported with TB in 2008.  Six percent were children under 15 years of age, 11% were age 15 to 
24, 33% were age 25 to 44, 30% were age 45 to 64, and 19% were at least 65 years old.
Slide 7. TB Case Rates by Age Group and Sex, United States, 2008.  This slide graphs the TB rates in 2008 
by age group and sex.  It shows that rates tended to increase with age, ranging from a low of less than 2 per 
100,000 in children to a high of 9 per 100,000 in men 65 years and older.  The rates in men 45 years and older 
were approximately twice those in same-age women.

Slide 8. TB Case Rates by Race/Ethnicity, United States, 1993–2008.  This slide shows the declining trend 
in TB rates by race/ethnicity during the last 16 years.  Asians and Pacific Islanders had the highest TB rates, 
which declined from 44.1 per 100,000 in 1993 to 25.3 in 2008, and had the smallest percentage decline over 
the time period (43%).  Rates declined by at least 57% over the time period in the other racial/ethnic groups: 
among non-Hispanic blacks or African-Americans, from 28.5 in 1993 to 8.8 in 2008 (69%); among Hispan-
ics, from 19.9 to 8.1 (59%); among American Indians and Alaska Natives, from 13.9 to 6.0 (57%); and among 
non-Hispanic whites, from 3.6 to 1.1 (69%).  Since 2003, the Asian and Pacific Islander race category has 
included persons who reported race as either 1) Asian only or 2) Native Hawaiian or Other Pacific Islander 
only.  Although these categories were reported separately beginning in 2003, they were merged for this slide 
to allow for continuity in reporting trends.
Several important factors likely contribute to the disproportionate burden of TB in minorities.  In persons who 
were born in countries where TB is common, TB disease may result from infection acquired in the country of 
origin.  Unequal distribution of TB risk factors, such as HIV infection, may also contribute to increased expo-
sure to TB or to an increased risk of developing TB once infected with M. tuberculosis. 
Slide 9. TB Case Rates by Age Group and Race/Ethnicity, United States, 2008.  This slide presents TB 
rates in 2008 by age group and race/ethnicity.  Risk increased with age across racial and ethnic groups, and 
rates were consistently higher in minority racial and ethnic groups than in non-Hispanic whites with the 
exception of American Indian or Alaskan Native in the 15-24 year-old age group.  Rates were the highest in 
Asians and Native Hawaiians and Other Pacific Islanders, particularly in adult age groups.  The impact of 
foreign birth is a consideration in interpreting rate variations by race/ethnicity.  For example, 95% of cases in 
the Asian group occurred in foreign-born persons, compared with 76% of cases in Hispanics and 32% of cases 
in non-Hispanic blacks or African-Americans.  Persons reporting two or more races totaled less than 1% of all 
cases.  
Slide 10. Reported TB Cases by Race/Ethnicity, United States, 2008.  In 2008, 83% of all reported TB 
cases occurred in racial and ethnic minorities (29% in Hispanics, 26% in Asians, 25% in non-Hispanic blacks 
or African-Americans, 1% in American Indians or Alaska Natives, and  <1% in Native Hawaiians or Other 
Pacific Islanders), whereas 17% of cases occurred in non-Hispanic whites.  Persons reporting two or more 
races totaled less than 1% of all cases.  This is the fifth year that Hispanics have constituted the single largest 
percentage of TB cases among all racial/ethnic groups and the first year that Asians have surpassed non-
Hispanic blacks or African Americans as the second largest percentage of TB cases among all racial/ethnic 
groups. 
Slide 11. Number of TB Cases in U.S.-born vs. Foreign-born Persons, United States, 1993–2008.  This 
graph plots the number of U.S.-born vs. foreign-born persons reported with TB each year, from 1993 through 
2008.  It illustrates the increase in the percentage of cases occurring in foreign-born persons during this 
period, from 29% in 1993 to 58% in 2008.  Overall, the number of cases in foreign-born persons remained 
virtually level, with approximately 7,000–8,000 cases each year, whereas the number in U.S.-born persons 
decreased from more than 17,000 in 1993 to less than 5,300 in 2008.
Slide 12. Trends in TB Cases in Foreign-born Persons, United States, 1988–2008.  This slide shows trends 
in TB cases in foreign-born persons in the United States from 1988 through 2007. The number of TB cases in 
foreign-born persons increased from nearly 5,000 in 1988 to 7,000–8,000 each year since 1991.  The percent-
age of TB cases accounted for by foreign-born persons increased from 22% in 1988 to 59% in 2008.
Slide 13. Reported TB Cases by Origin and Race/Ethnicity, United States, 2008.  Among U.S.-born 
persons with TB in 2008, 42% were non-Hispanic black or African-American, 33% were non-Hispanic white, 
17% were Hispanic or Latino, 3% were Asian, 3% were American Indian or Alaska Native, and 1% were 
Native Hawaiian or Other Pacific Islander.  Among the foreign-born, 43% were Asian, 38% were Hispanic or 
Latino, 14% were non-Hispanic black or African-American, and 5% were non-Hispanic white.  Cases among 
American Indians or Alaska Natives and among Native Hawaiians or Other Pacific Islanders constituted less 
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than 1%, respectively, of the cases among the foreign-born and are not shown.  Persons reporting two or more 
races totaled less than 1% of all cases.  
Slide 14. Percentage of TB Cases Among Foreign-born Persons, United States, 1996 and 2008.  The 
percentage range of the total number of TB cases that occurred in foreign-born persons in each state is high-
lighted for 1998 and 2008 in these side-by-side maps.  The number of states with at least 50% of cases in the 
foreign-born increased from 12 states in 1998 to 29 states and the District of Columbia in 2008. The number 
of states with at least 70% of cases in the foreign-born increased from two (HI and MN) in 1998 to fourteen 
(CA, CO, CT, MA, MD, ME, MN, NH, NJ, NY, OR, RI, VA and WA) in 2008 (not shown on slide). 
Slide 15. TB Case Rates in U.S.-born vs. Foreign-born Persons, United States, 1993–2008.  TB rates in 
foreign-born persons remain higher than those in the U.S.-born population.  From 1993 through 2008, the 
rates in U.S.-born persons decreased from 7.4 per 100,000 to 2.0, whereas the rates in foreign-born persons 
decreased from 34.0 per 100,000 to 20.3.
Slide 16. TB Case Rates in U.S.-born vs. Foreign-born Persons, United States, 1993–2008.  This is the 
same as Slide 15, but the rates are presented on a logarithmic scale to better illustrate the trend in TB rates 
among the U.S.-born and foreign-born. The lines show a greater rate of decline among the U.S.-born com-
pared with the foreign-born during this period.
Slide 17. Countries of Birth of Foreign-born Persons Reported with TB, United States, 2008.  This slide 
shows the overall distribution of the countries of birth of foreign-born persons reported with TB in 2008, with 
the top seven highlighted.  The list of countries has remained relatively constant since 1986, when informa-
tion on country of birth was first reported by all areas submitting reports to CDC. The seven top countries 
accounted for 61% of the total, with Mexico accounting for 23%; the Philippines, 11%; India, 8%; Vietnam, 
8%; China, 5%; Guatemala, 3%; and Haiti, 3%.  Persons from more than 135 other countries each accounted 
for 2% or less of the total, but altogether accounted for 38% of foreign-born persons reported with TB.
Slide 18. Percent of Foreign-born with TB by Time of Residence in U.S. Prior to Diagnosis, 2008.  The 
length of U.S. residence among foreign-born persons prior to their TB diagnosis in 2008 is shown in these 
stacked bars.  Overall, 16% had been in the United States for less than 1 year, 21% between 1 and 4 years, 
and 52% for at least 5 years.  The distribution is also shown for the top three countries of birth: Mexico, the 
Philippines, and India.  Among persons born in Mexico, 13% had been in the United States for less than 1 
year, 18% between 1 and 4 years, and 58% for at least 5 years. Among persons born in the Philippines, 16% 
had been in the United States for less than 1 year, 15% between 1 and 4 years, and 57% for at least 5 years.  
Among persons born in India, 20% had been in the United States for less than 1 year, 24% between 1 and 4 
years, and 42% for at least 5 years.
Slide 19. Primary Anti-TB Drug Resistance, United States, 1993–2008.  Primary drug resistance is shown 
for the past 16 years.  The graph starts in 1993, the year in which the individual TB case reports submitted to 
the national surveillance system began collecting information on initial susceptibility test results for patients 
with culture-positive TB.  Data were available for more than 85% of culture-positive cases for each year.  
Primary resistance was calculated by using data from persons with no reported prior TB episode. Resistance 
to at least isoniazid remained between 7.0% and 8.4%.  However, resistance to at least isoniazid and rifampin, 
known as multidrug-resistant TB (MDR TB), decreased from 2.4% in 1993 to 1.1% in 1997, and remained at 
approximately 1.1 % up to and including 2008.
Slide 20. Primary MDR TB, United States, 1993–2008.  This graph focuses on trends in primary MDR TB 
(based on initial isolates from persons with no prior history of TB) in the United States from 1993 through 
2008.  The number of primary MDR TB cases, represented by bars, steadily declined from 407 in 1993 to 115 
in 2001.  Since then the total number of primary MDR TB cases has fluctuated from 86 to 132 cases, with 86 
cases reported for 2008.  Primary MDR TB, shown by the line, decreased from 2.5% in 1993 to approximate-
ly 1.1% in 1997, and remained approximately at 1.1% up to and including 2008.
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Slide 21. Primary Isoniazid Resistance in U.S.-born vs. Foreign-born Persons, United States, 1993–2008.  
This graph shows primary isoniazid resistance in U.S.-born vs. foreign-born persons.  Based on initial isolates 
from persons with no prior history of TB, the percentage of isoniazid resistance was approximately two times 
higher among foreign-born persons than among U.S.-born persons.  In foreign-born persons, the percentage 
declined from 12.4% in 1993 to 10.3% in 2008.  In U.S.-born persons, the percentage decreased from 6.8% in 
1993 to 4.9% in 2008.  
Slide 22. Primary MDR TB in U.S.-born vs. Foreign-born Persons, United States, 1993–2008.  This graph 
highlights primary MDR TB in U.S.-born versus foreign-born persons.  The percentage with primary MDR 
TB has declined among both groups, although the decline in the U.S.-born has been greater.  As a result, the 
proportion of primary MDR TB cases reported in foreign-born persons increased from approximately 25% 
in 1993 to 77% in 2008 (not shown on slide).  Among the U.S.-born, the percentage with primary MDR TB 
remained between 0.4% and 0.7% from 1998 through 2008 and was 0.6% in 2008.  The percentage among for-
eign-born persons has fluctuated year by year, while averaging approximately 1.4% from 1998 through 2008.
Slide 23. Extensively Drug Resistant (XDR) TB, as Defined on Initial Drug Susceptibility Testing (DST), 
United States, 1993–2008.  This graph shows the annual number of counted XDR TB cases as defined on 
initial DST from 1993-2008, reported as of May 20, 2009. Four XDR TB cases were reported in 2008. The 
most reported in a single year was 10 in 1993, while there were no cases reported in 2003. There is no apparent 
trend in the number of cases over time. 
Slide 24. Reporting of HIV Test Results in Persons with TB by Age Group, United States, 1993–2008.  
This slide shows the completeness of reporting of HIV test results in persons with TB by age group from 1993 
through 2008.  The percentage of TB patients for whom test results were reported increased from 30% among 
all ages in 1993 to 62% in 2008.  Among adults aged 25–44 years, the percentage increased from 46% to 72% 
in 2008.  The numerator includes TB patients with positive, negative, or indeterminate HIV test results and 
persons from California reported with AIDS (HIV test results are not reported to CDC from California or Ver-
mont).
Slide 25. Estimated HIV Coinfection in Persons Reported with TB, United States, 1993–2008.  This slide 
provides minimum estimates of HIV coinfection among persons reported with TB from 1993 through 2008.  
Since the addition of the request for HIV status to the individual TB case report in 1993, incomplete reporting 
has provided a challenge to calculating reliable estimates.  Results from the cross-matching of TB and AIDS 
registries have been used to supplement reported HIV test results.  For all ages, the estimated percentage of 
HIV coinfection in persons reported with TB decreased from 15% to 6% overall and from 29% to 10% in per-
sons aged 25 to 44 years during this period. 
Slide 26. Mode of Treatment Administration in Persons Reported with TB, United States, 1993–2006.  In 
1993, the reporting areas began providing information about mode of treatment administration on the individu-
al TB case report form.  Treatment administered as only directly observed therapy (DOT) increased from 21% 
in 1993 to 57% in 2006, the latest year with available data.  There was also an increase in the proportion of 
patients who received at least some portion of their treatment as DOT (based on combining the percentage of 
patients who received only DOT and the percentage for whom some portion was self-administered).  In 2006, 
87% of patients received at least some portion of their treatment as DOT.
Slide 27. Completion of TB Therapy, United States, 1993–2006.  The reporting areas began providing infor-
mation on completion of therapy in 1993 through the individual TB case report form.  The calculations exclude 
patients with an initial isolate resistant to rifampin as well as children with meningeal, bone or joint, or miliary 
disease.  Overall completion of therapy has remained at approximately 92% from 1998 through 2006. Comple-
tion in 1 year or less increased from 64% in 1993 to 84% in 2006, the latest year with available data.  The cur-
rent DHHS Healthy People 2010 objective is completion of therapy in 1 year or less in 90% of patients.  CDC 
is working with state and local health departments to determine and evaluate reasons for apparently delayed 
completion of therapy, which may vary by jurisdiction..
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Tuberculosis Case Definition for Public Health Surveillance1
Tuberculosis (Revised 9/96)
Clinical description
A chronic bacterial infection caused by Mycobacterium tuberculosis, characterized pathologically by 
the formation of granulomas. The most common site of infection is the lung, but other organs may be 
involved. 
Clinical case definition
A case that meets all of the following criteria:
• A positive tuberculin skin test result; and
• Other signs and symptoms compatible with tuberculosis, such as an abnormal, unstable (i.e., 
worsening or improving) chest radiograph, or clinical evidence of current disease; and
• Treatment with two or more antituberculosis medications; and
• A completed diagnostic evaluation.
Laboratory criteria for diagnosis
• Isolation of M. tuberculosis from a clinical specimen,* or
• Demonstration of M. tuberculosis from a clinical specimen by nucleic acid amplification test,† or
• Demonstration of acid-fast bacilli in a clinical specimen when a culture has not been or cannot be 
obtained.
Case classification
Confirmed:  a case that meets the clinical case definition or is laboratory confirmed.
Comment
Only one case should be counted in a person within any consecutive 12-month period. However, a 
case in a patient who had previously had verified disease should be reported again if more than 12 
months have elapsed since the patient was discharged from treatment. A case should also be re-
ported again if the patient was lost to supervision for >12 months and disease can be verified again. 
Mycobacterial diseases other than those caused by M. tuberculosis complex should not be counted 
in tuberculosis morbidity statistics unless there is concurrent tuberculosis.
                                                                                                                  
1Case definition applicable to this report: CDC. Case definitions for infectious conditions under public health surveil-
lance. Morbid Mortal Weekly Report 1997;46(No. RR-10):40- 41. Case definition (revised 2009): CDC. Report of 
Verified Case of Tuberculosis (RVCT) Instruction Manual.  Atlanta, GA: U.S. Department of Health and Human 
Services, CDC, June 2009.
*Use of rapid identification techniques for M. tuberculosis (e.g., DNA probes and mycolic acid 
high-pressure liquid chromatography performed on a culture from a clinical specimen) are accept-
able under this criterion.
†Nucleic acid amplification (NAA) tests must be accompanied by culture for mycobacteria species. 
However, for surveillance purposes, CDC will accept results obtained from NAA tests approved by 
the Food and Drug Administration (FDA) and used according to the approved product labeling on 
the package insert.  
Appendix A
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Appendix B
Recommendations for Counting Reported Tuberculosis Cases
(Revised July 1997)
Since publication of the “Recommendations for Counting Reported Tuberculosis Cases”
1 in Jan-
uary 1977, numerous changes have occurred and many issues have been raised within the field of 
tuberculosis (TB) surveillance.  This current version† updates and supersedes the previous ver-
sion; it clarifies the parameters for counting TB cases among (a) immigrants, resident aliens, and 
border crossers, (b) military personnel stationed in the United States and abroad, and (c) persons 
diagnosed within the Indian Health Service and correctional facilities.
A distinction should be made between reporting TB cases to a health department and counting 
TB cases for determining incidence of disease.  Throughout each year, TB cases and suspected 
cases are reported to public health authorities by sources such as clinics, hospitals, laboratories, 
and health care providers.  From these reports, the state or local TB control officer must deter-
mine which cases meet the current surveillance definition for TB disease.  These verified TB 
cases are then counted and reported to the Centers for Disease Control and Prevention (CDC).
I. Reporting TB Cases. CDC recommends that health care providers and laboratories be 
required to report all TB cases or suspected cases to state and local health departments 
based on the current “Case Definition for Public Health Surveillance.”
2
 This notification 
is essential in order for TB programs to
• Ensure case supervision,
• Ensure completion of appropriate therapy,
• Ensure completion of timely contact investigations,
• Evaluate program effectiveness, and
• Assess trends and characteristics of TB morbidity.
II. TB Surveillance. For purposes of surveillance, a case of TB is defined on the basis of   
 laboratory and/or clinical evidence of active disease due to M. tuberculosis complex.*
________________________________
*Because most laboratories use tests that do not routinely distinguish Mycobacterium tuberculosis from very closely related spe-
cies, these laboratories report culture results as being positive or negative for “Mycobacterium tuberculosis complex.” Although in 
almost all cases of human disease, isolates in the M. tuberculosis complex are, in fact, M. tuberculosis, other species are possible. For 
example, one study in San Diego found that 6% of human tuberculosis was caused by Mycobacterium bovis; cultures from these cases 
would be reported by most laboratories as being positive for M. tuberculosis complex. Other species in the Mycobacterium tuberculo-
sis complex include M. africanum, M. microti, M. canetii, M. caprae, and M. pinnipedii. Although M.  microti,  M. canetii,  M. caprae, 
and M. pinnipedii are newly described species, their inclusion in M. tuberculosis complex should not impact public health laboratories 
or programs because only a few laboratories identify to the species level. These seven species are almost identical in DNA homol-
ogy studies. In terms of their ability to cause clinical disease and be transmissible from person to person, M. bovis, M. africanum, M. 
microti, and M. canetti behave like M. tuberculosis; therefore, disease caused by any of the organisms should be reported as TB, using 
the Report of Verified Case of Tuberculosis (RVCT). The only exception is the BCG strain of M. bovis, which may be isolated from 
persons who have received the vaccine for protection against TB or as cancer immunotherapy; disease caused by the BCG strain of M. 
bovis should not be reported as TB because the transmission is iatrogenic (treatment-induced), rather than person-to-person or com-
municable.
†Recommendations applicable to this report: Recommendations for Counting Reported TB Cases. Atlanta; CDC, 
July 1997. Recommendations (revised 2009): CDC. Report of Verified Case of Tuberculosis (RVCT) Instruction 
Manual.  Atlanta, GA: U.S. Department of Health and Human Services, CDC, June 2009:
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a. Laboratory Case Definition
• Isolation of M. tuberculosis complex from a clinical specimen.  The use of rapid identi-
fication techniques for M. tuberculosis performed on a culture from a clinical specimen, 
such as DNA probes and high-pressure liquid chromatography (HPLC), is acceptable 
under this criterion.
OR
• Demonstration of M. tuberculosis from a clinical specimen by nucleic acid amplifica-
tion (NAA) test.  NAA tests must be accompanied by cultures of mycobacterial species.  
However, for surveillance purposes, CDC will accept results obtained from NAA tests 
that are approved by the Food and Drug Administration (FDA).  
   
OR   
• Demonstration of acid-fast bacilli (AFB) in a clinical specimen when a culture has not 
been or cannot be obtained; historically this criterion has been most commonly used to 
diagnose TB in the postmortem setting.  
b. Clinical Case Definition. In the absence of laboratory confirmation of M. tuberculosis com-
plex after a diagnostic process has been completed, persons must have all of the following 
criteria for clinical TB:
• Evidence of TB infection based on a positive tuberculin skin test result
AND
• One of the following:
(1) Signs and symptoms compatible with current TB disease, such as an abnormal, 
unstable (worsening or improving) chest radiograph, or
(2) Clinical evidence of current disease (e.g., fever, night sweats, cough, weight 
loss, hemoptysis)
AND
• Current treatment with two or more anti-TB medications 
NOTE: The case definition described herein was developed for use in this document and is not intended 
to replace the case definition for TB as stated in the current “Case Definitions for Infectious Conditions 
Under Public Health Surveillance.”  
In addition, the software for TB surveillance developed by CDC includes a calculated variable called “Ver-
crit,” for which one of the values is “Provider Diagnosis.”  “Provider Diagnosis” is selected when the user 
chooses to override a “Suspect” default value in the case verification screen as “Verified by Provider Diag-
nosis.”  Thus, “Provider Diagnosis” is not a component of the case definition for TB in the current “Case 
Definitions for Infectious Conditions Under Public Health Surveillance” publication.  CDC’s national mor-
bidity reports have traditionally included all cases that are considered verified by the reporting areas, without 
a requirement that cases meet the published case definition.
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III. Counting TB Cases. Cases that meet the current CDC surveillance case definition for 
verified TB are counted by 52 reporting areas with count authority (50 states, District of 
Columbia, and New York City) to determine annual incidence for the United States.  The 
remaining 7 reporting areas (American Samoa, Federated States of Micronesia, Guam, 
Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Islands) report 
cases to CDC, but are not included in the annual incidence for the United States. The 
laboratory and clinical case definitions are the two diagnostic categories used by the CDC 
“Case Definitions for Infectious Conditions Under Public Health Surveillance.”
Most verified TB cases are accepted for counting based on laboratory confirmation 
of M. tuberculosis complex from a clinical specimen.
A person may have more than one discrete (separate and distinct) episode of TB.  
If disease recurs in a person within any 12-consecutive-month period, count only 
one episode as a case for that year.  However, if TB disease recurs in a person, and 
if more than 12 months have elapsed since the person was discharged from or lost 
to supervision, the TB is considered a separate episode and should be counted as a 
new case.  Note: Discharged from supervision implies completion of therapy.  
Mycobacterial diseases other than those caused by M. tuberculosis complex should 
not be counted in TB morbidity statistics unless there is concurrent TB. 
a. Verified TB Cases
COUNT
Count only verified TB cases that meet the laboratory or clinical case definitions 
(see Section II).  The diagnosis of TB must be verified by the TB control officer 
or designee.  The current CDC surveillance case definition for TB describes and 
defines the criteria to be used in the case definition for TB disease. 
DO NOT COUNT
If diagnostic procedures have not been completed, do not count; wait for confirma-
tion of disease.  Do not count a case for which two or more anti-TB medications 
have been prescribed for preventive therapy for exposure to multidrug- resistant 
(MDR) TB, or while the diagnosis is still pending.
b. Nontuberculous Mycobacterial Diseases (NTM)
COUNT
An episode of TB disease diagnosed concurrently with another nontuberculous my-
cobacterial disease should be counted as a TB case.
DO NOT COUNT
Disease attributed to or caused by nontuberculous mycobacteria alone should not be 
counted as a TB case.
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c. TB Cases Reported at Death
COUNT
TB cases first reported to the health department at the time of a person’s death are 
counted as incident cases, provided the person had current disease at the time of 
death.  The TB control officer should verify the diagnosis of TB.
DO NOT COUNT
Do not count as a case of TB if there is no evidence of current disease at the time of 
death or at autopsy.
d. Immigrants, Refugees, Permanent Resident Aliens, Border Crossers,* and Foreign Visi-
tors3
COUNT
Immigrants and refugees who have been screened overseas for TB and
• have been classified as Class B (B1, B2, or B3)
4 or resident aliens,
• are not already on anti-TB medications for treatment of TB disease, and
• are examined after arriving in the United States and diagnosed with clini-
cally active TB requiring anti-TB medications, and
• should be counted by the locality of their current residence at the time of 
diagnosis regardless of citizenship status.
Border crossers* and permanent resident aliens who are diagnosed with TB and 
plan to receive anti-TB therapy from a locality in the United States for 90 days or 
more should be counted by the locality where they receive anti-TB therapy.
Foreign visitors (e.g., students, commercial representatives, and diplomatic person-
nel) who are diagnosed with TB, are receiving anti-TB therapy, and plan to remain 
in the United States for 90 days or more should be counted by the locality of current 
residence.
*Border crosser — defined, in part, by the U.S. Citizenship and  Immigration 
Services (USCIS)
3  as “a nonresident alien entering the United States across the 
Mexican border for stays of no more than 72 hours.”  Border crossers may go back 
and forth across the border many times in a short period.
DO NOT COUNT
TB cases in immigrants or refugees who have been classified as Class A with a 
waiver (TB, Infectious, Noncommunicable for travel purposes)4 should not be 
counted as new cases even if the persons receive routine initial work-ups in the 
United States.  TB in persons who are temporarily (<90 days) in the United States, 
for whom therapy may have been started but who plan to return to their native 
country to continue therapy, should not be counted in the United States.
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e. Out-of-State or Out-of-Area Residents 
COUNT 
A person’s TB case should be counted by the locality in which he or she resides at 
the time of diagnosis.  TB in a person who has no address should be counted by the 
locality that diagnosed and is treating the TB.  The TB control officer should notify 
the appropriate out-of-state or out-of-area TB control officer of the person’s home 
locality to (1) determine whether the case has already been counted to avoid “dou-
ble counting,” and (2) agree on which TB control office should count the case if it 
has not yet been counted. 
DO NOT COUNT 
Do not count a case in a newly diagnosed TB patient who is an out-of-area resident 
and whose TB has already been counted by the out-of-area TB control office.
f. Migrants and Other Transients 
COUNT
Persons without any fixed U.S. residence are considered to be the public health 
responsibility of their present locality and their TB case should be reported and 
counted where diagnosed.
DO NOT COUNT
Cases in transient TB patients should not be counted when there is evidence that 
they have already been counted by another locality.
g. Federal Facilities (e.g., Military and Veterans Administration Facilities)  
COUNT
Cases in military personnel, dependents, or veterans should be reported and counted 
by the locality where the persons are residing in the United States at the time of 
diagnosis and initiation of treatment.
However, if military personnel or dependents are discovered to have TB at a mili-
tary base outside the United States but are referred elsewhere for treatment (e.g., a 
military base located within the United States), the TB case should be reported and 
counted where treated and not where the diagnosis was made.
DO NOT COUNT
Do not count if the case was already counted by another locality in the United 
States.
h. Indian Health Service
COUNT
TB should be reported to the local health authority (e.g., state or county) and count-
ed where diagnosed and treatment initiated.  However, for a specific group such as 
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the Navajo Nation, which is geographically located in multiple states, health depart-
ments should discuss each case and determine which locality should count the case.
DO NOT COUNT
Do not count if the case was already counted by another locality.
i. Correctional Facilities (e.g., Local, State, Federal, and Military)
COUNT
Persons who reside in local, state, federal, or military correctional facilities may 
frequently be transferred or relocated within and/or between various correctional 
facilities. TB in these persons should be reported to the local health authority and 
counted by the locality where the diagnosis was made and treatment plans were 
initiated.
DO NOT COUNT
Do not count correctional facility residents’ TB cases that were counted elsewhere 
by another locality or correctional facility, even if treatment continues at another 
locale or correctional facility.
j. Peace Corps, Missionaries, and Other Citizens Residing Outside the United States
DO NOT COUNT
TB in persons diagnosed outside the United States should not be counted.  TB in 
these persons should be counted by the country in which they are residing regard-
less of their plans to return to the United States for further work-up or treatment.
IV. Suggested Administrative Practices
To promote uniformity in TB case counting, the following administrative procedures 
are recommended:
(a) All TB cases verified by the 52 reporting areas with count authority (50 states, District 
of Columbia, and New York City) during the calendar year (by December 31) will be 
included in the annual U.S. incidence count for that year.  All tuberculosis cases verified 
during the calendar year by a reporting area with count authority from one of the remain-
ing 7 reporting areas (American Samoa, Federated States of Micronesia, Guam, Northern 
Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Islands) are also count-
ed but are not included in the annual incidence for the United States.  Cases for which 
bacteriologic results are pending or for which confirmation of disease is questionable 
for any other reason should not be counted until their status is clearly determined; they 
should be counted at the time they meet the criteria for counting.  This means that a case 
reported in one calendar year could be included in the morbidity count for the follow-
ing year.  The reporting area with count authority should ensure that there is agreement 
between final local and state TB figures reported to CDC. Currently, some reporting areas 
may not use this suggested protocol.  Some of these areas may wait until the beginning of 
the following year when they have received and processed all of the TB cases for inclu-

sion in the annual case count for the previous year.  If reporting areas decide to revise 
their protocols, they should be aware that their TB trends may change.
(b) TB is occasionally reported to health departments over the telephone, by letter or fax, or 
on forms other than the Report of Verified Case of Tuberculosis (RVCT).  Such informa-
tion should be accepted as an official morbidity report if sufficient details are provided; 
otherwise, the notification should be used as an indicator of a possible TB case (suspect) 
which should be investigated promptly for confirmation.
V. TB Surveillance Definitions
Case - an episode of TB disease in a person meeting the laboratory or clinical cri-
teria for TB as defined in the document “Case Definitions for Infectious Conditions 
Under Public Health Surveillance”
2 (see Section II for criteria).
Suspect - a person for whom there is a high index of suspicion for active TB (e.g., 
a known contact to an active TB case or a person with signs or symptoms consistent 
with TB) who is currently under evaluation for TB disease.
Verification of a TB case - the process whereby a TB case, after the diagnostic 
evaluation is complete, is reviewed at the local level (e.g., state or county) by a TB 
control official who is familiar with TB surveillance definitions; if all the criteria for 
a TB case are met, the TB case is then verified and eligible for counting. 
Counting of a TB case - the process whereby a reporting area with count author-
ity evaluates verified TB cases (e.g., assesses for case duplication).  These cases 
are then counted for morbidity in that locality (e.g., state or county) and reported to 
CDC for national morbidity counting.
Mycobacterium tuberculosis complex (M. tuberculosis complex) - Because most 
laboratories use tests that do not routinely distinguish Mycobacterium tuberculosis 
from very closely related species, these laboratories report culture results as being 
positive or negative for “Mycobacterium tuberculosis complex.” Although in almost 
all cases of human disease, isolates in the M. tuberculosis complex are, in fact, M. 
tuberculosis, other species are possible. For example, one study in San Diego found 
that 6% of human tuberculosis was caused by Mycobacterium bovis; cultures from 
these cases would be reported by most laboratories as being positive for M. tuber-
culosis complex. Other species in the Mycobacterium tuberculosis complex include 
M. africanum, M. microti, M. canetii, M. caprae, and M. pinnipedii. Although M.  
microti, M. canetii, M. caprae, and M. pinnipedii are newly described species, their 
inclusion in M. tuberculosis complex should not impact public health laboratories or 
programs because only a few laboratories identify to the species level. These seven 
species are almost identical in DNA homology studies. In terms of their ability to 
cause clinical disease and be transmissible from person to person, M. bovis, M. 
africanum, M. microti, and M. canetti behave like M. tuberculosis; therefore, dis-
ease caused by any of the organisms should be reported as TB, using the Report of 
Verified Case of Tuberculosis (RVCT). The only exception is the BCG strain of M. 
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bovis, which may be isolated from persons who have received the vaccine for pro-
tection against TB or as cancer immunotherapy; disease caused by the BCG strain 
of M. bovis should not be reported as TB because the transmission is iatrogenic 
(treatment-induced), rather than person-to-person or communicable.
 
Nontuberculous mycobacteria (NTM) - mycobacteria other than Mycobacterium 
tuberculosis complex that can cause human infection or disease.  Common nontu-
berculous mycobacteria include M. avium complex or MAC (M. avium, M. intracel-
lulare), M. kansasii, M. marinum, M. scrofulaceum, M. chelonae, M. fortuitum, and 
M. simiae.  Other terms have been used to represent NTM, including MOTT (myco-
bacteria other than TB) and “atypical” mycobacteria.
Reporting area - areas responsible for counting and reporting verified TB cases to 
CDC.  Currently there are 60 reporting areas: the 50 states, District of Columbia, 
New York City, American Samoa, Federated States of Micronesia, Guam, Northern 
Mariana Islands, Marshall Islands, Puerto Rico, Republic of Palau, and U.S. Virgin 
Islands.  The annual incidence of tuberculosis for the United States is based on 52 
reporting areas (the 50 states, District of Columbia, and New York City).
Alien - defined by the U.S. Citizenship and Immigration Services (USCIS)3  as “any 
person not a citizen or national of the United States.”
Border crosser - defined, in part, by the USCIS3 as “a nonresident alien entering 
the United States across the Mexican border for stays of no more than 72 hours.”  
Border crossers may go back and forth across the border many times in a short 
period.
No TB Classification - Applicants with normal tuberculosis screening examina-
tions.
Class A TB with waiver - All applicants who have tuberculosis disease and have 
been granted a waiver.
Class B1 TB, Pulmonary - 
No treatment
• Applicants who have medical history, physical exam, HIV, or CXR findings 
suggestive of pulmonary tuberculosis but have negative AFB sputum smears 
and cultures and are not diagnosed with tuberculosis or can wait to have 
tuberculosis treatment started after immigration.
Completed treatment
• Applicants who were diagnosed with pulmonary tuberculosis and success-
fully completed directly observed therapy prior to immigration. The cover 
sheet should indicate if the initial sputum smears and cultures were positive 
and if drug susceptibility testing results are available.
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Class B1 TB, Extrapulmonary - Applicants with evidence of extrapulmonary 
tuberculosis. Document the anatomic site of infection.
Class B2 TB, LTBI Evaluation - Applicants who have a tuberculin skin test 
≥10 mm but otherwise have a negative evaluation for tuberculosis. The size of 
the TST reaction, the applicant’s status with respect to LTBI treatment, and the 
medication(s) used should be documented. For applicants who had more than one 
TST, whether the applicant converted the TST should be documented (i.e., initial 
TST <10 mm but subsequent TST ≥10 mm).
Class B3 TB, Contact Evaluation - Applicants who are a recent contact of a 
known tuberculosis case. The size of the applicant’s TST reaction should be docu-
mented. Information about the source case, name, alien number, relationship to 
contact, and type of tuberculosis should also be documented.
Immigrant - defined by the USCIS3  as “an alien admitted to the United States as 
a lawful permanent resident.  Immigrants are those persons lawfully accorded the 
privilege of residing permanently in the United States.  They may be issued immi-
grant visas by the Department of State overseas or adjusted to permanent resident 
status by the USCIS of the United States.”
Permanent Resident Alien - see Immigrant. 
Waivers - A provision allows applicants undergoing pulmonary or laryngeal tuber-
culosis treatment to petition for a Class A waiver. Waivers should be pursued for 
any immigrant or refugee who has a complicated clinical course and would benefit 
from receiving treatment of their tuberculosis in the United States. Applicants diag-
nosed with tuberculosis disease who are both smear- and culture-negative and will 
be traveling to the United States prior to start of treatment do not need to complete 
the waiver process.
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Notes 
- Reference to details of FDA-approved labeling for NAA (IIa) was deleted from this 
document in September 2002.
- A note of clarification was added to Section III, Counting TB Cases, in September 
2003.
- Clarification of TB classification of immigration applicants was modified in Section V, 
TB Surveillance Definitions, in September 2007.
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